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Abstract
There are prominent individual differences in sleep patterns and some o f these can be 
observed within the EEG. In order to determine whether the EEG can effectively serve as a 
biomarker for individual differences and in order to establish whether such differences 
constituted trait-like individual differences, we assessed the stability and robustness of sleep 
and the sleep EEG in physiological and pharmacological studies.
The spectral composition of the EEG and PSG derived sleep measures were assessed for trait­
like inter-individual variability by calculating ICCs in 1) a study investigating the effects of 
sleep extension, sleep restriction and total sleep deprivation on sleep and the EEG and the 
contribution o f the PER2> polymorphism to individual differences 2) a study investigating the 
effects o f polychromatic light mixtures on the EEG and 3) a study investigating the effects of  
prolonged-release melatonin, temazepam and zolpidem on sleep and the EEG.
Absolute power density values derived from the spectral composition of the EEG were 
particularly stable and robust and the ICCs were rated as ‘moderate’ to ‘almost perfect’ for 
NREM and REM sleep across the studies. ICCs for PSG measures were more variable. ICCs 
were also calculated on relative data in order to assess the stability and robustness o f the 
response to sleep-wake manipulations in the first study; however, these ICCs were very low 
in comparison to those obtained for absolute data. The PER3 polymorphism differentially 
affected the some PSG measures and the EEG in our study population.
In conclusion, we have provided further evidence for trait-like individual differences within 
sleep and the EEG, and as such the EEG does effectively serve as a biomarker for individual 
differences. However, whether these individual differences relate only to phenomena o f the 
EEG or whether they relate to individual differences in sleep-wake regulation needs fiirther 
investigation.
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Chapter 1
Chapter 1 : Introduction
Sleep is a complex and diverse phenotype that is essential for life. It can be defined 
behaviourally as ‘a reversible behavioural state of perceptual disengagement from and 
unresponsiveness to the environment’ (Carskadon and Dement, 2011). Sleep and wakefulness 
can be characterized by the assessment o f a wide variety of physiological variables and based 
on the quantification of these variables it has become increasingly evident that there are 
substantial inter-individual differences in normal sleep physiology. Sleep, occurring at night, 
as well as during the day, can provide mueh information about these inter-individual 
differences and such differences become particularly evident when the sleep-wake regulatory 
system is ehallenged either through experimental sleep research, manipulations, or as a result 
of social and environmental factors.
The electroencephalogram (EEG) provides an objective means of assessing sleep-wake 
regulation and various characteristics o f the EEG can now be attributed to underlying 
physiological and neurochemical processes. Some EEG characteristics display trait-like inter­
individual differences, that is, those which are statistically significant, stable over time and 
robust to intervention and are also likely to arise fi*om a genetic origin (Van Dongen et al., 
2005). The notion that the EEG is one of the most heritable traits is supported by both human 
(van Beijsterveldt et al., 1996, De Gennaro et al., 2008) and animal research (Franken et al., 
1998, Franken et al., 1999, Franken et al., 2001) and understanding the phenotypic diversity 
of this trait will allow for a greater understanding of sleep-wake regulation.
A biomarker is a process that can be objectively measured and relates to the underlying 
proeesses. It has been proposed that the EEG may serve as a biomarker for individual 
differences in sleep-wake regulation and may reflect alterations in physiological and
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neurochemical processes as they may occur in both health and disease, and after behavioural 
or pharmacological interventions. The title o f the research presented in this PhD thesis is 
“The EEG as a biomarker for individual differences in the physiology and pharmacology of 
sleep-wake regulation”. The primary aim of the research was to better characterise individual 
differences in the EEG, including their stability during manipulations o f sleep through sleep 
deprivation and pharmacological interventions, and to establish how these individual 
differences in the EEG relate to processes involved in sleep-wake regulation.
1.1 The electroencephalogram
The EEG is a non-invasive measurement of electrical activity of the cerebral cortex whereby 
electrodes are attaehed to the surface of the scalp to detect voltage changes within the 
cerebral eortex which are then amplified and recorded. The earliest EEG work was carried 
out by Richard Caton who in 1875 reported electrical signals in the brains of animals. In 
1929, Hans Berger was the first to publish electrical brain activity in human subjects and 
since this time EEG analysis has developed into an invaluable method for both research and 
clinical diagnoses (Haas, 2003). By using EEG methods it is possible to obtain a 
representation of the brain’s ftinctional state and to quantify aspects of sleep regulation.
The EEG is typically recorded alongside the eleetromyogram (EMG) to record muscle tone 
and the electrooculogram (EOG) to record eye movements and these measures are 
collectively termed polysomnography (PSG). In order to assess the changes in the EEG 
various methods o f analysis have been developed. The two main methods that will be 
discussed here are visual scoring of the EEG and a quantitative EEG (qEEG) method known 
as spectral analysis.
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1.1.1 Visual scoring of electroencephalogram recordings
Visual scoring o f the EEG is a method of manually assigning stages to EEG recordings 
across the course of a period o f sleep. Rechtschaffen and Kales published the first uniform 
guidelines for assigning stages to the EEG recordings based on the frequency and amplitude 
of waveforms (Rechtschaffen and Kales, 1968). To visually score EEG recordings according 
to these criteria discrete 30 second sections called epochs, are considered at any one time and 
a stage is assigned to each epoch. The EOG and EMG are inspected to assist with 
determining the stage and detailed methods o f visual scoring of the EEG are described in 
Chapter 2.3.1. Whilst newer guidelines for staging sleep EEG recordings have been 
established such as the American Academy of Sleep Medicine (AASM) guidelines (Iber et 
al., 2007), these deviate very little from the original method of staging sleep.
1.1.2 Spectral analysis of electroencephalogram recordings
EEG patterns can be objectively evaluated using qEEG methods. The linear qEEG frequency 
analysis method, known as spectral analysis, is perhaps the most traditional method and 
assumes that EEG signals are stationary processes i.e. they do not vary over the segments 
analysed. Spectral analysis of the EEG is commonly conducted by using the Fast Fourier 
Transform (FFT) an algorithm first introduced in 1965 (Cooley and Tukey, 1965). FFT 
analysis is an efficient method of calculating the Discrete Fourier Transform (DFT) 
(reviewed in Thakor and Tong, 2004), which is used to extrapolate further information about 
the amplitude and frequency of waveforms within the EEG. Essentially the FFT takes the 
EEG signal as displayed as voltage across time and converts this into information about what 
voltages are present at different frequencies and a power (power = amplitude^) density 
spectrum is produced. Detailed methods o f spectral analysis o f the EEG are described in 
Chapter 2.3.2. Spectral analysis is a useful tool for quantifying the phenotypic diversity of
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sleep and the sleep EEG and owing to its high sensitivity it has been used extensively to 
assess drug efficacy (Luthringer et al., 1995) and drug safety (Bastien et al., 2003). It is 
therefore hypothesised that spectral characteristics of the EEG may serve as biological 
markers for processes underlying sleep-wake regulation as well as the inter-individual 
differences therein.
1.2 Manifestation of rhythmic brain oscillations
Waveforms observed within the EEG are a topographical depiction of the eleetrical activity 
occurring below the scalp which arises fi*om the pyramidal cells o f the cerebral cortex. The 
thalamus is connected to the cortex via reciprocal projections and is able to act as a 
pacemaker to the cortex (Bear et al., 2001, and reviewed in McCormick and Bal, 1997, 
Steriade, 2003). When pyramidal neurons become excited, voltage changes are elicited and 
can be measured at the level of the scalp and therefore the more synchronous the excitation 
is, the greater the amplitude o f the waves observed within the EEG (Bear et al., 2001). There 
are prominent individual differences in the amplitude and frequency of the waveforms, and 
recently these differences have been attributed to differences in anatomical differences such 
as volume and structure of white matter (Buchmann et al., 2011, Piantoni et al., 2013)
The brain alternates between three distinct vigilance states including wakefulness, non-rapid 
eye movement (NREM) sleep and rapid eye movement (REM) sleep. Across the vigilance 
states the EEG is characterised by distinctive waveforms of varying fi*equencies and 
amplitudes and these waveforms are classified according to the frequency range in which 
they fall and are given names fi'om the Greek alphabet (Bear et al., 2001). Whilst asleep our 
brain oscillates between NREM sleep and REM sleep and in the adult human it typically 
takes around 90 minutes to complete one NREM-REM sleep cycle (Carskadon and Dement,
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2011). Wakefulness and REM sleep are both characterised by desynchronised or tonic 
thalamocortical activity, which is reflected in the EEG as low amplitude, fast rhythms. 
During wakefulness and REM sleep, thalamocortical and thalamic reticular neurons are 
depolarised by brainstem structures involved in the ascending arousal system whieh causes 
cortieal activation and EEG rhythms are generated in the beta (20-3OHz) and gamma (30- 
60Hz) frequeney ranges (reviewed in McCormick and Bal, 1997, Steriade, 2003).
NREM sleep is eharacterised by synchronised thalamoeortical activity which results in high 
amplitude, slow rhythms within the EEG. Spindle waves and delta or slow-waves 
characterise NREM sleep and distinct thalamocortical mechanisms are involved in the 
generation of these waveforms (reviewed in Steriade et al., 1993a, Steriade, 2003). Spindles 
are seen during the early stages o f sleep and are generated in the thalamic reticular nucleus 
whereby spike-burst firing in the thalamic reticular nucleus causes inhibition of 
thalamocortical neurons (Steriade et al., 1985, Steriade et al., 1987). Two types of slow- 
waves are generated including clock-like waves and cortical waves. Clock-like waves are 
termed as such due to their pattern of expression and are intrinsically generated within the 
thalamus at a frequeney range l-4Hz. They involve the interplay between two inward 
thalamocortical currents to cause the hyperpolarisation of thalamic cells to a greater extent 
than occurs during the generation of sleep spindles (Steriade et al., 1991, Dossi et al., 1992, 
McCormick and Pape, 1990). Cortical waves are generated in the cortex at a frequency of 
<lH z and arise due to neurons cycling between depolarised and hyperpolarised states 
(Steriade et al., 1993b, Steriade et al., 1993c). The generation of spindles and slow-waves 
represents a progressive hyperpolarised state which occurs with the deepening o f sleep and 
the generation of such waveforms in thalamocortical systems inhibits sensory inputs to the
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cortex, allowing the individual to become disconnected from the environment (reviewed in 
McCormick and Bal, 1997, Steriade, 2003).
1.3 Neuronal mechanisms underlying sleep and wakefulness 
Whilst the function of sleep is not yet understood, several theories imply that sleep is for the 
repair and maintenance o f neurons and are based on use-dependent hypotheses. One theory is 
that sleep maintains and preserves populations of synapses critical for survival by stimulating 
them during sleep if  they are not sufficiently stimulated during wakefulness (reviewed in 
Krueger et al., 1995). Another theory is that of synaptic plasticity, whereby during 
wakefulness a net increase in synaptic weight is caused by the induction o f long-term 
potentiation genes and slow-wave sleep (SWS) is required for synaptic downscaling 
(reviewed in Tononi and Cirelli, 2003, Tononi and Cirelli, 2006).
Various types of neurotransmitters and neuromodulators are involved in sleep-wake 
regulation; some contribute to arousal systems, whilst others work in an opposite manner to 
induce sleep. An understanding of how these systems interact to induce waking, NREM and 
REM sleep not only provides and understanding of how the sleep-wake cycle is regulated on 
a neuronal level, but also provides a means for identifying targets for sleep-wake related 
pharmacologieal intervention.
1.3.1 Wakefulness
The brainstem reticular formation is fundamental in maintaining cortical activation and 
arousal via the ascending reticular activating system. The ascending reticular activating 
system is formed from two main neuronal branches which project from the basal forebrain, 
the hypothalamus and the brainstem and innervate the thalamus and the cerebral cortex to
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induce a desynchronised aroused state which inhibits the generation of synchronised low- 
frequency activity typical of NREM sleep (Figure 1.1).
The first ascending branch o f the ascending reticular activating system extends from the 
laterodorsal tegmental nuclei (LDT) and pedunculopontine tegmental nuclei (PPT) located in 
the upper brainstem region known as the pons. Acetylcholine (Ach)-producing neurons from 
the LDT and PPT innervate the thalamus, which relays information to the cerebral cortex to 
maintain wakefulness. The second branch o f the ascending arousal system originates from 
monoaminergic neurons in the brainstem and caudal hypothalamus, which project to the 
lateral hypothalamus (LH), the basal forebrain (BF) and the cerebral cortex to induce an 
aroused state. The monoaminergic neurons include noradrenaline (NA)-producing neurons in 
the locus coeruleus (LC), serotonin (5-HT)-producing neurons in the dorsal raphe nucleus 
(DRN), dopamine (DA)-produeing neurons in the ventral periaqueductal grey (vPAG) matter 
and histamine (His)-producing neurons in the tuberomammillary nuclei (TMN) o f the LH. 
These neurons fire rapidly during wakefulness, decrease firing during REM sleep and cease 
firing during NREM sleep. Additionally, peptidergic neurons also contribute to the second 
branch of the ascending arousal system, specifically orexins (ORX) released from the 
perifomical area (PeF) of the LH and melanin-concentrating hormone (MCH), also released 
from the LH, facilitate arousal (reviewed in Saper et al., 2001, Saper et al., 2005).
A reciprocal relationship is said to exist between wake-promoting and sleep-promoting 
neurons, whereby mutual inhibition allows for transition to either sleep or wakefulness. This 
reciprocal relationship has been described as a ‘flip-flop’ switch, and serves to minimise time 
spent in transitional states and when either side of the switch is weakened, the switch is 
pushed closer to its transition point, thereby causing more frequent transitions into both
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sleeping and waking (reviewed in Saper et al., 2001, Saper et al., 2005). ORX has been 
implicated as a stabiliser of the switch, but likely serves to reinforce the arousal system since 
the ventrolateral preoptic area (VLPO) involved in sleep does not possess ORX receptors 
(reviewed in Saper et al., 2001), and the link between ORX deficiency and narcolepsy 
provides further support for this theory (reviewed in Nunez et al., 2009).
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Figure 1.1: Neuronal networks regulating wakefulness
Components of the ascending reticular activating system can be divided into two branches. 
The first branch (orange) consists of the cholinergic (Ach) laterodorsal tegmental nuclei 
(LDT) and pedunculopontine tegmental nuclei (PPT) located in the pons of the upper 
brainstem project to the thalamic relay and thalamic reticular nuclei to facilitate 
thalamocortical transmission and induce arousal. The second branch (red) consists of 
monoaminergic cells groups including, noradrenaline (NA)-producing neurons in the locus 
coeruleus (LC), serotonin (5-HT)-producing neurons in the dorsal and median raphe nuclei, 
dopamine (DA)-producing neurons in the ventral periaqueductal grey (vPAG) matter and 
histamine (His)-producing neurons in the tuberomammillary nuclei (TMN) which project to 
the cerebral cortex. Peptidergic cell groups in the lateral hypothalamus including, melanin- 
concentrating hormone (MCH) and orexins (ORX), as well as GABAergic and cholinergic 
(Ach) cell groups in the basal forebrain (BF), also contribute to cortical activation during 
wakefulness (from Saper et al., 2005).
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1.3.2 NREM sleep
Neurons of the VLPO have been identified as those responsible for inducing sleep (Sherin et 
al., 1998, Gallopin et al., 2000). Lesions of the VLPO lead to insomnia, and a decrease in this 
cell population results in a proportional decrease in SWS (Lu et al., 2000). During NREM 
sleep the VLPO projects to neurons of the ascending arousal system to inhibit cortical arousal 
as occurs during wakefulness and REM sleep (Figure 1.2).
The VLPO is formed of dense cluster as well as an extended more diffuse network, known as 
the extended VLPO (eVLPO). Neurons of the VLPO produce the inhibitory neurotransmitters 
y-aminobutyric acid (GABA) and galanin (Gal) which project to the cholinergic, 
monoaminergic, and peptidergic cell groups that form the ascending reticular activating 
system and silence these cell groups during NREM sleep. It is likely that the suprachiasmatic 
nucleus (SON) activates neurons within VLPO (reviewed in Saper et al., 2001, Saper et al., 
2005, Luppi, 2010).
It has been postulated that entrance into NREM sleep is induced by the build-up of 
somnogenic substances such as adenosine (reviewed in Landolt, 2008, Bjomess and Greene, 
2009), which is known to increase with time awake and decrease during sleep (Porkka- 
Heiskanen et al., 1997) and has been implicated in the activation of VLPO neurons (Gallopin 
et al., 2005). Additionally, individuals who possess a genetic variant o f adenosine deaminase 
which results in a decreased ability to metabolise adenosine, display enhanced levels of slow- 
wave activity (SWA) (Retey et al., 2005).
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Figure 1.2: Neuronal networks regulating NREM sleep
The pathways regulating sleep involves inhibitory projections from the ventrolateral preoptic 
area (VLPO) to components of the ascending reticular activating system, y-aminobutyric acid 
(GABA) and galanin are released from the GABAergic cells of the VLPO which project to 
the cholinergic cell groups (orange), monoaminergic cell groups (red) and the peptidergic cell 
groups of the perifomical (PeF) area of the hypothalamus (green) (Saper et al., 2005).
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1.3.3 REM sleep
The generation o f REM sleep requires the activation o f several complex networks 
(Figure 1.3). Structures of the brainstem are necessary to induce and maintain REM sleep, 
specifically sublaterodorsal tegmental nucleus (SLD). The SLD contains two sub-populations 
of excitatory neurons, which were originally thought to be cholinergic but evidence now 
suggests they are glutamatergic. The first project rostrally to and are involved in cortical 
activation. The second project caudally and are responsible for muscle atonia during REM 
sleep (reviewed in Luppi et al., 2006).
It has been proposed that GABAergic and MCH containing neurons in the posterior 
hypothalamus (PH) gate REM sleep by inhibiting the GABAergic REM-off neurons in the 
vPAG and the dorsal deep mesencephalic nucleus (dDPMe) that tonically inhibit the SLD 
during wake and NREM sleep (reviewed in Luppi et al., 2013). Additionally, during REM 
sleep GABAergic neurons in the dorsal paragigantocellular nucleus (DPGi) and the vPAG 
also contribute to inhibition of the REM-off GABAergic neurons in the vPAG and dDPMe 
and also inhibit the monoaminergic neurons in the DRN and the LC. GABAergic and MCH 
containing neurons in the PH also inactivate ORX neurons in the PH and His neurons in the 
TMN (reviewed in Fort et al., 2009, Luppi et al., 2013). During REM sleep cortical activation 
is induced via excitatory glutamatergic (Glu) projections fi*om the SLD and cholinergic 
projections from the BF and the LDT and PPT, which innervate the cerebral cortex and the 
intralaminar thalamic nuclei. The caudal projections fi*om the SLD innervate premotor 
neurons in the raphe magnus (RMg), alpha (Gia) and ventral (GiV) gigantocellular and the 
lateral paragigantocellular (LPGi) reticular nuclei, which have GABAergic and glycinergic 
(Gly) projections to spinal motoneurons induce the muscle atonia characteristic o f REM sleep 
(reviewed in Fort et al., 2009, Luppi et al., 2013).
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Figure 1.3: Neuronal networks regulating REM sleep
Cortical activation during REM sleep arises from innervations from glutamatergic (Glu) 
sublaterodorsal tegmental nucleus (SLD), and cholinergic (Ach) laterodorsal tegmental nuclei 
(LDT), pedunculopontine tegmental nuclei (PPT) and the basal forebrain (BF) cell groups. 
Additionally, descending Glu projections from the SLD activates glycinergic (Gly) and 
GABAergic transmission from the raphe magnus (RMg), alpha (Gia) and ventral (GiV) 
gigantocellular and lateral paragigantocellular (LPGi) reticular nuclei and induces the muscle 
atonia typically present during REM sleep. During wakefulness and NREM sleep there is a 
tonic GABAergic transmission from the ventral periaqueductal grey (vlPAG) and dorsal deep 
meseneephalie nucleus (dDPMe) and during REM sleep this tonic transmission is inhibited 
by GABAergic transmission from the vlPAG and dDPMe and posterior hypothalamus (PH). 
GABA and Melanin-concentrating hormone (MCH) are also released from the PH to inhibit 
orexins (Hcrt) and histamine in the tuberomammillary nucleus (TMN). GABA transmission 
from the vlPAG and dorsal paragigantocellular nucleus (DPGi) inhibits monoaminergic 
neurons involved in wakefulness (from Luppi et al., 2013).
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1.4 Models of sleep-wake regulation
1.4.1 Two process model of sleep regulation
Models of sleep-wake regulation provide a means of clearly defining the processes involved 
in the maintenance of vigilance state. The two process model of sleep regulation devised by 
Alexander Borbély describes the interaction o f homeostatic (process S) and circadian 
(process C) processes which govern sleep and wakefulness (Figure 1.4) (Borbely, 1982, Daan 
et al., 1984, Borbely and Achermann, 1999). Sleep propensity is the probability at a given 
moment in time to fall or remain asleep, and this is mediated by a combination of process S 
and process C. Process S tracks time awake and it exponentially increases during 
wakefiilness, causing an increase of sleep pressure, and ensuing sleep mediates its 
dissipation. Process C promotes wakefulness and oscillates across a 24 hour period, when 
process C is at its highest it opposes process S and when process C declines it allows for 
sleep to occur (Borbely, 1982, Dijk and Czeisler, 1995). The interaction of process C and 
process S influences the timing o f the sleep-wake cycle and consolidates both sleep and 
wakefulness (reviewed in Dijk and Lockley, 2002). During the early evening hours the 
circadian pacemaker strongly promotes wakefulness and the propensity to sleep is very low, 
this short period of time is known as the wake maintenance zone (Cajochen et ah, 2002).
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Figure 1.4: Two process model of sleep regulation
The two process model of sleep regulation for baseline and extended periods of wakefulness. 
The model depicts the interaction between the circadian process (process C; green line) and 
the homeostatic process (process S) under baseline conditions (i.e. 16 hours of wakefulness; 
blue line) and under extended periods of wakefulness (i.e. 36 hours of wakefulness; red line). 
During the day process C serves to promote wakefulness and opposes process S which 
represents the propensity for sleep and exponentially increases with time awake. During the 
evening hours process C declines allowing sleep to occur (grey shaded areas) and thus 
process S declines. Slow-wave activity during sleep periods is a well-established 
physiological EEG marker of the rise and decline of process S (adapted from Borbely, 1982).
There are physiological markers o f both homeostatic and circadian processes which are 
evident in the EEG. SWA is a measure of sleep intensity and forms the basis of process S in 
the two process model of sleep-wake regulation and is perhaps the most robust sleep 
homeostatic marker in the EEG since it tracks prior sleep-wake history and does not appear to 
be affected by circadian phase (Dijk et al., 1987a, Dijk et a l, 1990a). Following total sleep 
deprivation there is a rebound in SWA (Dijk et a l, 1990b, Dijk et a l, 1993), whereas under 
sleep restriction protocols SWA is largely preserved (Brunner et a l, 1993, Akerstedt et a l, 
2009). Sleep spindles have an inverse relationship to slow-waves (Dijk et a l, 1993, Dijk et 
al, 1995) and are thought to be a marker of homeostatic changes when sleep pressure is high
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since following sleep deprivation spindles increase in amplitude and intra-spindle variability 
decreases indicating greater stability (Knoblauch et al., 2003). In the waking EEG there are 
also markers o f sleep homeostasis, for example, the presence of alpha and theta waves have 
been used as indicators o f homeostatic processes regulating sleep propensity (Cajochen et al., 
1995, Finelli et al., 2000).
Elements of the EEG are also influenced by circadian processes. For example, it is known 
that sleep spindles are under circadian regulation (Aeschbach et al., 1997a, Aeschbach et ah, 
1997b, Dijk et al., 1997). It is also known that REM sleep is under strong circadian control, 
peaking maximally just after the minimum of the core body temperature. The time course o f 
REM sleep is largely dependent on the phase at which sleep is initiated, if  it is initiated prior 
to the minimum of the core body temperature, REM sleep progressively increases over the 
course of the sleep period, however, if  sleep is initiated after the minimum core body 
temperature then the opposite effects are observed. In addition to circadian markers within 
the EEG the endogenous rhythm of the core body temperature and the endogenous rhythm of 
melatonin secretion display circadian rhythmicity (Dijk and Czeisler, 1995) and therefore 
both these physiological variables could be used to determine circadian phase. However, core 
body temperature is also sensitive to factors such as the menstrual cycle and activity. By 
contrast, melatonin, the pineal gland hormone, provides a reliable humoral link to the 
circadian system. In normally entrained individuals, melatonin is secreted during the dark 
phase at approximately 10-11pm, peaks at around 2-4am and falls to baseline levels in the 
morning. Melatonin is considered a robust physiological marker of circadian phase (reviewed 
in Lewy et al., 2006, Skene and Arendt, 2006).
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1.4.2 Extensions of the two process model of sleep regulation
Whilst the two process model is useful for predicting changes in SWA, various shortfalls of  
the model have led to its adjustment. Firstly, the cycling between NREM and REM sleep 
demonstrates that there is an ultradian process within sleep, a process that was not 
represented by the original two process model. The model has subsequently been adjusted to 
accommodate the ultradian dynamics o f sleep regulation (Achermann and Borbely, 1990). In 
addition, others have extended the two process model into a three process model to 
accommodate level of alertness, to enable prediction of performance when sleep is altered or 
disturbed (Akerstedt and Folkard, 1997). The model therefore has practical implications for 
individual work-rest schedules. The three process model encompasses not only prediction of 
daytime alertness (Akerstedt and Folkard, 1995), but other aspects such as sleep termination 
(Akerstedt and Folkard, 1996a) and sleep latency (Akerstedt and Folkard, 1996b).
Models of sleep-wake regulation are difficult to relate to physiology due to their being 
derived from sleep phenomena only. In an attempt to overcome these shortfalls Phillips and 
Robinson devised a model of the dynamics of sleep and wakefulness based directly on the 
ascending reticular activating system (Phillips and Robinson, 2007) (Figure 1.5). The 
cholinergic and monoaminergic neurons involved in cortical arousal and the VLPO neurons 
involved in sleep are considered in the model. The circadian drive is modelled by time and 
the homeostatic drive is modelled by levels of the somnogen adenosine which increase in the 
basal forebrain during wakefulness. The model focuses on the flip-flop switch mechanism to 
describe transitions between sleep and wakefulness and also includes a bistable zone, which 
allows for the co-existence of wake and sleep states. The model therefore explains the ability 
for sleep or wake states to occur at a timing that would not be usual and in such a way the 
model is able to predict phenomena such as narcolepsy (Phillips and Robinson, 2007). The
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model has been further developed to accurately predict recovery following sleep deprivation 
and is therefore a useful tool for optimising rest-activity sehedules (Phillips and Robinson,
2008).
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Figure 1.5: Phillips & Robinson model of sleep-wake dynamics
A) Neuronal populations of the ascending arousal system and B) sleep model proposed by 
Phillips & Robinson. Solid arrow heads indicate exeitatory pathways and open arrow heads 
indieate inhibitory pathways. In both A) and B) the top left and right boxes represent 
monoamine (MA) and aeetylcholine (Aeh) neuronal populations respeetively. In A) 
monoamine neuronal populations consist of the locus coeruleus (LC), dorsal raphe nucleus 
(DR) and the tuberomammillary nucleus (TMN) and acetyleholine neuronal populations 
eonsist of cholinergic laterodorsal and peduneulopontine tegmentum (LDT/PPT) and 
glutamatergic brainstem reticular formation (BRF). The GABAergie ventrolateral and 
extended ventrolateral preoptic area (VLPO/eVLPO) inhibits the ascending retieular 
activating system. The drive (D) in B) consists of homeostatic and circadian components. 
Thick black lines in B) represent interactions used in model (Figure from Phillips & 
Robinson, 2008).
1.5 Circadian clock regulation of sleep and wakefulness
The SCN of the anterior hypothalamus is the circadian pacemaker and serves as the ‘master 
clock’, synchronising peripheral oscillators throughout the body to regulate the circadian 
rhythm of various physiological variables, including the sleep-wake cycle, core body 
temperature, melatonin secretion and the transcription and translation of clock genes (Stephan 
and Zucker, 1972, and reviewed in Reppert and Weaver, 2001, Reppert and Weaver, 2002).
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The SCN is entrained by external time cues known as zeitgebers, the most potent of these 
being light (Zeitzer et al., 2000), which sets the circadian clock to an endogenous period of 
24.18 hours (Czeisler et al., 1999). The molecular mechanisms that underlie the genesis of  
circadian rhythms are complex and involve interactions between various genes and gene 
products. A number o f clock genes have been identified as having a role in the generation of 
circadian rhythms and the timing of the sleep-wake cycle; these include Clock, Bmall, 
Cryptochrome, (Cry) and Period (Per) genes (reviewed in Reppert and Weaver, 2002).
Molecular mechanisms o f the circadian clock in the SCN and in peripheral oscillators involve 
transcription-translation feedback loops which drive the circadian expression of key clock 
components (Figure 1.6). CLOCK and BMALl belong to the basic helix-loop-helix-PAS 
{Period-Arnt-Single-minded)-contSimmg transcription factor family and these are positive 
transcription factors involved in circadian timing. During the day CLOCK and BMALl form 
a dimer and bind to E-box promoter elements of Per and Cry genes to induce their 
expression. PER and CRY proteins are translated in the cytoplasm, where they are 
phosphorylated by casein kinase 1 8 (CKle) and casein kinase 1 5 (CKlô) which regulate 
protein turnover (reviwed in Ko and Takahashi, 2006, Takahashi et al., 2008). Depending on 
the phosphorylation site the proteins are either marked for degradation or their translocation 
back into the nucleus is enhanced (Akashi et al., 2002). PER and CRY dimerise in the 
nucleus to provide negative feedback on their own expression by inhibiting CLOCK and 
BMALl, this PER-CRY complex is degraded during the night and allows for a new cycle of  
expression to begin. The interaction of CLOCK and BMALl and the binding o f these 
transcription factors to promoter elements also causes Rev-erba and Rora to be transcribed, 
and whilst REV-ERBs negatively feeds back onto Bmall to inhibit its transcription, RORs 
forms a positive feedback loop which enhances transcription of Bmall (reviewed in Ko and
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Takahashi, 2006, Takahashi et ak, 2008). Several other candidate clock genes have been 
identified, including D ecl and Dec2, whose products are also basic helix-loop-helix 
transcription factors and whilst the roles of DECl and DEC2 have not been entirely 
established it is thought that they are inhibitors of the CLOCK-BMALl complex (Honma et 
al., 2002). These feedback loops set the endogenous period of the circadian clock.
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Chapter 1
1.6 Individual differences in sleep-wake regulation
There are prominent individual differences in sleep and they are particularly evident within 
the EEG. Merica and Gaillard (1985) were the first to comprehensively investigate inter­
individual differences in the EEG and demonstrate that the inter-individual variability was 
greater than intra-individual variability in both NREM and REM sleep (Merica and Gaillard, 
1985). Later studies have demonstrated that fi*equency components of the EEG are stable 
over repeated assessment (Tan et al., 2000, Tan et al., 2001, Buckelmuller et al., 2006), as 
well as robust to experimental manipulations such as sleep deprivation (Finelli et al., 2001, 
De Gennaro et al., 2005, Tinguely et al., 2006, Tucker et al., 2007).
Trait-like variability in sleep research, as well as in clinical sleep, is an area that is poorly 
researched. It is becoming increasingly important to study individual differences within sleep 
and also to identify which individual differences constitute traits since this will likely provide 
insights into the mechanisms underlying sleep-wake regulation as well as to the function of 
sleep. Individual differences are considered trait-like if  they can be demonstrated to be 
significant, stable over time and robust to experimental challenges, or if genetic influences 
can be demonstrated i.e. they are not merely state induced individual differences (Van 
Dongen et al., 2005). There is also a need to study individual differences in sleep in order to 
identify which traits constitute vulnerability in terms of cognition and performance following 
alterations in sleep-wake schedules, such as those caused by sleep loss (Van Dongen et al., 
2003, Van Dongen et al., 2004a, Rupp et al., 2012, Van Dongen et al., 2012) or shift work 
(reviewed in Van Dongen and Belenky, 2009). In addition, it is important to understand 
which individual differences in sleep increase or predict susceptibility to certain clinical 
disorders such as insomnia and depression (Krystal et al., 2002, Modell et al., 2002). 
Individual differences may be assessed in a variety of ways including investigation o f the
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stability and robustness of the EEG across experimental conditions using the Intraclass 
Correlation Coefficient (ICC) to calculate inter-individual variability. ICCs have been used 
across all age groups to demonstrate the stability of the EEG (Tucker et al., 2007, Geiger et 
al., 2011, Tarokh et al., 2011).
1.6.1 Genetics and the EEG
It is clear that brain oscillations are under strong genetic control and therefore they are able to 
be used as biomarkers in health and disease (reviewed in Begleiter and Poijesz, 2006) and 
twin studies have provided strong evidence for a genetic basis for the trait-like inter­
individual differences in sleep and the EEG (Partinen et al., 1983, van Beijsterveldt et al., 
1996, Linkowski, 1999, De Gennaro et al., 2008). It is already established that the circadian 
and homeostatic regulation of sleep is partially determined by genetic factors, indeed the 
genetic control of homeostatic sleep regulation has been demonstrated in inbred mice strains 
in several studies (Franken et al., 1998, Franken et al., 1999, Franken et al., 2001). An 
understanding of how genetic components regulate sleep and wakefulness may provide new 
insights about the function of sleep and may also explain some of the individual differences 
observed in healthy and pathological sleep (reviewed in Dauvilliers et al., 2005).
1.6.1.1 Genetic contributions to individual differences in human sleep
It is known that the circadian clock is in part responsible for the timing o f sleep and therefore 
it seems logical to investigate known circadian clock genes for their contribution to 
individual differences in sleep. Several gene polymorphisms have been identified as 
contributing factors to such individual differences. Diurnal preference for example is highly 
variable amongst individuals and may be due to differences in both homeostatic and circadian 
factors (Ishihara et al., 1987, Kerkhof and Lancel, 1991, Taillard et al., 2003, Mongrain et al..
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2006). The single nucleotide polymorphism (SNP) S l l lT ^ C  in CLOCK has been linked to 
diurnal preference in some studies (Katzenberg et al., 1998, Mishima et al., 2005), whereas 
others failed to detect any link with momingness and eveningness (Robilliard et al., 2002, 
Pedrazzoli et al., 2007) and so the contribution of this gene polymorphism, like many others, 
remains to be determined.
Polymorphisms in circadian clock genes also contribute to more extreme sleep phenotypes 
and sleep disorders. For example, a single nucleotide polymorphism in PER2 (C lllG ) has 
also been associated with diurnal preference whereby the frequency of the C allele was 
significantly more prevalent in those with extreme morning preference than those with 
extreme evening preference (Carpen et al., 2005). Similarly, a silent polymorphism in PERI 
(T2434C) has been linked to extreme diurnal preference, whereby the frequency of the C 
allele was significantly greater in extreme morning types compared with extreme evening 
types (Carpen et al., 2006). Familial advanced sleep phase syndrome (FASPS) is a circadian 
behavior whereby sleep onset is advanced by approximately 4 hours and a recent study has 
identified a missense mutation in the phosphorylation site in PER2 in individuals affected 
with FASPS (Toh et al., 2001). At the other end of the spectrum is delayed sleep phase 
syndrome (DSPS), whereby patients suffer from sleep onset insomnia and sleep at a much 
later time than the general population. A Variable Number Tandem Repeat (VNTR) 
polymorphism in the coding region of PERS results in different PER3 protein lengths and has 
been associated with DSPS (Ebisawa et al., 2001, Archer et al., 2003, Pereira et al., 2005). 
The gene coding for the enzyme arylalkylamine V-acetyltransferase (AANAT) plays a role in 
the synthesis of melatonin and in one study it was discovered that a single nucleotide 
polymorphism in this gene was also more prevalent in individuals with DSPS than the 
healthy controls (Hohjoh et al., 2003).
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The study of the contribution o f polymorphic genes to individual differences within the EEG 
is limited; however, some gene polymorphisms have been identified that contribute to inter­
individual variation within the EEG. It is thought that adenosine acts as a somnogenic 
substance regulating sleep homeostasis (reviewed in Landolt, 2008, Bjomess and Greene,
2009) and a polymorphism in the gene coding for adenosine deaminase (ADA) is the only 
other identified gene polymorphism, in addition to PER3, known to affect sleep architecture. 
The ADA polymorphism results in an increase in levels of adenosine and such individuals 
who possess the polymorphism display increased levels o f SWS (Retey et al., 2005). A 
polymorphism in the gene coding for the adenosine A2A receptor (AD0RA2A) has also been 
identified as a modulator of EEG generating mechanisms, and individuals with the 
polymorphic gene display increased power at 7.5-lOHz across all vigilance states (Retey et 
al., 2005). The gene coding for the enzyme catechol-O-methyltransferase (COMT) which 
contains a polymorphism (Lachman et al., 1996) that causes fi*equency specific variation in 
EEG power and those homozygous for the polymorphism display increased power in the high 
alpha range during wakefulness, NREM and REM sleep (Bodenmann et al., 2009).
Whilst some single gene mutations may cause certain sleep and circadian disorders or indeed 
induce susceptibility for certain disorders, it is likely that the interaction of several genes is 
causing the phenotypic variation observed in the population. The effect o f some 
polymorphisms on sleep-wake measures and the EEG has been characterised to some extent, 
but how exactly these genetic variations affect sleep-wake regulation is not fully understood 
and remains to be explored further.
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1.6.1.2 The Period genes: roles in sleep-wake regulation and contribution to 
individual differences in sleep
The Per gene family has been shown to play a central role in circadian rhythmicity and 
contributes to individual differences in sleep timing. Mice deficient in Perl and Per2 show 
severe circadian arrhythmia suggesting that these genes are likely to be involved in setting the 
periodicity of the circadian clock. (Bae et al., 2001). Additionally, Per2 deficient mice 
demonstrate altered Bmall rhythms, which indicate a role o f Per2 in the negative feedback 
loop to Bmal and Clock genes (Shearman et al., 2000b). Per3 deficient mice do not display 
any major circadian phenotype suggesting that the gene does not have a role essential to the 
core functioning of the circadian clock (Shearman et al., 2000a). Per3 deficient mice do 
however show decreased sensitivity to light, suggesting that Per3 is likely to be involved in 
light input pathways to the circadian clock (van der Veen and Archer, 2010).
Per3 was first described in 1998 (Takumi et al., 1998) and possesses a primate specific 
VNTR polymorphism in its coding region, whereby a 54-basepair sequence in the gene 
coding region is repeated either 4 or 5 times (Jenkins et al., 2005). The PER3 VNTR 
polymorphism has been implicated in diurnal preference and delayed sleep phase syndrome 
(Ebisawa et al., 2001, Archer et al., 2003, Pereira et al., 2005) and has consequently attracted 
much interest in an attempt to understand the roles of the gene in sleep-wake regulation and 
its contribution to individual differences. Archer et al., found that the 5-repeat allele was 
significantly more common in morning types than evening types and that patients with DSPS 
have a high frequency o f the 4-repeat allele (Archer et al., 2003). However, Pereira et al., 
found that in Brazil DSPS is associated with a significantly higher frequency of the 5-repeat 
allele (Pereira et al., 2005). The differing findings are likely due to environment and latitude, 
whereby the circadian clock has adopted latitude dependent entraining strategies, resulting in
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differing circadian phenotypes. This would therefore imply that DSPS sufferers could 
ameliorate their condition by moving latitude (Pereira et al., 2005). More recently it has been 
shown that there are PER3 genotype dependent differences in the circadian regulation of 
sleep (Lazar et al., 2012).
Trait-like individual differences in sleep likely have a genetic basis and therefore there is a 
need to identify predictors of vulnerability such as genetic polymorphisms. It is thought that 
the PER3 polymorphism contributes to some extent to individual differences within the EEG. 
It has been observed that individuals homozygous for the 5-repeat allele have higher levels of 
delta or SWA compared with individuals homozygous for the 4-repeat allele (Viola et al., 
2007, Goel et al., 2009, Viola et al., 2012). These individual differences observed in the EEG 
are markers of inter-individual differences in sleep homeostasis and indicate that the 
polymorphism has an influence on the process governing sleep-wake regulation. The PER3 
polymorphism also likely affects susceptibility to cognitive decline (Viola et al., 2007, 
Groeger et al., 2008). The contribution o f the PER3 polymorphism to individual differences 
within the EEG will be explored further within this thesis.
1.7 Thesis aims
The EEG is one o f the most heritable human traits and aspects o f it serve as biomarkers for 
circadian and homeostatic markers regulating sleep and wakefulness. There is however, 
considerable inter-individual variation within sleep and the sleep EEG, and this variation may 
constitute individual differences in sleep-wake regulation. The aim of this thesis was to 
investigate whether the sleep EEG can effectively serve as a biomarker for individual 
differences and to establish if  any of the individual differences observed constitute trait-like 
inter-individual differences. In order to assess whether observed individual differences in
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sleep and the sleep EEG are trait-like, various experimental intervention protocols will be 
used to calculate the ICC as a measure of variance, including 1) a study investigating the 
effects o f sleep extension, sleep restriction and total sleep deprivation on sleep and the EEG 
2) a study investigating different polychromatic light mixtures on sleep and the EEG, and 3) a 
study investigating the effects o f temazepam, zolpidem and prolonged-release melatonin on 
sleep and the EEG. In addition, in order to address the need for identifying genes underlying 
trait-like inter-individual differences, the contribution of the PERS polymorphism to the 
EEG, which has not previously been measured in response to sleep extension or chronic 
partial sleep restriction conditions, will be investigated in the first protocol. It was 
hypothesised that there would be trait-like inter-individual differences within aspects o f sleep 
and the sleep EEG, that were stable across time and robust to the interventions present within 
each study. It was also hypothesised that some of the variance within the data could be 
explained by the PER3 VNTR polymorphism.
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Chapter 2: General Methods
2.1 Actigraphy
An actiwatch is a small wrist worn device that allows monitoring of activity-rest cycles by 
measuring body movement. The device contains a piezo-electronic accelerometer that detects 
movement in all directions and digitally captures the activity o f the wearer. The device 
samples the amplitude o f movement several times per second and then captures the highest 
amplitude sampled in that second, and the amplitude captured is proportional to the intensity 
of movement. Data per second is then summed over a defined time period, typically 1 minute 
epochs.
Data captured on the actiwatch is viewed on an actogram whereby the intensity of movement 
per epoch is plotted against time. When visualising actigraphy data collected over long 
periods of time it is typical to view it on a double-plotted actogram (Figure 2.1), whereby two 
24 hour periods are displayed on each line of the actogram and the second 24 hour period on 
each line is repeated at the beginning of the following line. Double plotted actograms allow 
periods of sleep and wakefulness to be easily deduced, wakefulness is characterised by 
periods of high intensity movements, and periods of rest or sleep are characterised by periods 
of very little or no movement.
In all studies described in this thesis a wrist actiwatch was worn by participants, with each 
study having a specific actiwatch protocol and the detailed actiwatch protocols is described 
individually for each study in relevant chapters.
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Figure 2.1: Double-plotted actogram
A double-plotted actogram depicting periods of activity and rest recorded by a wrist 
actiwatch (Actiwatch-L®; Cambridge Neurotechnology Ltd, Cambridge, UK) worn for 
approximately one week. Black vertical lines represent the intensity of activity recorded over 
consecutive 1 minute epochs. Yellow shading behind the black vertical lines represents 
external light intensity detected by a sensor located on the face of the actiwatch. The light 
presence of a light sensor is dependent on the model of actiwatch.
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2.2 Recording polysomnography
Polysomnography (PSG) measures comprising the electroencephalogram (EEG), 
electromyogram (EMG) and electrooculogram (EOG) were recorded throughout scheduled 
sleep periods in each study described in this thesis. In addition, PSG was recorded during 
some periods of wakefulness where alertness was being assessed.
In each study the internationally standardised 10-20 electrode placement system was used to 
determine positioning of surface electrodes on participants’ scalps (Malmivuo and Plonsey, 
1995), see Figure 2.2 for an overview of the 10-20 electrode placement system. The EEG 
electrode montage used for each study will be described for each study separately in relevant 
chapters. EOG electrodes were placed at the outer canthus o f the left (LOG) and right (ROC) 
eyes and two EMG leads were placed under the chin to record muscle tone. All electrode 
impedances were checked for a reading o f < 5KO at the beginning of each PSG recording in 
order to ensure that all EEG recordings were of optimum quality.
Sleep and wake PSG measures were recorded using either Siesta 802 devices (Compumedics 
Ltd., Abbotsford, Victoria, Australia) and Vitaport 3 recorders (Temec Instruments B.V., 
Kerkrade, The Netherlands). The sampling and storage rates were 256Hz for both Siesta and 
Vitaport recordings. Filters were applied to all EEG signals in order to eliminate any non- 
physiological high frequency or low frequency activity. The low-pass filter was set to 70Hz 
for both recording devices and the high-pass filter was set to 0.3Hz and 0.159Hz for Siesta 
and Vitaport devices respectively. Data from Siesta devices was captured and stored directly 
onto a server and viewed with ProFusion PSG software (Compumedics Ltd., Abbotsford, 
Victoria, Australia). Data from Vitaport systems was stored on a memory card before being
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manually downloaded into Vitaport data (VPD) files and viewed with Columbus software 
(Temec Instruments B.V., Kerkrade, The Netherlands).
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Chapter 2
2.3 Polysomnography data analysis
2.3.1 Staging polysomnography recordings
PSG data in this thesis were visually scored according to the criteria set by Rechtschaffen and 
Kales (Rechtschaffen and Kales, 1968) by either qualified Registered Polysomnographic 
Technologists (RPSGT’s) or the author of this thesis who received full training by RPSGT 
qualified staff prior to scoring, and this was quality controlled by means of checking -10% of 
PSG recordings for 90% scoring concordance with qualified staff. Staging o f sleep EEG 
recordings captured using Siesta 802 devices was performed in ProFusion PSG software 
(Compumedics Ltd., Abbotsford, Victoria, Australia). Discrete epochs of 30 seconds were 
assigned one stage including wake, non-rapid eye movement (NREM) sleep stage 1, NREM 
sleep stage 2, NREM sleep stage 3, NREM sleep stage 4 or rapid eye movement (REM) 
sleep, and the staged hypnograms were then analysed to provide information on various PSG 
variables. See Figures 2.3-2.8 for 30 second epoch examples o f EEG, EMG and EOG 
derivations during wakefulness and sleep and the typical characteristics associated with each 
stage.
2.3.1.1 Polysomnography characteristics of wakefulness and sleep stages
2.3.1.1.1 Wakefulness
The waking EEG typically comprises low-amplitude, mixed frequency waves and is defined 
by the presence o f beta (>14Hz) and alpha (8-13Hz) waves and is typically accompanied by 
high muscle tone which is observed in the EMG and eye blinks which are observed in the 
EOG. When the eyes are closed and a state o f drowsiness is entered, there is an increase in 
the presence of alpha waves which are most prominent in the occipital derivations, whilst 
beta waves dissipate (Figure 2.3) (Rechtschaffen and Kales, 1968, Iber et al., 2007).
Page 49 of 257
Chapter 2
2.3.1.1.2 NREM sleep
NREM sleep is sub-divided into stages 1 , 2 , 3  and 4; and the latter two are eollectively 
termed slow-wave sleep (SWS) (Reehtschaffen and Kales, 1968, Hori et al., 2001). The 
transition period between wakefulness and sleep is referred to as sleep stage 1. This sleep 
stage is the lightest stage of sleep and is characterised by low-amplitude, mixed frequency 
waves that are typically 2-7Hz. Vertex sharp waves, lasting <0.5 seconds, may also be 
observed within the EEG derivations. Slow rolling eye movements observed within the EOG 
derivations are also a common indicator o f the transition from wakefulness to sleep 
(Figure 2.4) (Rechtschaffen and Kales, 1968, Hori et al., 2001, Iber et al., 2007).
Sleep stage 2 occupies approximately half of the night’s sleep. The appearance of rhythmic 
bursts known as spindles in the frequency range of 12-16Hz that last for >0.5 seconds, is 
characteristic of stage 2 sleep. Sleep spindles are most prominent in central derivations. 
Another common feature of stage 2 sleep is K-complexes, which are most prominent in 
frontal derivations. K-complexes are distinct negative sharp waves immediately followed by 
a positive deflection and last for >0.5 seconds (Figure 2.5) (Rechtschaffen and Kales, 1968, 
Hori et al., 2001, Iber et al., 2007).
SWS is identified by the presence of high-amplitude, low-frequency delta waves or ‘slow- 
waves’, in the frequency range of 0.5-4.5Hz. Slow-waves typically have peak to peak 
amplitudes of >75pV and the amplitude is usually maximal in frontal derivations. Stages 3 
and 4 are defined by slow-waves occupying 20-50% and >50% of a 30-second epoch 
respectively (Figures 2.6 and 2.7) (Rechtschaffen and Kales, 1968, Hori et al., 2001). The 
newer AASM guideline for scoring do not include stage 4, instead stage 3 is scored when 
slow-waves occupy >20% of a 30-second epoch (Iber et al., 2007).
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2.3.1.1.3 REM sleep
The most prominent feature o f REM sleep, also known as paradoxical sleep, is rapid 
movement of the eyes, indicating how this sleep stage obtained its name. The EEG during 
REM sleep is very similar to the EEG during stage 1 sleep with low-amplitude, mixed 
frequency waves and there is prominent alpha activity. Saw-tooth waves with a frequency of 
2-6Hz are also often present during REM sleep. REM sleep is associated with muscle atonia, 
so that dreams are not actualised and therefore low EMG tone is also characteristic of REM 
sleep (Figure 2.8) (Rechtschaffen and Kales, 1968, Hori et al., 2001, Iber et al., 2007).
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Figure 2.3: Eyes closed wakefulness
PSG derivations recorded during eyes closed wakefulness. Derivations from top to bottom 
represent right EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4- 
A l), right occipital EEG derivation (02-A l) and average left and right EMG. Wakefulness is 
characterised by alpha activity which is most prominent in the occipital derivation (indicated 
underneath 02-A l derivation by arrow) and high muscle tone (indicated underneath EMG 
derivation by arrow).
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Figure 2.4: Stage 1 sleep
PSG derivations recorded during stage 1 sleep. Derivations from top to bottom represent right 
EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4-A1), right 
occipital EEG derivation (02-A l) and average left and right EMG. Stage 1 sleep is 
characterised by slow-rolling eye movements (indicated underneath EOG derivation by 
arrow) and low-amplitude, mixed frequency activity observed across all EEG derivations.
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Figure 2.5: Stage 2 sleep
PSG derivations recorded during stage 2 sleep. Derivations from top to bottom represent right 
EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4-A1), right 
occipital EEG derivation (02-A l) and average left and right EMG. Stage 2 sleep is 
characterised by k-complexes (indicated underneath F4-A1 derivation by blue arrow) and 
sleep spindles (indicated underneath F4-A1 derivation by red arrow)
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Figure 2.6: Stage 3 sleep
PSG derivations recorded during stage 3 sleep. Derivations from top to bottom represent right 
EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4-A1), right 
occipital EEG derivation (02-A1) and average left and right EMG. Stage 3 sleep is 
characterised by high-amplitude slow-waves that occupy 20%-50% of a 30-second epoch and 
are most prominent in the frontal derivations (indicated underneath derivation F4-A1 by 
arrow).
Page 53 of 257
Chapter 2
,F4-.
W
C4-A1
02^A1,
V'/\-
EMG
», A'rxi
Figure 2.7: Stage 4 sleep
PSG derivations recorded during stage 4 sleep. Derivations from top to bottom represent right 
EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4-A1), right 
occipital EEG derivation (02-A l) and average left and right EMG. Stage 4 sleep is 
characterised by high-amplitude slow-waves that occupy >50% of a 30-second epoch and are 
most prominent in the frontal derivations (indicated underneath derivation F4-A1 by arrow).
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Figure 2.8: REM sleep
PSG derivations recorded during REM sleep. Derivations from top to bottom represent right 
EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4-A1), right 
occipital EEG derivation (02-A1) and average left and right EMG. REM sleep is 
characterised by rapid eye movements (indicated underneath EOG derivation by arrow) and 
low muscle tone (indicated underneath EMG derivation by arrow).
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2.3.2 Quantitative EEG analysis
Quantitative EEG (qEEG) provides a means of objectively evaluating EEG patterns. The 
linear qEEG frequency analysis method known as spectral analysis is perhaps the most 
traditional method for quantitative analysis o f the EEG. Spectral analysis is an algorithm first 
introduced in 1965 (Cooley and Tukey, 1965), the Fast Fourier Transform (FFT), which is an 
efficient method of calculating the Discrete Fourier Transform (DFT) (reviewed in Thakor 
and Tong, 2004). Spectral analysis is commonly used in conjunction with visual scoring 
methods in order to extrapolate further information about the power of frequencies within the 
EEG. This is achieved by producing a power density spectrum, in which the power within 
defined frequency ranges is calculated.
Following completion of manual staging PSG recordings were exported from ProFusion PSG 
software as European data format (EDF) files and the staged hypnograms were exported as 
text files. The EDF files and staged hypnograms were imported into Vitascore software 
version 1.40 (RC.l) (Temec Instruments, B.V., Kerkrade, The Netherlands) for artefact 
removal prior to performing FFT spectral analysis. For studies where wake PSG recordings 
were obtained, data were imported into Vitascore in EDF format and manually staged as 
wake therein. EEG data within Vitascore were viewed in 30 second epochs.
2.3.2.1 Artefact removal
When recording PSG measures, there may be a variety of ways in which the EEG can 
become distorted by artefacts, these are imperfections within a recording that do not 
constitute physiological EEG characteristics. Common types o f artefact include dermal 
artefacts caused primarily by skin moisture (Figure 2.9) which increases electrode impedance 
and results in a low frequency drifting in the EEG derivations, sharp eye movements during
Page 55 of 257
Chapter 2
wake and REM sleep can result in large deflections in nearby EEG electrodes (Figure 2.10), 
major body movements can cause high frequency noise across EEG derivations (Figure 2.11) 
and the pulling of electrodes may cause deflections within EEG derivations.
Given that spectral analysis quantifies the power of waveforms across a frequency spectrum 
it was essential to remove all artefacts from the EEG derivations prior to performing the FFT, 
so as not to influence the power density spectra. Within Vitascore EEG derivations within 
each 30 second epoch o f data were visually inspected for artefacts in order to ensure data 
were clean prior to the FFT spectral analysis. Artefacts within the EEG derivations were 
manually highlighted, and subsequently EEG sub-epochs (see Chapter 2.3.2.2 for sub-epoch 
duration) containing areas highlighted as artefacts were automatically excluded from FFT 
analysis by Vitascore.
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Figure 2.9: Drift artefact
PSG derivations recorded displaying drift artefact. Derivations from top to bottom represent 
right EOG, right frontal EEG derivation (F4-A1), right central EEG derivation (C4-A1), right 
occipital EEG derivation (02-A l) and average left and right EMG. Grey shaded areas of the 
EEG derivations indicate areas highlighted for exclusion from FFT spectral analysis. Drift 
artefact occurs with dermal moisture, increasing eleetrode impedance and results in a low 
frequency drifting pattern across affected EOG and EEG derivations.
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Figure 2.10: Sharp eye movement artefact
PSG derivations recorded displaying sharp eye movement artefacts. Derivations from top to 
bottom represent right EOG, right frontal EEG derivation (F4-A1), right central EEG 
derivation (C4-A1), right occipital EEG derivation (02-A1) and average left and right EMG. 
Grey shaded areas of the EEG derivations indicate areas highlighted for exclusion from FFT 
spectral analysis. Sharp eye movement artefacts typically occur during wake or REM sleep 
when the eyes are rapidly moving. Large eye movements cause deflections in neighboring 
EEG derivations.
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Figure 2.11: Major body movement artefact
PSG derivations recorded displaying major body movement artefact. Derivations from top to 
bottom represent right EOG, right frontal EEG derivation (F4-A1), right central EEG 
derivation (C4-A1), right occipital EEG derivation (02-A l) and average left and right EMG. 
Grey shaded areas of the EEG derivations indicate areas highlighted for exclusion from FFT 
spectral analysis. Body movement causes contraction of the muscles which produces an 
electrical signal which often interferes with the EEG derivations, resulting in high frequency 
noise across the trace.
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2.3.2.2 FFT spectral analysis
Following manual artefact removal o f entire recordings, FFT spectral analysis was performed 
on discrete epochs known as sub-epochs for all EEG derivations. The sub-epoch window for 
sleep EEG derivations was 4-seconds, which resulted in a power spectra resolution of 
0.25Hz. The sub-epoch window for wake EEG derivations was 2-seconds, which resulted in a 
power spectra resolution of O.SElz. The 2-second sub-epoch window used for wake EEG 
gives a higher time resolution which allows for detection of faster changes occurring within 
the waking EEG.
Data were exported from Vitascore in two ASCII file formats per EEG derivation analysed. 
The first was the STGSP file type which provided power spectra for each EEG derivation per 
0.25Hz or 0.5Hz bin and per 8 user defined frequency bands across the spectrum up to 32Hz. 
In this format the power spectra data were available over various segments o f the EEG 
recording including the entire recording, per thirds o f the recording or per hour o f the 
recording. The second file type was the PASCI file which provided power spectra for each 
EEG derivation per 0.25Hz bin and per 8 user defined frequency bands across the spectrum 
up to 32Hz, on an epoch by epoch basis. Therefore the spectra are generated for each 30- 
second epoch within a recording.
For each study within this thesis export settings for the 8 traditional EEG frequency bands 
were 0.25-0.5Hz (low-delta), 0.75-4.5Hz (delta), 4.75-7.75Hz (theta), 8.0-11.75Hz (alpha), 
12.0-14.75Hz (sigma), 15.0-19.75Hz (beta-1), 20.0-24.75Hz (beta-2), 25.0-32.0Hz (beta-3) 
for sleep recordings and 0.5-0.75Hz (low-delta), 1.0-4.75Hz (delta), 4.75-9.25Hz (theta), 9.5- 
11.75Hz (alpha), 12.0-14.75Hz (sigma), 15.0-19.75Hz (beta-1), 20.0-24.75Hz (beta-2), 25.0- 
32.0Hz (beta-3) for wake EEG recordings.
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2.4 Preparation of power spectra for analysis
To collate data exported from Vitascore the power density values within the STGSP output 
files generated from FFT spectral analysis were extracted and tabulated using individually 
tailored SAS® software programs (SAS Institute Inc., Cary, NC, USA) for each study. Power 
spectra data for all derivations and nights/days within a study were then available within one 
SAS® generated table which could then be used within SAS® to visualise data and perform 
analyses.
The default option for calculating wave amplitude within Vitascore software is top-top, also 
known as peak-to-peak, which is the measure from the change in voltage between the peak 
and the trough o f a sine wave. However, it is more common to describe amplitude in terms of 
zero-top which is the change in voltage from the mid-point of a wave (0 volts) to the peak of 
a wave. Power values derived from spectral analysis are the square o f the amplitude 
(amplitude^); therefore power values generated from Vitascore in all studies were divided by 
4 so that power represented the square o f zero-top amplitude.
A further correction factor was applied to power values from Vitascore regarding frequency. 
Data were exported from Vitascore as 0.25Hz or 0.5Hz bins for sleep and wake EEG 
derivations respectively and in order to be able to convert power units to pV^/Hz, 2 or 4 
consecutive bins were averaged and the first bin was excluded from each study because the 
lowest frequency bin is known to be particularly sensitive to artefacts. The same principle 
was applied to power values for each of the 8 frequency bands automatically calculated 
within Vitascore, since these were simply an addition of the 0.25Hz or 0.5Hz bins contained 
within them, the bands were subsequently divided by the number of bins contained within 
them.
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2.5 Visualisation of EEG spectral analysis data
Data derived from FFT spectral analysis has been presented in several ways throughout this 
thesis, including frequency spectra where power density is plotted against frequency on the x- 
axis and time course where power density is plotted against time on the x-axis. For each type 
of presentation o f data, absolute power values were transformed to the base-10 logarithm 
(Log^ )^ in order to more clearly see differences between treatments, conditions and/or groups 
of participants.
In order to assess magnitude of the response to the interventions implemented in the studies 
presented in this thesis, some of the figures display a condition or group of individuals 
expressed as a percentage of a baseline night or placebo condition. For EEG spectral analysis 
data, geometric means were calculated whereby Log^  ^ transformed power density values of 
baseline night or placebo condition were subtracted from power density values of the night or 
condition to be expressed against baseline or placebo within an individual where possible. 
Values were then averaged across individuals before being retransformed and multiplied by 
100, so as that the baseline or placebo values represented 100% and all other data were 
expressed as a relative percentage.
2.6 Statistical analyses
To assess whether there were significant differences between conditions and/or groups of 
individuals described within this thesis, the differences between PSG measures/log^^ EEG 
power density values for conditions and/or groups of individuals were compared by 
performing paired and/or unpaired t-tests using FROG TTEST in SAS® or performing a 
general linear mixed models using PROG MIXED in SAS®, whereby the effects o f  
experimental condition and period (the visit number at which each experimental condition
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occurred i.e. the order o f the experimental conditions) were controlled for. Night was also 
controlled for within studies where there was more than one night within each experimental 
condition, as was PER2> genotype where studies allowed.
In order to determine whether inter-individual variability is trait-like, according to Van 
Dongen it must be shown to be significant, stable over time and robust to intervention (Van 
Dongen et ah, 2005) and the intraclass correlation coefficient (ICC) provides a means of 
quantifying whether these criteria have been met. The stability and robustness of inter­
individual differences in each study presented in this thesis was assessed by calculating the 
ICC, by means of taking the ratio of between-subject variance to total variance and the 
greater the between-subject variance is relative to the within-subject variance the closer the 
ICC value is to 1.0. This method of calculating the ICC is described by Van Dongen (Van 
Dongen et ah, 2004b), see equation below.
ICC =
0-6S+ ^ w s
Throughout this thesis ICCs were calculated for the PSG measures, 8 traditional EEG 
fi-equency band ranges (described in Chapter 2.3.2.2) and/or for individual IHz bins across 
the EEG frequency spectrum up to 32Hz, by inputting data into a general linear mixed model 
using PROC MIXED in SAS®. The effects o f experimental condition and period, as well as 
night (where studies allowed), were controlled for in order to assess whether variances within 
the data could be explained by trait-like inter-individual differences. The covariance 
parameters estimated by the mixed model were used to calculate the ICC, whereby the 
estimate for between subject variance was divided by the sum of the estimates for between
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and within subject variance. For studies where multiple nights o f data were available for each 
experimental condition a repeated statement was included in the mixed model which 
specified a variance-covariance matrix. The ICCs presented in this thesis were compared with 
previously defined benchmark ranges for the interpretation of such data (Landis and Koch, 
1977).
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Chapter 3: Biomarkers and individual differences: Effects of sleep extension, 
sleep restriction and total sleep deprivation on sleep and wakefulness
3.1 Introduction
The electroencephalogram (EEG) is one o f the most heritable traits and it is known to be 
under strong genetic control (van Beijsterveldt et al., 1996, De Gennaro et al., 2008, and 
reviewed in Begleiter and Poijesz, 2006) and various components of the EEG have been 
shown to be highly stable within individuals (Merica and Gaillard, 1985, Finelli et al., 2001, 
De Gennaro et al., 2005, Buckelmuller et al., 2006, Tinguely et al., 2006). The EEG is widely 
used in sleep research, however, there are prominent individual differences in sleep and 
exploration of such individual differences is now becoming an important area of research.
Understanding individual differences within sleep, particularly in response to sleep loss, is 
important because such individual differences may relate to individual differences in 
susceptibility to cognitive decline (Viola et al., 2007, Groeger et al., 2008) as well as certain 
health problems already known to be linked to sleep such as diabetes (Tasali et al., 2008, 
Robertson et al., 2013, and reviewed in Trenell et al., 2007). Many individual differences can 
be considered trait-like and Van Dongen and colleagues have set criteria for characterising 
such inter-individual differences observed within sleep, which should be shown to be 
significant, stable across time, robust to intervention, and if  possible a genetic influence 
should be demonstrated (Van Dongen et al., 2005).
The use o f sleep restriction and total sleep deprivation protocols enables investigation o f the 
processes regulating sleep and wakefulness and therefore provides a means for establishing 
trait-like individual differences. There are many aspects of the EEG that can be objectively
Page 64 of 257
Chapter 3
measured as a means of assessing processes underlying sleep-wake regulation. For example, 
slow-wave activity (SWA) is a classical marker of sleep homeostasis that tracks prior 
wakefulness (Dijk et al., 1987a, Dijk et al., 1990a), and following total sleep deprivation a 
rebound o f SWA can be observed in the EEG on subsequent recovery nights (Dijk et al., 
1990b, Dijk et al., 1993). Interestingly, under sleep restriction conditions imposed for 2-5 
days, nocturnal SWA is largely preserved (Brunner et al., 1993, Akerstedt et al., 2009). 
Similarly, homeostatic markers o f sleep-wake regulation can be found in the waking EEG, 
for example theta/alpha activity is known to rise during the day with increasing wakefulness 
(Cajochen et al., 1995, Aeschbach et al., 1997b).
Trait-like individual differences in sleep are likely to arise from a genetic origin and various 
polymorphic genes have been identified as contributing factors to such individual differences 
in sleep. Such genes include those involved in the circadian regulation of sleep and 
wakefulness, including CLOCK and PERIOD (PER) genes and also includes those involved 
with the regulation o f adenosine such as adenosine deaminase (ADA) which breaks down 
adenosine and the adenosine A2A receptor (AD0RA2A) (Landolt and Dijk, 2010). The 
contribution of the adenosine system to individual differences in sleep is perhaps not 
surprising given the purported role o f adenosine in sleep homeostasis (Landolt, 2008). The 
PER genes are known to have a central role in the regulation of circadian rhythmicity 
(Albrecht et al., 1997, Bae et al., 2001) and in mammals the PER gene family contains three 
genes, PERI, PER2 and PER3. PER3 was identified in 1998 (Takumi et al., 1998) and 
possesses a Variable Number Tandem Repeat (VNTR) polymorphism (RS57875989) within 
its coding region that is specific to primates (Jenkins et al., 2005). The polymorphism 
contains either 4 or 5 repeats of a 54-basepair sequence, resulting in three polymorphic 
variants o f the gene: PER3^ ^^  PER3 '^  ^ and PER3 '^  ^ that have been linked to diurnal preference
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and delayed sleep phase syndrome (DSPS) (Archer et ah, 2003, Pereira et al., 2005). PER3 is 
expressed primarily within the suprachiasmatic nucleus (SON) but also other areas o f the 
brain such as the organum vasculosum lamina terminalis (OVLT) (Takumi et al., 1998), an 
area of the brain likely to be involved in sleep-wake regulation (Uschakov et al., 2006) and 
therefore there has been considerable recent effort into understanding the contribution of 
PER3 to sleep-wake regulation. It is thought that the polymorphism contributes to some 
extent, to individual differences observed within the EEG and the polymorphism has recently 
been shown to affect sleep homeostasis (Viola et al., 2007, Goel et al., 2009, Viola et al., 
2012), as well as susceptibility to the detrimental effects of sleep loss (Groeger et al., 2008, 
Vandewalle et al., 2009).
The primary aim was to assess the effects of sleep extension, sleep restriction and total sleep 
deprivation under constant routine conditions on polysomnography (PSG) measures and the 
spectral composition of the EEG; and to test the hypothesis that aspects of sleep would be 
stable over time and robust to intervention, thereby identifying trait-like inter-individual 
differences within the EEG. The secondary aim was to test the hypothesis that some inter- 
individual differences within the EEG could be explained, at least in part, by the PER3 
VNTR polymorphism by stratifying the study population based on their PER3 genotype. 
Other aims were to investigate aspects o f sleep homeostasis in the sleep and wake EEG.
3.2 Methods
The study presented in this chapter was conducted at the Surrey Sleep Research Centre and 
the study protocol was approved by the Institutional Review Board of the Air Force Research 
Laboratory and was reviewed by the University of Surrey Ethics Committee and received a 
favourable opinion in November 2008.
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3.2.1 Participants
3.2.1.1 Screening phase
After giving written informed consent 364 healthy men and women (225 men) aged 20-35 
years, completed a series of questionnaires including a general medical questionnaire, the 
Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Big Five 
Personality Questionnaire, the Positive and Negative Affect Scale (PANAS), the Insomnia 
Severity Scale, the Home-Ostberg Diurnal Preference Scale, The Munich Chronotype 
Questionnaire (MCQ), the SF36 Health Survey, the Surrey Sleep Survey, an assessment of IQ 
(Ravens), a verbal reasoning task, the Karolinska Sleep Diary (KSD), the Karolinska 
Sleepiness Scale (KSS), the Social Rhythm Metric diary, the Behavioural 
Inhibition/Behavioural Approach Systems questionnaire and the Dutch Eating Behaviour 
questionnaire. Responses to questionnaires determined suitability for participation in the 
laboratory study and also provided a database of subjective measures.
A buccal swab was obtained from participants to determine their PER3 genotype. The buccal 
swabs were processed by extracting the cells from the swabs, performing a polymerase chain 
reaction (PCR) protocol to extract the DNA and then running the DNA in an electrophoresis 
gel, the exact procedures are those previously described (Vandewalle et al., 2009). Variants 
of the genotype include homozygosity for the 4-repeat allele (FERj"^ )^, homozygosity for the 
5-repeat allele (PER3^^ )^ or a heterozygous genotype (PER3'^ ^^ ).
3.2.1.2 Sleep laboratory phase
A total o f 36 individuals were selected to participate in the laboratory study; 12 PER3'^ '^^  
participants (mean age 27.1 years, SD 4.4), 10 PER3'^ ^^  participants (mean age 27.5 years, SD 
3.5) and 14 PER3^ ^  ^participants (mean age 28.1 years, SD 4.2). One participant took part in
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only one laboratory session, one participant withdrew on the sixth day of their second 
laboratory session and one participant withdrew during the constant routine o f their second 
laboratory session at approximately 11:00 hours (day 2 of the constant routine). One 
participant did not have PSG recorded on the overnight on one occasion (extension condition 
night 5) due to skin irritation caused by electrode placement.
The sleep laboratory phase consisted of two laboratory sessions and enrolment in the study 
required subjects to be eligible in accordance with strict inclusion criteria and to comply with 
study related restrictions. Participants were in good health, were not taking any medication 
(excepting oral contraceptives), were non-smokers, did not consume more than 5 caffeinated 
beverages per day, did not consume more than 14 units of alcohol per week, did not suffer 
from any self-reported sleep disorders or sleep complaints such as apnoea or insomnia, were 
not shift workers, had not travelled across more than 1 time zone in the 2 months preceding 
the laboratory phase and had not given blood in the 6 weeks prior to the laboratory phase. 
Every attempt was made to match participants for age, gender, body mass index (BMI) and 
ethnicity at the group level.
3.2.2 Study design
The study was a single-centre, 2-way crossover design with two laboratory sessions. For 3 
weeks prior to the laboratory phase and for the duration of the study, participants were asked 
to refrain from all medications and recreational drugs. For 3 days prior to each laboratory 
session participants were asked to refrain from alcohol, chocolate, food supplements and 
strenuous exercise. Medical screening was carried out approximately one week before 
admission to the Centre and on the day of admission in order to assess general physical health
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and to perform toxicological screening of blood and urine samples. A pregnancy test was also 
required for female participants.
Participants were asked to wear an actiwatch (Actiwatch-L® or Actiwatch 4®, Cambridge 
Neurotechnology Ltd, Cambridge, UK) on their wrist for 2 weeks prior to the first admission 
to the Centre. The first week of actigraphy data were downloaded and viewed as an actogram 
(Actiwatch analysis v.5.54, Cambridge Neurotechnology Ltd, Cambridge, UK) and was used 
to determine an average habitual sleep-wake schedule for each participant, this was 
calculated by taking each participant’s habitual sleep time mid-point and calculating 4 hours 
either side to give an 8 hour sleep opportunity. During the second week of actigraphy 
participants were requested to maintain their calculated average sleep-wake schedule and a 
deviation of more than 30 minutes twice in the week preceding the laboratory session would 
result in that participant being replaced with a reserve. Participants were required to wear the 
actiwatch for one week prior to the second admission to the Centre and were required to sleep 
at their calculated average sleep-wake schedule, unless there was a particularly long time 
period between the 2 visits, in which case participants habitual sleep-wake schedule was re­
assessed and therefore 2 full weeks of actigraphy was required. Participants were also asked 
to complete the KSD on a daily basis for approximately 2 weeks prior to each admission to 
the Centre.
Each laboratory session lasted 11 days and consisted o f a habituation night, a baseline night, 
7 condition nights o f restricted or extended sleep opportunities, followed by a ~40 hour total 
sleep deprivation period under constant routine conditions. Each laboratory session ended 
with a recovery sleep period. Participants took part in both conditions and each laboratory 
session was separated by a minimum of 10 days. At night, participants slept in a windowless.
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sound attenuated, temperature controlled room and during the day participants remained 
within the unit. See Figure 3.1 for a diagram of sleep-wake schedule during laboratory 
sessions. Cognitive test batteries were administered 5 times a day on sleep extension and 
sleep restriction condition days (approximately every 2-3 hours) to assess cognitive 
performance and alertness (details of all tests included in the battery are not relevant to the 
data presented in this chapter and are therefore not described). Each battery started and ended 
with the Karolinska Drowsiness Test (KDT), which provided a means o f objectively 
assessing participants’ level of drowsiness. During the KDT participants were asked to stare 
at a black dot on a white background on the computer screen for 2 minutes, whilst remaining 
as still as possible.
On habituation and baseline nights the participants’ sleep-wake schedules were the same as 
their calculated habitual averages. The habituation night also served as a polysomnographic 
screening for sleep disorders such as sleep apnoea and periodic leg movements. No 
participants were identified as sufferers from these sleep disorders. During the sleep 
restriction condition participants’ sleep was restricted by removing one hour from either side 
of their calculated habitual sleep period, resulting in a 6 hour sleep opportunity once every 24 
hours for 7 nights. During the sleep extension condition participants’ sleep was extended by 
adding one hour either side of their calculated habitual sleep period, resulting in a 10 hour 
sleep opportunity once every 24 hours for 7 nights. The order o f the two conditions was 
balanced within each genotype and participants within each genotype were randomly 
assigned to one of the two orders.
The total sleep deprivation period lasted for 39 hours if  the preceding condition was sleep 
extension and 41 hours if the preceding condition was sleep restriction (details of the constant
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routine are not relevant to the data presented in this chapter and are therefore not described). 
The total sleep deprivation period was followed with a 12 hour recovery night, which was 
timed to begin at participants calculated habitual sleep time (i.e. the same time as on 
habituation and baseline nights).
S lee p  e x te n s io n  co n d itio n  
00:00 00:00 00:00 00:00 00:00 00:00 00:00 00:00 00:00 00:00 00:00 00:00 00:00
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Figure 3.1: Study design for sleep extension and sleep restriction conditions 
Example sleep-wake schedule for the sleep extension (top schedule) and sleep restriction 
(bottom schedule) conditions. Yellow bars represent waking periods and black bars represent 
sleep opportunities (lights off) with the number of hours sleep opportunity displayed in white. 
HD: habituation day; HN: habituation night; BD: baseline days 1-2; BN: baseline night; CD: 
condition days 1-6; CN: condition nights 1-7 (10 or 6 hour sleep opportunities); RN: recovery 
night; TSD: total sleep deprivation.
3.2.3 Procedures
3.2.3.1 Polysomnography
PSG measures comprising the EEG, submental electromyogram (EMG) and 
electrooculogram (EOG) were recorded throughout scheduled sleep periods and the 
scheduled cognitive test batteries as described in Chapter 2.2. Participants also wore a 
thoracic band and a nasal airflow sensor to monitor breathing and leg electrodes to monitor 
leg movements on the first night of the first laboratory session. The electrocardiogram (ECG) 
was also recorded during all scheduled sleep periods.
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The electrode montage used gold-plated no-tangle wire electrodes (Astro-Med®, Inc., 
Berkshire, UK) and included EEG electrodes positioned at Fz, F3, F4, Cz, C3, C4, P3, P4, 
01 , 02 , as well as T3 and T4 on occasion during cognitive testing. Electrodes were 
referenced to the A1 and A2 mastoid electrodes on the contralateral side o f the scalp to 
minimise interference. The ground and reference electrodes were positioned at FPz and Pz 
respectively. Sleep measures were recorded using Siesta 802 devices (Compumedics Ltd., 
Abbotsford, Victoria, Australia) and wake measure were recorded using Vitaport 3 recorders 
(Temec Instruments B.V., Kerkrade, The Netherlands).
3.2.3.2 Polysomnography data analysis 
3.2.3.2.1 Staging polysomnography recordings
The PSG data for all protocol nights, excepting habituation night, were manually scored as 
described in Chapter 2.3.1, according to the criteria set by Rechtschaffen and Kales 
(Rechtschaffen & Kales, 1968). A total o f 20 EEG recordings were not available for PSG 
analysis due to participant withdrawal or due to technical errors. Following completion of 
manual staging hypnograms were comprehensively assessed for completeness. A total o f 6 
hypnograms which contained between 2.5% and 5% data loss (i.e. short recording or 
undefined epochs) were manually modified and included in the analysis. A total o f 21 
hypnograms were excluded due to having >2.5% data loss. Hypnograms with <2.5% 
undefined epochs were automatically corrected for by using for the ratio between the 
unidentified and identified epochs to correct for all vigilance stages.
3.2.3.2.2 Spectral analysis of sleep and wake recordings
Following completion of manual staging the sleep EEG EDF files and staged hypnograms 
were used to perform FFT spectral analysis as described in Chapter 2.3.2 using Vitascore
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software version 1.40 (RC.l) (Temec Instruments, B.V., Kerkrade, The Netherlands). A total 
of 23 EEG recordings were unavailable for spectral analysis due participants missing nights 
or due to technical errors. In addition, recordings where the staged hypnograms contained 
>30% missing data were excluded; this resulted in a further 6 recordings being excluded from 
spectral analysis. Artefacts were manually removed from the EEG derivations before FFT 
spectral analysis was performed on 4 second sub-epochs for sleep EEG. Power spectra were 
exported from Vitascore for the entire night, thirds o f the night and per hour of the night for 
each nocturnal EEG recording. The criteria set for the amount of sub-epochs o f data 
remaining in the entire night for each derivation following artefact removal was 62.5%; this 
resulted in a total of 92 derivations being excluded from analysis following artefact removal. 
For derivations meeting the criteria, corrections were applied to the power values as 
described in Chapter 2.4, and EEG power density values for matching contralateral EEG 
derivations were subjected to a weighted averaging within an individual for each night within 
a condition prior to performing statistical analyses (those derivations which no longer had a 
matching contralateral derivation due to exclusions were also excluded from analysis). 
Additionally, for the 6 hour analyses presented in this chapter a weighted averaging was 
performed on the first 6 one hour segments of the night prior to averaging over derivations.
The first (Tl) and the last (T5) cognitive test battery on baseline day 1, and condition days 1, 
3 and 6 (Figure 3.1) of the protocol were considered for waking EEG analysis. A total o f 59 
KDT test recordings were unavailable for spectral analysis due participants missing days or 
due to technical errors. In each test battery the first 2 minute KDT was subjected to spectral 
analysis, which was manually scored as wake within Vitascore software. Artefacts were 
manually removed from the EEG derivations within the 2 minute test windows before FFT 
spectral analysis was performed on 2 second sub-epochs for wake EEG and data were
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exported. Following artefaet removal derivations in the top 5% of power density values for 
the theta activity band were revisited and a comprehensive assessment o f data quality 
determined whether derivations were included in the analysis, in addition, those derivations 
with no remaining data were also excluded; this resulted in a total of 150 derivations being 
excluded from the analysis. For derivations meeting the criteria, corrections were applied to 
the power values as described in Chapter 2.4, and EEC power density values for matching 
contralateral EEC derivations were subjected to a weighted averaging within an individual 
for each night within a condition prior to performing statistical analyses (those derivations 
which no longer had a matching contralateral derivation due to exclusions were also excluded 
from analysis).
3.2.4 Statistical analyses
Analyses in this chapter were primarily performed in SAS® version 9.2 (SAS Institute Inc., 
Cary, NC, USA). In order to determine whether there were significant differences between 
conditions and groups of participants general linear mixed models were performed on PSG 
derived sleep measures and the 8 traditional EEC frequency bands (described in Chapter 
2.3.2.2) using PROC MIXED in SAS®, with main effects o f condition (sleep extension and 
sleep restriction), genotype (PER3 variant), night and period (the visit number at which the 
condition occurred i.e. the order o f the conditions). The interaction of the main effects was 
also assessed and for analysis o f PSG measures non-signifieant interactions were removed 
from the mixed model, whereas for analysis of the 8 EEG frequency bands all interactions 
remained in the mixed model. In order to determine whether there were significant 
differences between baseline and recovery nights within conditions, general linear mixed 
models were performed only with these nights in the model, on individual I Hz EEG
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frequency bins up to 32Hz using PROC MIXED in SAS®, with main effects of condition, 
night and period, as well as the interaction of condition and night.
In order to establish whether there were trait-like individual differences within the EEG that 
were stable over time and robust to the sleep extension and sleep restriction conditions 
intraclass correlation coefficients (ICCs) were computed using PROC MIXED in SAS® with 
main effects of condition, night and period. ICCs were calculated for PSG derived sleep 
measures and the 8 EEG frequency bands using both absolute and relative EEG power 
density values. The ICC was calculated by using the covariance parameter estimates from the 
mixed model output from which the between subject variance was divided by the total 
variance. The ICCs were interpreted by using ranges previously described (Landis and Koch, 
1977). The general linear mixed models used for all analyses in this chapter can be found in 
Appendix A.
Correlation analyses were performed for wake and sleep EEG markers of homeostasis by 
calculating the Pearson’s r correlation for pairs o f observations in the wake and sleep EEG 
per individual. Correlation analyses were performed using IBM® SPSS® Statistics version 
21.0 or 22.0 for Windows (IBM Corp. Armonk, New York, USA).
3.3 Results
3.3.1 Effect of sleep manipulation on PSG measures
3.3.1.1 Entire night
Table 3.1 shows a summary of sleep parameters derived from the manual staging o f the sleep 
EEG recordings for each experimental night, in each condition, in their entirety. There was a 
significant effect o f condition on all PSG measures except for proportion o f rapid eye
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movement (REM) sleep and slow-wave energy (SWE; SWA*minutes in non-rapid eye 
movement (NREM) sleep) and a significant effect of night on all PSG measures except for 
proportion of slow-wave sleep (SWS). Total sleep time (TST), Sleep Latency (SL; lights off 
to first epoch of sleep), Latency to Persistent Sleep (LPS; lights off to 10 minutes continuous 
sleep). Wake After Sleep Onset (WASO), and proportion of stages wake, 1 and 2, were all 
significantly higher under the sleep extension condition compared with the sleep restriction 
condition. Whereas, proportion of SWS and sleep efficiency (SE) were both significantly 
higher under sleep restriction conditions compared with the sleep extension condition. 
Significant effects o f genotype were seen for proportion of SWS and REM sleep and SWE.
Post-hoc analysis revealed that there was a significant interaction between condition and 
night on all PSG measures; asterisks in Table 3.1 indicate a significant change from the 
baseline night within that condition. On condition nights TST was affected by the protocol 
and was increased on sleep extension nights and decreased on sleep restriction nights, 
however, there was a decrease in TST on sleep extension night 7, by approximately 1 hour, 
compared with the other sleep extension nights. Sleep latency measures tended to increase 
under sleep extension condition and decrease under sleep restriction condition compared with 
baseline nights, as did WASO and proportion of stages wake, 1 and 2. Whereas, SWS and SE 
increased under sleep restriction conditions and decreased under sleep extension conditions 
compared with baseline nights. Proportion of REM sleep was only significantly different 
from baseline during the sleep restriction condition on the last condition night (CN7), 
whereby a decrease was observed and on the recovery night whereby an increase from 
baseline was observed. SWE was not significantly different from baseline under either sleep 
extension or sleep restriction conditions, except for condition nights 1 and 6 under the sleep 
restriction condition, whereby SWE was significantly lower than baseline nights.
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The recovery night following total sleep deprivation typically induced a change from the 
baseline night in the same direction for both the sleep extension and sleep restriction 
conditions; however, in some cases the extent o f the change was affected by the sleep 
condition prior to the total sleep deprivation constant routine. TST, SE, and proportion of 
REM sleep were significantly higher on the recovery night following the sleep restriction 
condition than after the sleep extension condition. SL, LPS, WASO and proportion o f stages 
wake and 1 were significantly higher on the recovery night following the sleep extension 
condition than after the sleep restriction condition. Proportion of stage 2, SWS, and SWE did 
not significantly differ whether the recovery night followed either the sleep extension or sleep 
restriction conditions.
Some effects of genotype were apparent in the PSG derived sleep variables, namely there 
were main effects of genotype for proportion of SWS and REM sleep, and SWE. Post-hoc 
analysis evidenced that there was a significant difference between the PER3 '^  ^ and PER3^’^  
groups in SWS and SWE (p=0.0059, 0.0104 respectively), whereby the PER3 '^  ^ group had 
significantly less SWS and SWE. The PER?)^ '^  group had significantly more REM sleep than 
the PER3 '^  ^group (p=0.0063).
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Chapter 3
3.3.1.2 First 6 hours of the night
In order to directly compare the PSG analysis across the different nights of the protocol, the 
analysis was repeated but only for the first 6 hours of each night. Table 3.2 shows a summary 
of sleep parameters derived from the manual staging o f PSG recordings for the first 6 hours 
of each experimental night. There was a significant effect of condition and night on all PSG 
measures. Proportion of stages wake, 1 and 2 were all significantly higher under the sleep 
extension condition compared with the sleep restriction condition. Whereas, TST, SE, SWE 
and proportion o f SWS and REM sleep were significantly higher under sleep restriction 
conditions compared with the sleep extension condition. Significant effects of genotype were 
seen for both SWS and REM sleep.
Post-hoc analysis revealed that there was a significant interaction between condition and 
night on all PSG measures; asterisks in Table 3.2 indicate a significant change from the 
baseline night within that condition. On condition nights, TST was affected by the protocol 
and tended to be lower on sleep extension nights compared with the first 6 hours of baseline 
night and slightly higher than the first 6 hours o f baseline night under sleep restriction 
conditions. Proportion of stage wake was increased in the first 6 hours of the night under 
sleep extension condition compared with the first 6 hours of baseline and was slightly lower 
than baseline night under sleep restriction conditions, as was proportion o f stage 1. 
Proportion o f stage 2 tended to be lower in the first 6 hours of the night under sleep 
restriction conditions compared with baseline, but was largely unaffected under sleep 
extension conditions. SE decreased compared with baseline night under sleep extension 
conditions, and slightly increased under sleep restriction conditions. SWE and proportion of  
SWS and REM sleep decreased slightly compared with baseline night under sleep extension
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conditions and increased under sleep restriction conditions within the first 6 hours of the 
night.
Total sleep deprivation induced a change from baseline in the first 6 hours o f the recovery 
night in the same direction for both sleep extension and sleep restriction conditions for all 
PSG variables measured. Previous sleep history did not appear to have any major effects on 
the PSG variables within the first 6 hours o f the night and the only variable where there was a 
significant difference between the conditions on the recovery nights was proportion of REM 
sleep which was higher on the recovery night following sleep restriction compared with sleep 
extension. When the first 6 hours of the recovery nights were compared with the first 6 hours 
of baseline nights, TST and SE were significantly increased compared with baseline nights 
under sleep restriction conditions. On the other hand, proportion of wake and stage 2 were 
significantly reduced compared with baseline night under sleep restriction conditions. 
Proportion of REM sleep was significantly lower under sleep extension conditions compared 
with baseline night. Proportion of SWS and SWE were significantly higher and proportion of 
stage 1 was significantly lower on recovery nights for both conditions compared with 
baseline night.
The 6 hour analysis did also reveal some effects of genotype on the PSG derived sleep 
variables. Main effects of genotype were significant for TST, SE, SWE and proportion of 
stages wake, SWS, and REM sleep. Post-hoc analysis evidenced that the PER3 '^  ^ group had 
significantly lower TST and SE than the PER3‘^'^  group (p=0.0142 and 0.014 respectively), 
and the significant interaction of genotype and condition revealed that the genotype 
differences were significant under the sleep extension condition (p=0.0004 for both 
variables). The PER3 '^  ^ group also had significantly more wake than did the PER3 '^  ^ group
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(p=0.0141), and the interaction o f genotype and condition revealed this was also within the 
sleep extension condition (p=0.0004). The genotype differences in SWS, SWE, and REM 
sleep were similar to the entire night analysis. The PER3 '^  ^ group had significantly less SWS 
and SWE than the PER3 '^  ^ group (p=0.0104 and 0.008 respectively). The PER3 '^  ^ group had 
significantly more REM sleep than the PER3^ ^^  group and the PER3 '^  ^ group (p=0.0023 and 
0.0252 respectively).
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Chapter 3
3.3.2 Effect of sleep manipulation on EEG power density spectra
3.3.2.1 EEG frequency spectrum
To investigate the effects o f sleep extension, sleep restriction and total sleep deprivation on 
the spectral composition of the sleep EEG, power density spectra up to 32Hz were plotted for 
the first 6 hours o f each night as a change from baseline night (100%).
The 7 condition nights and recovery nights during sleep extension and sleep restriction 
expressed relative to baseline night during NREM and REM sleep for frontal, central, parietal 
and occipital derivations can be seen in Figures 3.2-3.5. All derivations were similarly 
affected by the protocol and it was evident that the lower frequencies are particularly affected 
by both sleep extension and sleep restriction conditions in both NREM and REM sleep 
(Figures 3.2 and 3.4 respectively) and these effects were particularly pronounced in the 
frontal and central derivations. On sleep extension nights there was a tendency towards less 
SWA compared with baseline within the first 6 hours o f the night and on sleep restriction 
nights there was an increase in SWA compared with baseline night. The spindle frequency 
range during NREM sleep was also affected by the extension and restriction protocols during 
the first 6 hours o f the night, whereby on sleep extension nights there was an increase above 
baseline levels, whereas on sleep restriction nights there was a decrease below baseline. The 
higher frequency ranges during NREM sleep were also affected by the protocol and tended to 
be below baseline levels during the first 6 hours o f the night compared with baseline for both 
the sleep extension and sleep restriction conditions.
On recovery nights during NREM and REM sleep (Figures 3.3 and 3.5 respectively) both the 
sleep extension and sleep restriction conditions invoked a change from baseline in the same 
direction, whereby low frequency activity increased above baseline levels and increased more
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in the sleep restriction condition compared with the sleep extension condition. The most 
prominent changes relative to baseline night occurred at approximately l-12Hz for all 
derivations, and whilst the mixed model analyses did not reveal a significant interaction of 
condition and night for the majority o f IHz bins across all derivations for NREM and REM 
sleep, the differences between baseline and recovery nights within a condition were 
significant for many of the IHz bins as indicated in Figures 3.3 and 3.5. For NREM sleep 
EEG power on recovery nights following the sleep extension condition, EEG power 
significantly increased in most IHz bins up to 20-25Hz depending on derivation compared 
with baseline night. In contrast, on recovery nights following the sleep restriction condition, 
EEG power significantly increased in bins up to 12-15Hz, as well as in the beta-2 and beta-3 
ranges (excepting the occipital derivation which increased at nearly all IHz bins). During 
REM sleep, EEG power on recovery nights significantly increased in the majority o f IHz 
bins, up to approximately 20Hz following both the sleep extension and sleep restriction 
condition (excepting the occipital derivation which increased across nearly the whole 
fi-equency range), while the higher fi-equency ranges were largely unaffected.
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Chapter 3
3.3.2.2 Time course of low frequency bands
Visual inspection of the power density spectra during NREM sleep in Figures 3.2 and 3.3 
identified that the protocol had the most effect on the lowest EEG frequency ranges, in light 
of this and given the particular interest in the functional significance of SWS and SWA, the 
effects o f sleep extension and sleep restriction on the lowest three EEG frequency bands were 
further investigated. The low-delta (0.25-0.5Hz), delta (0.75-4.5Hz), and theta (4.75-7.75Hz) 
activity bands during NREM sleep were analysed and the analysis of these frequency ranges 
was restricted to the frontal and central derivations since low frequency activity is most 
pronounced in these brain areas (Cajochen et al., 1999). In order to directly compare the 
changes in EEG power spectra during the sleep extension and sleep restriction protocols, as 
well as the recovery sleep thereafter, the first 6 hours of the night for each protocol night 
were assessed and the effects o f the sleep extension and sleep restriction protocols on the 
low-delta, delta and theta frequency bands can be found in Figures 3.6, 3.7, and 3.8 
respectively. Results from mixed model analysis of the frequency bands can be found in 
Table 3.3 for the main effects. Tables 3.4 and 3.5 for the contrast between nights and Table 
3.6 for the comparison of PER3 genotypes.
The response to the sleep extension and sleep restriction conditions in the low-delta 
frequency range was similar in both the frontal and central derivations but was somewhat 
irregular. Under sleep extension conditions, EEG power initially decreased below baseline 
levels, and although the interaction of condition and night was not significant for either 
derivation, power was significantly reduced compared with baseline night on condition night 
2 in the central derivation. After condition night 3, power in the low-delta band reverted back 
towards baseline levels and in the frontal derivation power even increased above baseline 
levels. Under sleep restriction conditions power remained close to baseline levels until
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condition night 5, and then proceeded to decline below baseline levels. On recovery nights 
following total sleep deprivation power in the low-delta band significantly increased above 
baseline levels under both conditions, however, power was higher by as much as 
approximately 10% more when the previous sleep history was sleep extension compared with 
sleep restriction.
The delta frequency band, otherwise known as the SWA band, exhibited an interesting 
response, particularly to the sleep restriction condition. Power in the delta band increased 
above baseline levels under sleep restriction conditions and continued to increase until power 
peaked at around 5% above baseline levels on condition day 4, which was significant in the 
frontal derivation. After condition night 4 EEG power declined back towards baseline in 
fashion almost parallel to the increase observed at the beginning of the protocol. Under sleep 
extension conditions power in the delta band significantly decreased below baseline levels on 
condition night 2 and remained so until condition night 6, after which power returned to 
baseline levels. However, no trough in power relative to baseline night was observed in the 
middle of the protocol in opposition to power under sleep restriction conditions, in fact the 
decrease was at its lowest on condition days 2 and 5, whereby power was approximately 10% 
lower than baseline levels. On recovery nights following total sleep deprivation power in the 
delta band significantly increased above baseline under both the sleep extension and sleep 
restriction conditions, with previous sleep history seemingly affecting the response, with 
power being higher under sleep restriction conditions and increasing above baseline levels by 
almost 40%.
The sleep extension and sleep restriction protocols induced a similar response in the theta 
frequency band as in the delta frequency band; however, the response was less prominent in
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the theta band. Under sleep restriction conditions power tended to increase above baseline 
levels, and peaked on condition night 4 at approximately 3% above baseline levels before 
declining back towards baseline. Power in the theta band significantly decreased relative to 
baseline levels under sleep extension conditions and decreased by almost 10% below baseline 
on condition day 2 and by the last condition night power had reverted back to baseline level. 
On recovery nights following total sleep deprivation power significantly increased above 
baseline levels under both sleep extension and sleep restriction conditions with the response 
being slightly larger if  the previous condition was sleep restriction compared with sleep 
extension. Power in the theta band on recovery nights increased relative to baseline by as 
much as approximately 30% under sleep restriction conditions.
Figures demonstrating the relative change from baseline night per genotype can be seen in the 
middle and lower panels of Figures 3.6, 3.7, and 3.8. Visual inspection of the Figures showed 
that EEG power density tended across the course of the protocol to increase above baseline 
levels more so in the PER3 '^  ^ group than in the PER3 '^  ^ and PER3 '^  ^ groups in all three 
frequency ranges under the sleep restriction condition. EEG power density in the PER3 '^  ^
group also tended to decrease the least across the course of the protocol in the low-delta and 
delta frequency ranges and the most in the theta firequency range compared with baseline 
under the sleep extension condition. In the 6 hour analysis, the main effect of genotype was 
significant for both the central and frontal derivations in the delta and theta frequency ranges 
(Table 3.3), the main effect of genotype was also significant in the central derivation (mixed 
model estimation problems in frontal derivation) in the delta and theta frequency ranges in 
the entire night analysis (p=0.0088 and 0.0127 respectively, main effects not shown). The 
contrasts of genotypes can be seen in Table 3.6 for the 6 hour analysis and entire night 
analysis. The PER3 '^  ^genotype had significantly less delta and theta activity than the PER3^^^
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and PERS'^ '^  genotypes in both derivations, except for the contrast between the PERS '^  ^group 
and PERS '^  ^ group in the 6 hour analysis in the frontal derivation, which approached 
significance (p=0.0713). There were no interactions containing genotype that were 
significant.
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Figure 3.6: Low-delta activity (0.25-0.5Hz) during NREM sleep
Low-delta activity (0.25-0.5Hz) (geometric mean ± 95% CLs) during the first 6 hours o f each 
night (condition nights; CNl-7, and recovery night; RN, x-axis) from frontal (left figures) 
and central (right figures) derivations, expressed relative to the first 6hrs of baseline night 
(100%, y-axis). Top figures: entire population (n=27-34); triangles along x-axis indicate a 
significant difference between the associated night and the baseline night; open symbols = 
sleep extension condition and closed symbols = sleep restriction condition. Middle 
figures/open symbols = sleep extension condition stratified by genotype and bottom 
figures/closed symbols = sleep restriction condition stratified by genotype. •  = PER3 
genotype (n=9-12); •  =PER3^^ genotype (n=6-10); •  ^ PER3 '^  ^genotype (n=9-12).
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Figure 3.7: Delta activity (0.75-4.5Hz) during NREM sleep
Delta activity (0.75-4.5Hz) (geometric mean ± 95% CPs) during the first 6 hours of each 
night (condition nights; CNl-7, and recovery night; RN, x-axis) from frontal (left figures) 
and central (right figures) derivations, expressed relative to the first 6hrs of baseline night 
(100%, y-axis). Top figures: entire population (n=27-34); triangles along x-axis indicate a 
significant difference between the associated night and the baseline night; open symbols = 
sleep extension condition and closed symbols = sleep restriction condition. Middle 
figures/open symbols = sleep extension condition stratified by genotype and bottom 
figures/closed symbols = sleep restriction condition stratified by genotype. # = PER3‘^'^  
genotype (n=9-12); •  =PER3^^ genotype (n=6-10); •  = PER3 '^  ^genotype (n=9-12).
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Figure 3.8: Theta activity (4.75-7.75Hz) during NREM sleep
Theta activity (4.75-7.75Hz) (geometric mean ± 95% CTs) during the first 6 hours of each 
night (condition nights; CNl-7, and recovery night; RN, x-axis) from frontal (left figures) 
and central (right figures) derivations, expressed relative to the first 6hrs of baseline night 
(100%, y-axis). Top figures: entire population (n=27-34); triangles along x-axis indicate a 
significant difference between the associated night and the baseline night; open symbols = 
sleep extension condition and closed symbols = sleep restriction condition. Middle 
figures/open symbols = sleep extension condition stratified by genotype and bottom 
figures/closed symbols = sleep restriction condition stratified by genotype. # = PER3 
genotype (n=9-12); # =PER3^^ genotype (n=6-10); •  = PER3 '^  ^ genotype (n=9-12).
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Table 3.3: Mixed mode analysis main effects during the first 6 hours of NREM sleep
Effect
Frontal Central
DF F P DF F P
1  “  
- 2
Genotype 2,33.1 225 0.1210 2^2 222 0.1246
Condition 1,107 3.74 0.0556 1,118 3.91 0.0505
Night 8/U7 4.05 0.0001 8,414 528 <.0001
Period 1,118 0.65 0.4221 1,128 1.16 02834
G*C 2,107 0.07 0.9315 2,119 0.17 0.8416
C*N 8/U7 1.02 0.4190 8,414 1.56 0.1339
G*N 16,444 1.59 0.0688 16,447 1.66 0.0506
G*C*N 16,444 028 0.7062 16,447 0.77 0.7164
K
B ‘C
Q ^
s
Genotype 2^3 520 0.0109 2^2 5.43 0.0091
Condition 1,109 16.92 <.0001 1,133 15.27 0.0001
Night 8,421 61.20 <.0001 8 /2 3 6421 <.0001
Period 1,120 022 02979 1,145 022 02675
G*C 2J09 0.61 0.5472 2J23 1.76 0.1763
C*N 8,421 :L96 0.0031 8,433 2.90 0.0037
G*N 16,446 0.83 0.6522 16,461 1.03 0.4272
G*C*N 16,446 0.93 (15363 16,461 0.54 (19258
:
1^
s
Genotype 2^G 4.68 0.0163 2^2 5.10 0.0118
Condition 1,81.5 0.99 02226 1,105 1.10 0.2969
Night 8,406 64.17 <.0001 8,420 6028 <.0001
Period 1,90.3 0.01 (19032 1,117 0.09 02672
G*C 2,81.2 2.80 0.0665 2J05 0.69 0.5023
C*N 8,406 223 0.0061 8,420 2.99 0.0029
G*N 16/W5 0.64 (18486 16,451 029 (19850
G*C*N 16,435 1.21 (12539 16,451 0.60 (18817
Fixed effects and interactions for power density (log^ )^ in the low-delta (0.25-0.5Hz), delta 
(0.75-4.5Hz) and theta (4.75-7.75Hz) EEG frequency bands during the first 6 hours of 
NREM sleep for frontal and central derivations (n=36). Statistics obtained from general linear 
mixed model in SAS®, which included main effects of genotype, condition, night, period as 
well as the interactions of genotype * condition (G*C), condition*night (C*N), 
genotype*night (G*N) and genotype*eondition*night (G*C*N). All protocol nights were 
included in model. DF (numerator and denominator degrees of freedom), F values and p 
values are reported for each main effect and interaction.
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Chapter 3
3.3.2.3 Intra-night time course of slow-wave activity
The effects of the sleep restriction and the sleep extension protocols on the time course of 
SWA within a night was assessed by calculating the average SWA within the frontal 
derivation during NREM sleep per 2 hour time interval for each protocol night and 
expressing this as a percentage of SWA relative to the entire baseline night (Figure 3.9).
A clear decline in SWA across the night was seen for each protocol night and in both 
conditions. During baseline nights SWA declined rapidly across the night, however, a slight 
slowing of the decline can be observed in the last 2 hours o f the night. During the sleep 
extension condition the decline in SWA slowed considerably in the latter hours o f the nights 
and the figures show the decline beginning to plateau towards the end of the night on the 7 
condition nights. During the sleep restriction condition no plateau was observed on any o f the 
condition nights and the decline appeared to remain consistent on each night. SWA within the 
recovery night following total sleep deprivation behaved similarly whether the previous sleep 
conditions was sleep extension or sleep restriction, and began to curtail after approximately 
the first 6 hours of the recovery episode.
The effects of genotype on the decline of SWA across the night were also assessed by 
plotting the time course of SWA per 2 hour interval for each PER3 genotype individually 
(Figure 3.10). No prominent differences between the genotypes were observed, however, 
there was more of a distinction between the genotypes on the sleep extension condition nights 
compared with the sleep restriction condition nights and it appeared that at the beginning of 
the night under sleep extension conditions the PER3 '^  ^ group had slightly lower SWA in 
comparison to the other genotypes, and this difference was more prominent towards the end 
of the protocol, this was not the case under sleep restriction conditions
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Chapter 3
3.3.3 Individual differences in sleep
3.3.3.1 Individual differences in PSG and EEG spectral analysis parameters
In order to establish whether there were individual differences in various sleep parameters 
and to determine whether such parameters were stable and robust within individuals between 
sleep extension and sleep restriction conditions a Pearson’s r correlation was performed and 
associated r and p values were reported. Entire night TST, SWS and SWA were assessed and 
plotted for baseline and recovery nights per individual where possible (Figure 3.11), all 
correlations were positive and significant.
TST on baseline nights varied across individuals and ranged from 6.4 to 8.0 hours. TST on 
recovery nights following total sleep deprivation still varied across individuals and ranged 
from 8.4 to 11.6 hours. However, on recovery nights most individuals considerably increased 
their TST with the majority of individuals obtaining at least 11 hours TST out o f the 12 hours 
available i.e. the maximum sleep opportunity available on recovery nights. There was a 
positive correlation of TST under sleep restriction and sleep extension conditions for both 
baseline and recovery nights, indicating that TST is a robust variable within individuals.
SWS expressed as a proportion of TST and SWA during NREM sleep both displayed large 
inter-individual variation, whilst having a remarkably high intra-individual robustness across 
the sleep extension and sleep restriction conditions as indicated by high r values. The 
robustness within an individual was particularly high for SWA in the frontal derivation on 
both baseline nights and recovery nights following total sleep deprivation, indicating that this 
variable is also stable across time. There were no marked differences between baseline nights 
and recovery nights for either SWS or SWA.
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Figure 3.11: Total sleep time, slow-wave sleep and slow-wave activity per individual 
Scatter plots of individuals’ data for entire night total sleep time (TST), slow-wave sleep 
(SWS) and slow-wave activity (SWA; 0.75-4.5Hz; frontal derivation) during NREM sleep 
(top, middle and bottom figures respectively), for baseline and recovery nights. In each figure 
the sleep extension condition is displayed on the x-axis and the sleep restriction condition on 
the y-axis. •  = genotype (n=10-12); •  = PERS '^  ^ genotype (n=8-10); •  = PER3 '^^
genotype (n==10-13). Regression line for total population and r and p values derived from 
Pearson’s r correlation analysis are indicated on each plot.
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3.3.3.2 Intra-individual stability and robustness of PSG measures 
The ICC was used to assess whether there were stable and robust individual differences in the 
way that individuals responded to sleep extension, sleep restriction and total sleep 
deprivation. Analysis o f the PSG derived sleep variables across individual protocol nights 
(each protocol night contains a sleep extension and sleep restriction value for each participant 
where possible), as well as the combination o f all nights, revealed a large variation in ICCs 
(Table 3.7).
ICCs across different variables and nights ranged from 0.00 to 0.85, which according to 
benchmark ranges commonly used to interpret ICCs (Landis and Koch, 1977), equates to 
values ranging from ‘slight’ to ‘almost perfect’. The highest ICCs were observed for SWS 
minutes and SWS proportion of TST, with those values reaching ‘almost perfect’, and 
declined only to ‘moderate’ values at their lowest. The lowest ICCs were seen for TST and 
WASO with values as low as ‘slight’. However, these variables also showed the greatest 
variation in the ICCs, and reached ‘substantial’ and ‘moderate’ respectively, at their highest.
In addition to the variation observed across PSG variables, there was considerable within 
variable variation in the stability of ICCs over the protocol nights. On the whole the most 
stable night of the protocol across variables appeared to be the recovery nights. The baseline 
nights and the first condition nights also appeared very stable, whilst nights towards the 
middle of the protocol tended to be the least stable.
Page 105 of 257
CO
I
ÜCO
t4H
O
I
IJ
I
g-
, o
Uw
CO
i
1 ? 5o
CO
CO
o
oo
CO
o
VO
<N
d
VO
d
CO
CO
d
V3
CO
d
O s
CO
d
o
VO
d
O s
CO
d
I Î
00
'Ct
o
00
CN
d>
o \
o
VO
d
OV
d d
CO
I f
d
VO
I f
d
C\
VO
d
ov
CN
d
1 2 ooo
tr-
t>-
<5
(N
o
VO
d
VO
o
d
00
VO
d
VO
VO
d
VO
VO
d d
VO
VO
d
g |
CO 5
m
oo
o
VO00
o
<N00
o
or-
d
CO00
d
CO00
d
CO
f--
d
oo
r--
d
(N00
d
ov
d
(N  C e
CO ^
CO
VO
o
s
o
?
o
CO
d
CO
VO
d
VO
d
VO
CO
d
VO
(N
d
p
d
O n
I f
d
VO
o
I f
VO
o
VO
o
VO
M
d
(N
CO
d
00
d d
s
d d
CO ^
VO
o
s
o
o
f~ '
o
o o
VO
d
o
VO
d
I f
d
CN
VO
d
I f
VO
d
VO
CN
d
o
VO
d
1-H C
CO ’I
CZ\
u-
o
?
o
o
VO
d
Q!
d
CO
d
VO
CO
d
00
CO
d
(N
CO
d
VO
<N
d
VO
CO
d
CO
VO
o
O n
M
O
o
(N
d
M
d
CO
d
s
d d
(N
d
VO
VO
d
oo
CN
d
 ^ 1
CO
VO
o
VO
M
o d
CO
d
00
o
d
VO
d
CO
d
oo
o
d
VO
VO
d
CO
CN
d
pq C^
CO ^
CO
VO
o
0 \
CN
o
o
(N
d
(N
d
CO
d d
(N
d
(S
d
VO
VO
d
00
<N
d
O  ^  
1 1
I f
o
VO
o
o
CO
d
s
d
r~o
d
o
o
d
m
d
VO
o
d
o
d d
CO g
5 :
VO
VO
o
$
o
VO
I f
d
VO
d
I f
d
COm
d
00
I f
d
VO
VO
d
CO
d
00
CO
d
W  1 5o
VO
VO
o
00
CO
d
4
d d
I f
d
oo
CO
d
5
d
o
VO
d
CO
CO
d
g l
(N
VO
<d
VO
M
o
VO
d
CO
d
00
o
d
VO
d
<N
d
00
o
d
VO
VO
d
VO
o
d
# § g 6
CO
6 g
VO
5
VO
5 g 1
II
l i
a d
II
i> o
i2 CO
ii
CD 
X
^  V .
IIÆ » 
S , a
T3 T3
§  I  
—  =>
OCO
ÎI
CA II
§  g
I
•S)
Î
§■1TO
1-“kS c«
it
II
II
. w
ÎÏ
jH t 3 
<2 «
■ g - s
Ii
CO
14
CO
I
il
s s
Ii
I
ll% §
^  CO
l/J
1  ”
& - §1^
II
i|'3^
. 1  '§
G S  
o
^  wSI
11
r\ O
CO o
- T  Ë  
«  - g
i t
in
mI 
>
I
' S  ‘S
ii
II
> cn
bX) c/3 & &
O 13
a
a
Ü
X
IJ
I I
“  s
i |
o
c/3
0
1>1 
g -  "
CD
t!
O 0)
II
h3
1/3
 ^I 
d§
CO
pH CO
11 
.  CN
CL M
II
1 - 00 4-1
if
ii
IisO  . S  1 3  ^  (D
I I I
1 ^ ^
lOr44h
O
VO
0rH
1
P h
Chapter 3
3.3.3.3 Intra-individual stability and robustness of relative PSG measures 
In addition to calculating ICCs for PSG derived sleep variables using absolute values i.e. time 
and proportions, ICCs also were calculated using relative data for SWS and REM sleep 
(Table 3.8). The relative difference of condition night 6, condition night 7 and recovery night 
to baseline night and the relative difference o f recovery night to condition night 6 and 
condition night 7 for both the sleep extension and sleep restriction conditions were calculated. 
The relative percentages were then used in the general linear mixed model to calculate 
relative ICCs. Condition night 6 was used in addition to condition night 7 as the end of the 
protocol night due to the large drop in TST on condition night 7 for participants under the 
sleep extension condition, indicating that this night might more accurately represent sleep at 
the end of the protocol under such conditions.
The relative data for both SWS and REM sleep produced very low ICCs values compared 
with ICCs calculated from absolute data. In some cases the between subject variance 
estimated in the mixed model regressed to its lower boundary of 0 and therefore the ICC 
could not he determined for such cases (indicated by a in Table 3.8), this occurred only for 
SWS and not for REM sleep. However, both SWS and REM sleep produced ICCs so low that 
when expressed to 2 decimal places the resulting value is 0.00. For SWS, ICCs ranged from 
0.00 to O.II, which would be considered as ‘slight’, and for REM sleep ICCs tended to be 
slightly higher than for SWS and ranged from 0.00 to 0.39 which would all be considered as 
‘slight’, except for the 0.39 value which would be considered as ‘fair’.
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3.3.3.4 Intra-individual stability and robustness of EEG power densities 
The ICC was used to assess whether there were stable and robust individual differences in the 
sleep EEG power spectra during NREM and REM sleep across the sleep extension and sleep 
restriction protocols. The 8 EEG frequency band ranges: low-delta, delta, theta, alpha, sigma, 
beta-1, beta-2 and beta-3 were analysed and revealed high ICCs for all bands (Tables 3.9 and 
3.10 for NREM and REM sleep respectively).
Across all 8 frequency bands and all nights, ICCs ranged from 0.59 to 0.99 during NREM 
sleep and from 0.46 to 0.99 during REM sleep, which can be interpreted as ‘moderate’ to 
‘almost perfect’ for both NREM and REM sleep (Landis and Koch, 1977). ICCs across 
frontal, central and parietal derivations varied very little, however, ICCs for the occipital 
derivation tended to be slightly lower than the other derivations for both NREM and REM 
sleep.
During NREM sleep, the delta, theta, alpha and sigma produced the highest ICCs, this was 
particularly evident when all protocol nights were analysed together in the mixed model. The 
lowest and highest frequency ranges i.e. low-delta and beta-3 frequency ranges, tended to 
produce the lowest ICCs. The ICCs calculated for REM sleep were similar to those for 
NREM sleep; however, there was a shift towards higher ICCs at higher frequencies, 
particularly in the beta frequency ranges. Similarly to NREM sleep some o f the lowest values 
for REM sleep were found in the low-delta band.
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3.3.3.5 Intra-individual stability and robustness of relative EEG power densities 
In addition to calculating ICCs for absolute log^  ^ transformed EEG power density values, 
ICCs were calculated for relative data. ICCs were calculated across 8 EEG frequency band 
ranges: low-delta, delta, theta, alpha, sigma, beta-1, beta-2 and beta-3 for NREM and REM 
sleep (Table 3.11 and 3.12 respectively) by calculating the relative difference o f condition 
night 6, condition night 7 and recovery night to baseline night and calculating the relative 
difference of recovery night to condition night 6 and condition night 7 for the sleep extension 
and sleep restriction conditions and inputting the relative percentages into the general linear 
mixed model.
In striking contrast to the ICCs calculated on absolute power density values, the relative data 
produced some very low ICCs , and in some cases the between subject variance estimated in 
the mixed model regressed to its lower boundary of 0 and therefore the ICC could not be 
determined for such cases. This was particularly common for the higher frequency ranges 
(beta-1, beta-2 and beta-3) during NREM sleep, fri addition, ICCs were highly variable and 
ranged from 0.00 to 0.88 during NREM sleep, and interpreted as ‘slight’ to ‘almost perfect’. 
ICCs obtained for REM sleep tended to be lower than those for NREM sleep and ranged from 
0.00 to 0.51, which and interpreted as ‘slight’ to ‘moderate’. For both NREM and REM sleep 
frontal and central derivations produced considerably higher ICCs than did the parietal and 
occipital derivations.
The large variation in ICCs obtained made it difficult to interpret the stability o f the 
responses across the protocol. However, the response to the sleep extension and sleep 
restriction conditions assessed by expressing power in nights at the end o f the protocol 
relative to the baseline nights was seemingly more stable than the response to the total sleep
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deprivation as evidenced from ICCs produced from the power within recovery nights 
expressed relative to nights at the end of the protocol.
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3.3.3.6 Individual differences in relative power densities
To visualise the response to total sleep deprivation power densities from the recovery nights 
expressed relative to baseline nights were plotted across the across 8 EEG frequency band 
ranges: low-delta, delta, theta, alpha, sigma, beta-1, beta-2 and beta-3 for NREM sleep per 
individual where possible (Figure 3.12). The correlation of the relative power densities for 
sleep extension and sleep restriction conditions was assessed hy calculating the Pearson’s r 
correlation.
Relative power density was positively correlated in the low-delta, delta, theta, alpha and 
sigma EEG frequency ranges and these correlations were also significant, indicating that on 
recovery nights relative power density was similar under both sleep extension and sleep 
restriction conditions. The r values decreased with each EEG frequency band from the low- 
delta hand up to the sigma band and the respective p vales accordingly decreased in 
significance. Relative power density in the beta-1, beta-2 and beta-3 EEG frequency ranges 
was negatively correlated as indicated by the r values. However, the negative correlation was 
not significant in any o f these frequency bands and may be due to outliers within the data.
In none of the 8 EEG power density bands did there appear to be any distinct genotype 
dependent individual differences. Individuals’ responses to total sleep deprivation tended to 
cluster closely to each other, demonstrating low inter-individual variability.
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3.3.4 Correlation between wake and sleep homeostatic EEG markers
3.3.4.1 Time course of theta activity
Theta activity in the waking EEG can serve as a homeostatic marker o f sleepiness (Finelli et 
al., 2000) and therefore in order to assess whether homeostatic markers in the waking EEG 
follow the same profile as in the sleep EEG, the time course of wake theta activity across the 
protocol was compared with the time course of sleep theta activity during NREM sleep across 
the protocol (Figure 3.13).
The waking EEG was similar in both the frontal and central derivations and under sleep 
extension conditions waking theta activity tended to rise above baseline day theta activity and 
then, towards the end of the protocol, reverted back towards baseline day levels. Under sleep 
restriction conditions theta activity tended to be at or below baseline levels of theta activity.
In order to assess the effects of time of day on the time course o f waking theta activity, 
waking EEG from the first and last cognitive tests of the day were compared. Whilst the 
profile o f theta activity was similar for both the first test of the day (test 1) and last cognitive 
test of the day (test 5), the decrease in theta activity, particularly on condition day 3, was 
greater during the last test of the day compared with the first test of the day for the sleep 
restriction condition. There was no prominent difference between the tests for the sleep 
extension condition.
Comparison of waking theta activity to NREM sleep theta activity demonstrated that the 
relative power densities between sleep and wake were in opposition to each other i.e. theta 
activity under sleep extension conditions was high during the day and low at night and the 
opposite was true whilst under sleep restriction conditions.
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Figure 3.13: Wake and NREM sleep EEG theta activity across the protocol 
EEG theta activity during waking (5.0-9.0Hz; n=21-30) and sleep (4.75-7.75Hz; n=27-34) 
(geometric mean ± 95% Cl’s) across the protocol (condition days; GDI-6, condition nights; 
CNI-7, and recovery night; RN; x-axis) from frontal and central derivations expressed 
relative to baseline day 1 (wake) or baseline night (sleep; first 6 hours of condition night 
expressed relative to first 6 hours of baseline night) (100%, y-axis). Open symbols = sleep 
extension condition and closed symbols = sleep restriction condition.
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3.3.4.2 Correlation between wake EEG and sleep EEG
To further investigate the correlation between markers of sleep homeostasis in the wake and 
sleep EEG, theta activity (5.0-9.0Hz) from waking EEG recorded during KDTs occurring in 
the first and last cognitive test batteries was correlated with theta (4.75-5.75Elz) and delta 
(0.75-4.5Hz) activity during NREM sleep, recorded in the sleep EEG occurring in the night 
following the daytime EEG recordings per individual where possible. Wake theta activity 
recorded on baseline day 1 and condition days 1, 3 and 6 was correlated with sleep theta and 
delta activity during NREM sleep on baseline night and condition nights 2, 4 and 7 
respectively for sleep extension (Figures 3.14 and 3.16) and sleep restriction (Figures 3.15 
and 3.17) conditions. The correlation of the relative power densities for sleep extension and 
sleep restriction conditions was assessed by calculating the Pearson’s r correlation. Theta 
activity is most predominant in frontal and central derivations (Cajochen et al., 1999, 
Strijkstra et al., 2003) and therefore the wake EEG analysis was restricted to the central 
derivation.
There was a positive correlation between wake theta activity and sleep theta and delta activity 
during both sleep extension and sleep restriction conditions, as wake theta activity increased, 
so did sleep theta activity and delta activity during NREM sleep. The correlation between 
wake and sleep EEG theta activity was significant for all correlations assessed, except for 
CD6 vs CN7 Tl under sleep restriction conditions which approached significance. The 
correlations did not appear to consistently differentiate between the sleep extension and sleep 
restriction conditions, however, the correlation tended to be higher on test 5 compared with 
test 1 under both conditions.
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The correlation between wake theta activity and sleep delta activity were significant for all 
correlations assessed, except for CD6 CN7 Tl under sleep restriction conditions. Wake 
theta activity was less well correlated with sleep delta activity than with sleep theta activity 
and there was a tendency for higher delta activity in the sleep EEG compared with theta 
activity in the wake EEG. The correlations did not show any marked differences between the 
sleep extension and sleep restriction conditions. Correlations tended to be higher on test 5 
than on test 1, particularly whilst under the sleep restriction condition.
Wake theta activity correlated with sleep theta and delta activity did not show any vast 
differences across protocol days, however, some of the lowest r values were observed on the 
last day assessed (CD6 vs CN7) particularly for test 1. In addition, visual inspection of all 
correlation figures demonstrates that whilst there was no major distinction between the three 
PER3 genotypes, some inter-individual variation can be observed in that the PER3 '^  ^ groups’ 
power density values tended to cluster lower than the PER3 '^  ^and PER3 '^  ^groups’.
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Chapter 3
3.3.4.3 Correlation between relative wake EEG and sleep EEG 
To assess whether the response to sleep extension and sleep restriction conditions in the 
waking EEG correlated with the response in the sleep EEG, the protocol day/night where the 
largest changes from baseline were observed were selected for correlation analysis, this being 
condition day 3 and condition night 4.
Waking EEG theta activity power density values for condition day 3 were expressed relative 
to baseline day 1 and sleep EEG theta and delta power density values for condition night 4 
were expressed relative to baseline night, per individual where possible. The wake and sleep 
relative power density values were then correlated for the sleep extension and sleep 
restriction conditions (Figures 3.18 and 3.19 for correlation to sleep theta and delta activity 
respectively). The correlation of the relative power densities for sleep extension and sleep 
restriction conditions was assessed by calculating the Pearson’s r correlation.
All correlations based on relative data were positive despite the opposition of the conditions 
when expressed relative to the first condition day. However, each correlation resulted in 
fairly low r values, and only two of the associated p values were significant, this being the 
comparison between wake theta activity fi*om test 5 and sleep theta activity, under both sleep 
conditions. Theta activity in the wake EEG on condition day 3 expressed relative to condition 
day 1 tended to be higher within individuals than did theta and delta activity in the sleep EEG 
on condition night 4 expressed relative to baseline night. Inter-individual variation was low 
with individuals’ responses tending to cluster closely together, with the exception o f a few 
outliers, which tended to be observed within the waking EEG. There were no apparent PERS 
genotype dependent individual differences in the response to sleep extension and sleep
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restriction protocols as there was no clear distinction in the relative power density values 
between genotypes.
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Figure 3.18: Relative wake theta activity v.s' relative sleep theta activity 
Condition day 3 wake theta activity (5.0-9.0Hz; x-axis) from KDT test 1 (top row) and KDT 
test 5 (bottom row) correlated with condition night 4 sleep theta activity (4.75-7.75Hz; y- 
axis) from the central derivation per individual for sleep extension (left figures) and sleep 
restriction (right figures) conditions. Wake and sleep activity are expressed relative to data 
from baseline day 1 and baseline night respectively (100%). •  = PER3 '^  ^ genotype (n=8-ll);
•  = PER3 '^  ^ genotype (n=6-7); •  = PER3 '^  ^ genotype (n=8-9). Linear regression line for total 
population and r and p values derived from Pearson’s r correlation are indicated on each plot.
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Figure 3.19: Relative wake theta activity relative sleep delta activity 
Condition day 3 wake theta activity (5,0-9.0Hz; x-axis) from KDT test 1 (top row) and KDT 
test 5 (bottom row) correlated with condition night 4 sleep delta activity (0.75-4.5Hz; y-axis) 
from the central derivation per individual for sleep extension (left figures) and sleep 
restriction (right figures) conditions. Wake and sleep activity are expressed relative to data
from baseline day 1 and baseline night respectively (100%). # = PER3 '^  ^genotype (n=8-l 1);
•  = PERS'^ '^  genotype (n=6-7); •  = PER3 '^  ^genotype (n=8-9). Linear regression line for total 
population and r and p values derived from Pearson’s r correlation are indicated on each plot.
, 5 / 5 ______
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3.4 Discussion
3.4.1 Effects of the protocol on PSG and NREM sleep EEG 
The total sleep time measures confirmed that the protocol was successful in extending and 
restricting sleep by altering participants’ window of opportunity for sleep. The protocol 
significantly affected PSG measures o f sleep, as well as the spectral composition of the EEG. 
Following partial chronic sleep restriction SWS, SWE, REM sleep and SE increased and 
TST, sleep latencies and stages 1 and 2 decreased, indicating that there was an increased 
homeostatic drive for sleep and this increased homeostatic response was also reflected in the 
power density spectra, whereby delta and theta activity increased above baseline levels on 
restriction nights. Under sleep extension conditions, sleep latencies, stages 1 and 2 and TST 
increased, indicating that whilst more time was spent asleep, the sleep was lighter. The drop 
in TST on the last sleep extension night was likely due to an anticipation effect. Participants 
were aware that the following morning would be the start of the constant routine and since 
participants under the sleep extension condition were not sleep deprived they were able to 
wake up earlier than usual, whereas this did not occur under sleep restriction conditions. On 
recovery nights following total sleep deprivation there was a large rebound of SWS and SWA 
which was particularly evident in the 6 hour analysis and this is reflective o f more intense 
sleep.
These results from the PSG analysis and EEG spectral analysis are concordant with those 
from other sleep restriction and total sleep deprivation protocols, whereby sleep restriction 
usually results in conservation of baseline levels of SWS and SWA, with only small 
increases, whilst total sleep deprivation results in a large rebound of SWS and SWA (Dijk et 
al., 1987b, Dijk et al., 1990b, Brunner et al., 1993, Dijk et al., 1993, Lucidi et al., 1997, Van 
Dongen et al., 2003, Tinguely et al., 2006, Akerstedt et al., 2009). Extended sleep
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opportunities increased percentage of time awake and induced more superficial sleep as 
reflected by increased percentage and stages 1 and 2, as well as resulting in a significant 
reduction in power in the delta and theta activity bands during NREM sleep. These results 
indicate that there was a dissipation of sleep pressure on sleep extension nights and suggests 
that there was no sleep debt carried by participants on any of the nights under these 
conditions.
Previous sleep history had an effect on recovery nights following total sleep deprivation, 
whereby TST and SÈ were significantly higher on recovery nights following the sleep 
restriction condition compared with recovery nights following the sleep extension condition. 
Whilst it appeared that delta and theta activity during NREM sleep were higher on recovery 
nights following the sleep restriction condition compared with recovery nights following the 
sleep extension condition, mixed model analyses did not reveal any significant differences 
between the two conditions. It has previously been reported that extended sleep prior to 
periods of sleep deprivation has protective effects against performance and alertness 
decrements (Rupp et al., 2009) and cognitive data published from our study also reported that 
poorer cognitive performance was observed during total sleep deprivation when the prior 
sleep history was sleep restriction (Lo et al., 2012). It may be the case that recovery from 
total sleep deprivation may have been slower when the previous sleep history was sleep 
restriction and thus the concept of banking sleep may in reality serve a beneficial purpose 
given the negative health consequences commonly associated with sleep loss.
3.4.2 Homeostatic regulation of sleep
It was hypothesised that the greatest effect of the sleep extension and sleep restriction 
protocols would be observed in the lower frequency ranges and in particular in those
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participants with a PER3 '^  ^ genotype (Viola et al., 2007, Viola et al., 2012). However, the 
time course of SWA across the seven nights of sleep restriction revealed some surprising 
results, which are somewhat in contrast with those predicted. From previous research it was 
anticipated that under sleep restriction conditions SWA would be conserved and increase 
slightly above baseline levels. This was observed, however, the decline back towards baseline 
levels o f SWA from condition night 4 to condition night 7 was unexpected. Sleep propensity 
is governed by both homeostatic and circadian processes (process S and process C 
respectively) and the two process model o f sleep regulation states that process S rises with 
time awake until a threshold is reached and sleep is initiated (Borbely, 1982, Daan et ak, 
1984). EEG SWA is the most commonly used biomarker for the homeostatic process 
regulating sleep and during periods of sleep restriction/deprivation process S continues to 
rise, which is reflected in the ensuing sleep period as an increase in SWA at the beginning of 
the night (Borbely, 1982, Tobler and Borbely, 1986). If the two process model of sleep 
regulation was to accurately predict the response to chronic partial sleep deprivation then 
SWA would have remained above baseline levels on all sleep restriction condition nights and 
not return to baseline levels.
Chronic sleep restriction protocols of up to 5 days in rats have investigated the homeostatic 
response to sleep restriction, however, results have been somewhat inconsistent (Kim et al., 
2007, Leemburg et al., 2010, Deurveilher et al., 2012). One group reported a failure to 
increase delta power during NREM sleep beyond the first day of sleep restriction, and 
proposed that an allostatic response had occurred (Kim et ak, 2007). Allostasis is an adaptive 
response to a change in environment, resulting in behavioural or physiological changes in 
order to maintain stability. There has been a lack o f evidence to support the allostatic 
response theory and some investigators have concluded that sleep homeostasis is conserved
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under such conditions (Leemburg et al., 2010) and others have suggested that whilst some 
aspects of sleep remain under homeostatic control, others such as delta activity, are more 
prone to adaptive responses (Deurveilher et al., 2012). Very few studies that have 
investigated the changes in sleep whilst under sleep restriction conditions over long periods 
of time and previous chronic partial sleep restriction protocols in humans imposed for 2-5 
days typically report an increase above baseline levels of SWS and SWA on restriction nights 
that remains so until at least the first recovery sleep period (Brunner et al., 1990, Brunner et 
al., 1993, Akerstedt et al., 2009). One study did impose sleep restriction for 14 days but did 
not report any significant changes in delta power (Van Dongen et ak, 2003). Ours is the first 
study to our knowledge that demonstrates this adaptive response in delta activity during 
NREM sleep, and could be the first to show that allostatic responses do occur in some aspects 
of human sleep.
Other factors to consider are whether the 6 hour sleep deprivation was enough to elicit an 
increased sleep need over the course of the protocol since many other similar protocols have 
used shorter sleep opportunities to induce a sleep debt (Brunner et ak, 1993, Lucidi et ak, 
1997, Akerstedt et ak, 2009). Although not significant, sleep latency measures were reduced 
under sleep restriction conditions and there was a deficit in SWE still evident on the last 
condition night compared with the entire baseline night. This taken together with the 
cognitive performance deficits previously published (Lo et ak, 2012) would suggest that 
reducing sleep to 6 hours per night was sufficient to cause a sleep debt in our participants. It 
is possible that there was some dissipation of sleep pressure during the day under sleep 
restriction conditions, leading to the decline in delta activity towards the end of the protocol. 
However, if  it were the case that homeostatic mechanisms occurring during the day were 
compensating for the reduction in sleep delta power at the end of the protocol it would be
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expected that waking EEG theta activity would have been high on days preceding the reduced 
sleep delta activity that occurred towards the end of the protocol under sleep restriction 
conditions, and this was not observed and provides further support for allostatic mechanisms 
governing the change over time.
It is well known that elements within the EEG are useful indicators for sleepiness and arousal 
and in such a way the waking EEG can be used as a biomarker for sleep homeostasis. Waking 
EEG theta activity is reflective o f sleep propensity (Aeschbach et al., 1997a, Cajochen et ak, 
2002) and correlates with NREM sleep SWA (Finelli et ak, 2000, Vyazovskiy and Tobler, 
2005). Waking theta activity was assessed across several protocol days, and we found that 
power density tended to increase on sleep extension days and decrease on sleep restriction 
days relative to baseline day, these results were in opposition to what was expected given that 
theta activity increases with time awake.
Theta activity has been shown to undergo circadian modulation (Aeschbach et ak, 1997b, 
Aeschbach et ak, 1999) and this factor should be considered when attempting to understand 
the basis o f our results. In our protocol, irrespective of whether it was a baseline day, a sleep 
extension day or a sleep restriction day, there were five cognitive test batteries per day which 
resulted in varying lengths of time between tests and this could have indeed contributed to the 
dissonance between our results and others. On baseline days participants’ time awake was 
2.15h and 12.55h for test 1 and test 5 respectively, on sleep extension days participants’ time 
awake was 1.55h and 11.15h for test 1 and test 5 respectively and on sleep restriction days 
participants’ time awake was 2.35h and 14.35h respectively, and therefore these differences 
between the test times could have allowed for circadian influences to affect the results. In 
addition, participants’ sleep-wake schedules during the protocol were based on their habitual
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averages. These factors could have also given rise for the potential of circadian factors to 
influence power densities in the theta band. We also did not observe any major differences in 
theta activity between tests 1 and 5 and again this may have also been influenced by circadian 
factors. An alternative explanation is that the increase of theta power in extended wakefulness 
protocols tends to show the fastest rise after about 18 hours (Finelli et al., 2000), whereas 
participants in our study, even on the sleep restriction protocol, did not reach this duration of 
time awake before the last cognitive test and therefore could explain why no major 
differences were observed between tests.
The correlation analyses demonstrated that whilst absolute power density values o f wake 
theta activity correlated with absolute levels of theta and delta activity during NREM sleep, 
the relative values (i.e. expressed as a percentage of baseline day or night) did not show a 
significant correlation between wake and sleep activity as has previously been reported 
(Finelli et ak, 2000). This is perhaps not surprising given that the time course o f wake and 
sleep theta activity figures demonstrated that power during the day was somewhat in 
opposition to that during the night. Several factors may have contributed to the differences in 
our results and those previously reported, firstly, in the study by Finelli et ak, they did not 
find a significant correlation between wake and sleep theta activity and secondly, the 
correlation between wake theta activity and SWA during NREM sleep was restricted to SWA 
in the first NREM sleep episode, and this correlation was not made in our study. Therefore, 
our study does not necessarily suggest that markers of sleep homeostasis in the wake and 
sleep EEG are not related; rather they could not be demonstrated in our study due to factors 
that could have masked the relationship such as circadian modulation, as well as factors 
relating to analysis techniques.
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3.4.3 Individual differences in sleep
The PSG parameters showed large variation across protocol nights and particularly so for the 
recovery nights, ICC analysis of PSG variables demonstrated that there were inter-individual 
differences within at least some o f the variables, in particular SWS. The ICCs presented here 
are in some cases lower than those reported by others investigating the stability and 
robustness of sleep parameters in a sleep deprivation study (Tucker et al., 2007), particularly 
for TST, WASO and wake. This is likely due to the differing lengths o f night in our study 
which was not the case in the Tucker et al., study and this would therefore be expected to 
influence the ICCs calculated for individual condition nights (10 hours TIB vs 6 hours TIB), 
and the ICCs calculates with all nights in the model. However, the ICCs calculated for 
baseline nights which were the same duration in both the sleep extension and sleep restriction 
conditions, were directly comparable to those o f Tucker et al.,. Analysis o f the ICC with 
differing lengths of night input into the mixed model allowed investigation as to which 
variables were conserved under the differing length of sleep opportunities; in particular the 
proportion of stage 1, stage 2 and the proportion and minutes of SWS produced high ICCs 
across all nights. The ICC analysis on absolute EEG power density values for NREM and 
REM sleep ICCs were consistently high across all derivations and frequency bands, in spite 
of the differing lengths of night input into the mixed model and were in accordance with 
those reported by others who have calculated ICCs calculated at various EEG frequencies, 
including those in children, adolescents and adults (Tucker et ak, 2007, Geiger et ak, 2011, 
Tarokh et ak, 2011), our research therefore contributes to the growing evidence that trait-like 
inter-individual differences exist in the EEG.
ICCs calculated from EEG power density values and PSG derived sleep variables expressed 
as a relative change (i.e. expressed as a percentage relative to another night such as baseline)
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were very low in comparison to ICCs calculated for absolute data, and in some cases the ICC 
value could not be obtained due to the between subject variance estimate regressing to 0. A 
reduction in ICCs based on relative EEG power density values was expected, since each 
participant is standardised to the same scale, and thus inter-individual differences are reduced 
and this loss of inter-individual variation was observed in the scatter plots depicting the 
relative difference in EEG power densities between baseline and recovery night. However, 
such low values were not expected since it was anticipated that individuals would respond, at 
least to some extent, differentially to each other given the literature detailing inter-individual 
differences in sleep homeostasis. For example, inter-individual differences in the time 
constants of process S have recently been shown with nocturnal EEG SWA (Rusterholz et al., 
2010, Rusterholz and Achermann, 2011) and have also been shown with wake EEG theta 
activity (Aeschbach et ak, 2001, Taillard et ak, 2003). The low ICCs derived from relative 
data and the high ICCs derived from absolute data indicates that whilst the amplitude o f the 
EEG in particular may be highly individual, this does not reflect stable and robust individual 
differences in sleep-wake regulation.
The ICC is a valid measure for quantifying the variability within a population (Van Dongen 
et ak, 2004a, Van Dongen et ak, 2004b) and the purpose of calculating the ICCs was to 
establish whether any aspects of sleep in our study showed trait-like inter-individual 
variability, which according to Van Dongen et ak, must be a variable that can be shown to be 
significant, stable over time and robust to intervention (Van Dongen et ak, 2005). Our study 
design made it possible to examine these variables in that repeated nights within a condition 
and the differing experimental conditions allowed for demonstration of both stability and 
robustness. A high ICC value is indicative that the variable is significant and as such we have 
been able to show that some aspects o f sleep structure are trait-like. The results presented in
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this chapter have shown that the amplitude of the EEG is highly individual, whereas the 
response to sleep-wake manipulations may not necessarily be trait-like. Taken together the 
ICC analysis confirms the hypothesis that trait-like individual differences exist within the 
EEG, however, the highest ICCs were those which related to the amplitude of the EEG, and 
not those for the response to intervention. This implies that the high ICCs relate to the 
phenomena of the EEG rather than aspects o f sleep-wake regulation.
3.4.4 Contribution of the PER3 VNTR polymorphism to individual differences 
There were significant differences between PER3 genotypes on PSG measures and the 
spectral composition of NREM sleep. The PER3 '^  ^ group had less SWS compared with the 
PER3 '^  ^ group as well as less TST, SE and more wake than the PER3 '^  ^ group within the 
analysis of the first 6 hours of the night. The PER3 '^  ^ group also had more REM sleep than 
the other genotype groups. In addition, the PER3 '^  ^ group had significantly less delta and 
theta activity during NREM sleep than the PER3 '^  ^ and PER3 '^  ^ groups, and seemingly had 
lower absolute levels of theta activity in the waking EEG as evidenced by the scatter plots, 
indicating that the PER3 '^  ^group do not compensate for the reduction in sleep delta power by 
increasing daytime levels of theta activity. The significant differences relating to the PER3^’^  
groups’ sleep were particularly surprising considering recent research that described an 
increase in delta power in PER3 '^  ^group compared with the PER3 '^  ^group in both young and 
elderly participants (Viola et ak, 2007, Viola et ak, 2012). Findings in previous research has 
led to the hypotheses that PER3 '^  ^ individuals live under higher sleep pressure than the other 
PER3 variants, and this population is more vulnerable to the effects of sleep loss on cognitive 
deficits (Groeger et ak, 2008, Lo et ak, 2012, and reviewed in Dijk and Archer, 2010).
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It is likely that study design was a factor in the observed differences between the studies. The 
increase in delta activity within the PER3 '^  ^ group compared with the PER3‘^'^  group in the 
study by Viola et al., was only significant at baseline. In the study described here, although 
genotype did not significantly interact with any other main effect, the PER3 '^  ^ group had 
lower SWA on all experimental nights compared with the other PER3 genotype groups, 
indicating a stable and robust genotype dependent difference. Duration of sleep was also 
likely a major contributor to the differences in delta activity observed in the PER3 '^  ^
participants in the two studies, for example, participants in the Viola et ak, study slept at their 
habitual sleep schedule, and given that PER3 '^  ^ individuals are more likely to have shorter 
sleep durations compared with the other PER3 genotypes (Lazar et ak, 2012), it is feasible 
that the increase in delta power observed in Viola’s study was due to a sleep debt carried by 
these participants. The differences in delta power during NREM sleep between genotypes in 
our study related to absolute EEG power density values, and despite the PER3 '^  ^ group 
having the lowest absolute levels of SWA, when data were expressed per genotype relative to 
the baseline night it was evident that the response in the PER3 '^  ^ group particularly to the 
sleep restriction condition, was comparable to, if  not greater than, the other PER3 genotypes. 
Recently, a significant increase in homeostatic response in PER3 '^  ^ individuals following 
total sleep deprivation has been reported (Goel et ak, 2009), which suggests that absolute 
power density of the EEG does not necessarily constitute individual differences in sleep-wake 
regulation.
Other implications can of course arise from the demographics of participants used in the 
studies, the need for research detailing differences in sleep arising from sex and ethnicity has 
been highlighted (Van Dongen et ak, 2005), and at present there is very little systematic 
research in this area. Of relevance to our data is some research demonstrating reduced SWS
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in black ethnic populations (Profant et al., 2002, Stepnowsky et al., 2003) and interestingly, 
the PERS '^  ^ group in our study included two black participants, who produced some of the 
lowest levels of SWS and SWA, in contrast to one black participant in each of the other 
PER3 groups. In the study by Viola et al., there were no black participants in the PER3 '^  ^
group, but two in the PER3 '^  ^group (Viola et al., 2007). These differences in ethnicity could 
have accounted for the differences in SWS and SWA between the two studies.
The database o f subjective measures from candidates for this study and two other studies 
(Lazar et ak, 2012), revealed that PER3 '^  ^individuals were more likely to be morning types, 
with earlier bed times and wake up times and shorter sleep durations compared with the other 
genotype variants, however, on non-work days PER3 '^  ^ individuals had the longest time in 
bed duration. The PER3 '^  ^ individuals also rated themselves as less sleepy compared with the 
other genotype variants (Lazar et ak, 2012). The results from the subjective measures, 
combined with the lower SWA observed during NREM sleep could imply that there is a 
reduced sleep need or perhaps a reduced ability for sleep in PER3 '^  ^ individuals, which may 
account for the cognitive vulnerability observed in these individuals.
Despite conflicting results o f the PER3 polymorphism on homeostatic (Viola et ak, 2007, 
Goel et ak, 2009, Viola et ak, 2012) and circadian (Archer et ak, 2010, Barclay et ak, 2011, 
Lazar et ak, 2012) aspects of sleep, it is evident that the PER3 polymorphism differentially 
affects sleep-wake regulation with genotype dependent differences being centred around 
homozygosity for the longer allele, implying a differential regulation o f sleep propensity and 
its dissipation within this genotype variant. It is likely that other factors other than PER3 
genotype are influencing the differences which may include demographics, and ethnicity may 
have influenced differences in allelic susceptibility to DSPS (Archer et ak, 2003, Pereira et
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al., 2005); age is also known to affect the phenotypic characterisation of the polymorphism, 
and genotype dependent individual differences associated with the polymorphism attenuate 
with increasing age (Jones et ak, 2007). Polymorphisms in other genes related to sleep-wake 
regulation may also influence the data (reviewed in Dauvilliers et ak, 2005) and in such a 
way sleep-wake regulation may co-vary, perhaps with the PER3 '^  ^ population most 
susceptible to such variation.
3.4.5 Conclusions
The results presented here conclude that there is trait-like variability within certain aspects of 
the sleep EEG in healthy individuals and as such the EEG is able to serve as a biomarker for 
individual differences, certainly with respect to the amplitude of the EEG, and the research 
presented here on such individual differences contributes to current understanding of 
individual differences in the context of normal physiological sleep. Whilst the response to the 
experimental challenges of sleep extension, sleep restriction and total sleep deprivation was 
somewhat investigated in this chapter, there is a need for further investigation in this area in 
order to establish whether there are trait-like individual differences in the homeostatic 
regulation of sleep.
This data also contributes to research attempting to identify the genetic underpinnings o f  
sleep-wake regulation and we have demonstrated that the VNTR polymorphism in the PER3 
gene differentially affects the EEG in healthy individuals. This data also serves to 
demonstrate how such polymorphisms may contribute either advantageously or 
disadvantageously to the ability to cope with sleep restriction and total sleep deprivation, 
which in our 24 hour society, is becoming an important concern for public health.
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Chapter 4: Biomarkers and individual differences: The effects of light 
interventions on sleep
4.1 Introduction
Light is the most powerful zeitgeber or ‘time giver’ for our circadian pacemaker and allows 
our internal clock to become entrained to the external environment (reviewed in Duffy and 
Wright, 2005, Golombek and Rosenstein, 2010). Light energy is refracted onto retina at the 
back of the eye where it is absorbed by photoreceptors and converted into electrical signals 
which are transmitted centrally via the optic nerve to induce both visual (i.e. image forming) 
and non-visual (non-image forming) responses to light.
The two photoreceptors primarily involved in the visual system are the highly light sensitive 
rods which contain the photopigment rhodopsin and are responsible for night time scotopic 
vision and the less light sensitive cones which are responsible for daytime photopic vision. 
There are three subtypes of cones, each containing a different photopigment responsible for 
colour vision; S-cone cells absorb short-wavelength blue light, M-cone cells absorb medium- 
wavelength green light and L-cone cells absorb long-wavelength red light (Brown and Wald, 
1964). Retinal ganglion cells (RGCs) relay light information via the lateral geniculate nucleus 
of the thalamus to the primary visual cortex and extrastriate areas in the occipital lobe o f the 
brain where visual processing begins. Light information is then transferred via dorsal and 
ventral visual pathways to the parietal cortex and temporal cortex respectively and 
information regarding location and motion of objects as well as shape colour and texture is 
generated.
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It was recently discovered that a subset o f retinal ganglion cells are intrinsically 
photosensitive (ipRGCs), and these cells mediate the non-visual effects of light via the 
photopigment melanopsin (Brainard et al., 2001, Thapan et al., 2001, Provencio et al., 2000) 
and the retinohypothalamic tract directly relays information from ipRGCs to the master 
circadian pacemaker located in the suprachiasmatic nucleus (SCN) of the hypothalamus 
(Berson et al., 2002, Hattar et al., 2002). The peak sensitivities of the photoreceptors have 
been characterised and melanopsin is maximally sensitivity to short-wavelength light with a 
wavelength of approximately 480nm (Panda et ak, 2005, Brainard et ak, 2008), which is 
different from the maximum sensitivity o f the photopic and scotopic systems primarily 
mediating vision, with these being at the longer wavelength end o f the spectrum at 550nm 
and 505nm respectively. Although melanopsin is likely to be the major contributor of inputs 
to the circadian pacemaker, it is thought that other photoreceptors such as rod and cone cells 
contribute to some of the non-visual effects of light by directly interacting with ipRGCs 
(Ruby et ak, 2002, Gooley et ak, 2010), and it is also likely that melanopsin contributes to 
image forming vision (Dacey et ak, 2005, Brown et ak, 2010, Ecker et ak, 2010). The relative 
contribution of each photoreceptor type to the effects of light on circadian timing has been 
the subject o f recent review (reviewed in Lucas et ak, 2012).
The non-visual responses to light are of importance because light is known to impact on our 
physiological and psychological functions. The non-visual effects o f light include those 
which affect circadian timing and sleep-wake regulation such as, suppression of melatonin 
(Zeitzer et ak, 2000, Lockley et ak, 2003), altered sleep propensity (Dijk et ak, 1991, Carrier 
and Dumont, 1995) and alertness (Lockley et ak, 2006), as well as other effects including 
altered mood (Brunner et ak, 1996, Grimaldi et ak, 2008), emotion (Vandewalle et ak, 2010) 
and cognitive functioning (Vandewalle et ak, 2011). Recent animal literature has also
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detailed the direct effects o f light on sleep regulation which appear to be mediated by 
melanopsin via circadian clock independent pathways (Lupi et ak, 2008, Tsai et ak, 2009). 
Disruption of sleep-wake regulation caused by inappropriately timed light may not only 
affect an individuals’ ability to perform, but may also be a predisposing risk factor for 
illnesses such as cancers and cardiometabolic disorders, and these serious physical health 
consequences caused by light disruption have been reviewed in recent years (Stevens et ak, 
2007, Scheer et ak, 2009, and reviewed in Ruger and Scheer, 2009).
Our 24-hour society means we are more often exposed to inappropriately timed, artificial 
indoor lighting, as opposed to natural outdoor light and given the ever mounting research in 
the area of light and well-being; this has important implications for indoor lighting design. 
Research has shown that there are beneficial effects of bright light exposure during the day, 
such as improved subjective alertness and improved response to tasks (Phipps-Nelson et ak, 
2003, Vandewalle et ak, 2006). The positive effects of daytime light exposure may be 
enhanced by adjusting the contribution of different wavelengths (Lockley et ak, 2006, Viola 
et ak, 2008). Ascertaining which light mixtures support the visual system and allow the 
benefit from desirable non-visual effects, whilst minimising detrimental non-visual effects 
will be required in order to develop polychromatic lighting regimes that are optimal for 
health.
At present there is little evidence on the effects o f light on the spectral composition o f the 
EEG, and assessing the effects of light on EEG will be important factor in establishing the 
neurological basis for the non-visual effects o f light. Intervention studies are necessary for 
determining how the EEG responds to various challenges and for quantifying such responses 
within the EEG. In addition, intervention studies also allow for assessment o f individual
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differences in sleep-wake regulation. It is aheady known that there are prominent individual 
differences in sleep and in recent years there has been a focus towards establishing whether 
such inter-individual differences are trait-like and this is important for determining factors 
underlying such differences, establishing the significance o f such differences and perhaps 
most importantly, identifying which differences relate to a susceptibility to negative health 
consequences (Van Dongen et ak, 2005). In such a way the EEG may be able to serve as a 
biomarker for systematic inter-individual differences that become apparent under 
experimental challenge.
The aim of this study was to characterise and quantify the effects of different spectral 
compositions of polychromatic light on nocturnal EEG power density in normally sighted 
individuals. Previous research showed that a high blue light content of polychromatic light 
has more profound effects on melatonin and subjective measures of alertness compared to 
polychromatic light containing less blue light and it was suggested that this was due to 
increased efficacy of the blue enhanced light conditions on the melanopsin system (Santhi et 
ak, 2011); therefore the results on the sleep EEG were hypothesised to be in the same 
direction. The aim of this study was also to establish whether there were inter-individual 
differences in the EEG that were stable and robust to the light intervention and could 
therefore be considered as trait-like. The EEG is one o f the most heritable human traits 
(Buckelmuller et ak, 2006), and it was therefore hypothesised that the differences across 
individuals would be greater than the differences within individuals that were robust to 
intervention with the polychromatic light conditions and therefore indicate that there were 
trait-like inter-individual differences within the EEG.
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4.2 Methods
The study presented in this chapter was conducted at the Surrey Sleep Research Centre and 
the study protocol was reviewed by the University of Surrey Ethics Committee and received a 
favourable opinion in May 2009.
4.2.1 Participants
Following a successful telephone interview seventy-four individuals (49 males, mean age 24 
years) were invited to attend a screening session at the Surrey Clinical Research Centre. After 
giving written informed consent, individuals were asked to complete a series of 
questionnaires. Questionnaires included a general medical questionnaire, an expectation 
questionnaire, a headache and eye strain questionnaire, the Groningen Sleep Quality Scale, 
the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Big Five 
Personality Questionnaire, the Positive and Negative Affect Scale (PANAS), the Insomnia 
Severity Scale Index, the Home-Ostberg Diurnal Preference Scale, The Munich Chronotype 
Questionnaire (MCQ), the SF36 Health Survey, an assessment of IQ (Ravens), a verbal 
reasoning task, the Karolinska Sleep Diary (KSD), the Karolinska Sleepiness Scale (KSS), 
the Social Rhythm Metric diary, the Behavioural Inhibition/Behavioural Approach Systems 
questionnaire, the Dutch Eating Behaviour questionnaire, the National Sleep Survey, the 
Beck’s Depression Inventory and Visual Analogue Scales (VAS) rating hunger and thirst. 
Responses to questioimaires determined suitability for participation in the laboratory study 
and also provided a database of subjective measures.
Buccal swabs were also obtained from participants in order to determine their genotype for 
the PERIOD (PER) clock gene PER3 which contains a Variable Number Tandem Repeat 
(VNTR) polymorphism in its coding region (rs57875989). The buccal swabs were subjected
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to a previously described polymerase chain reaction (PGR) protocol to extract and amplify 
participants’ DNA to determine the genotype (Vandewalle et al., 2009). Variants of the 
genotype include homozygosity for the 4-repeat allele homozygosity for the 5-
repeat allele (PER3^^ )^ or a heterozygous genotype (PER3"^ ^^ ).
From the screening population twenty-six individuals, aged 18-35 years, were invited to 
participate in the laboratory phase o f the study. Three participants withdrew from the study 
due to personal reasons and one participant was withdrawn from the study due to breach of 
protocol and therefore twenty-two individuals (15 males and 7 females) aged 18-34 years 
(mean age 23.14 years, SD 4.67) completed the protocol; 10 PER^ ^^ '^ ’s (mean age 23.68 
years, SD 5.04), 4 PPRj^^’s (mean age 20.08 years, SD 1.51) and 8 PPRj^^’s (mean age 24 
years, SD 5.01).
A full medical screening of the selected participants was carried out approximately 7-10 days 
before the first admission to the Centre and involved review of the medical questionnaire 
completed at screening, assessment of general physical health (including the Ishihara test for 
colour blindness) and standard biochemistry and haematology. A urine pregnancy test was 
also required for female participants. In addition, participants were not taking any 
medications (excepting oral contraceptives and topical creams), were non-smokers, did not 
consume more than 5 cups of caffeinated beverages per day, and/or more than 14 units of 
alcohol per week, did not suffer from any self-reported sleep disorders or sleep complaints 
such as apnoea or insomnia as assessed by the PSQI, were not shift workers, had not travelled 
across more than 1 time zone in the month preceding the first laboratory session and had not 
given blood in the 6  weeks prior to the first laboratory session. For the 3 days prior to each
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laboratory period participants were asked to refrain from alcohol, chocolate, food 
supplements and strenuous exercise.
On admission to the Centre at each laboratory session a reduced screening of participants was 
performed. Breath alcohol tests and urinary drug screens were carried out, as well as urine 
pregnancy tests for female participants. Positive results for non-permissible substances, or 
pregnancy would have resulted in exclusion from the study.
4.2.2 Study design
The study was a single-centre, 6 -way crossover design with seven laboratory sessions, each 
lasting one overnight stay at the Centre. The first visit to the Centre was an acclimation night 
in order to allow participants to become familiarised with the laboratory environment, and 
also served as a polysomnography (PSG) screening for sleep disorders, such as sleep apnoea 
and periodic leg movements. The remaining 6  visits to the Centre were experimental light 
intervention conditions.
Participants were asked to wear a spectral actiwatch (Actiwatch Spectrum, Philips 
Respironics, Murrysville, Pennsylvania, USA) to monitor rest-activity cycles and were also 
asked to complete the KSD and the Groningen Sleep Quality questionnaire on a daily basis, 
for a minimum of 7 days preceding the first laboratory visit to the Centre and for the duration 
of the study. Prior to the first laboratory visit participants were asked to sleep at their habitual 
time, for 8  hours each night. On the first visit to the Centre participant’s actiwatch data were 
downloaded and viewed in an actogram (Respironics Actiware 5.0, Philips Respironics, 
Murrysville, Pennsylvania, USA) and from this an average 8  hour sleep schedule was 
calculated for each participant. Participants were then asked to maintain this sleep schedule
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for at least 7 days preceding each visit to the Centre. Participants were not allowed to deviate 
from their schedule by more than 30 minutes more than 3 times preceding each visit. 
Participants’ actograms were checked at each visit for compliance. Non-compliance would 
have resulted in exclusion from the study. No participants were excluded due to non- 
compliance.
During the day participants remained within the unit and neutral density light filters were 
used to keep light levels within the laboratory at <5 lux. During the light exposure the 
surrounding room was in complete darkness. At night participants slept in a windowless, 
sound attenuated, temperature controlled room in complete darkness. At each visit, 
participants slept at their calculated average habitual bed time and were given an 8  hour sleep 
opportunity. See Figure 4.1 for a diagram of the study design.
The 6  light intervention visits involved exposure to varying polychromatic light mixtures and 
the order for which was balanced across 4 groups of participants to minimise the effects o f  
order. Participants took part in all 6  light exposure conditions, each separated by a minimum 
of one intervening day.
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Figure 4.1 : Study design for adaptation and light intervention visits
An example illustration of the sleep-wake schedule for the sleep adaptation (top schedule) 
and light intervention (bottom schedule) visits. Yellow bars represent waking periods and 
black bars represent sleep opportunities (lights off). Arrival at the Centre was at 17:00 and 
light intervention occurred approximately 4.5 hours before scheduled lights off time and 
lasted for 4 hours. Lights off was scheduled at participants calculated habitual sleep time and 
participants were given an 8 hour sleep opportunity at each visit to the Centre. PSG was 
recorded during the light exposures and all sleep opportunities.
4.2.3 Procedures
4.2.3.1 Light exposure
On the evening of arrival to the Centre participants received one of 6  polychromatic light 
conditions which were administered in a randomised counter-balanced sequence. Each group 
of participants was randomised to one of four light sequences. Light was delivered to 
participants from within purpose-designed light-boxes (Philips Lighting, Eindhoven, The 
Netherlands) measuring 138x80x90cm. Each box contained 3 fluorescent tubes on the top 
side, with a diffuser in front. The boxes each had the front face open to deliver the light to the 
participants. The 6  light conditions included dim light, blue depleted light, blue intermediate 
light, blue enhanced light, bright blue enhanced light and red intervention light which
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included 3.5 hours initially o f the blue intermediate light followed by pulsing red light for the 
last 30 minutes of exposure, see Table 4.1 for characteristics of the 6  polychromatic light 
mixtures used in the protocol. Participants were aware they would be receiving different light 
interventions at each visit, but were not told anything about which light conditions they 
would receive. At the beginning of each light exposure an expectation questionnaire was 
completed by participants, in order to assess whether participants had any expectations about 
the light they were about to be exposed to. At 2 hours into the light exposure a headache and 
eye-strain questionnaire was completed by participants, in order to assess for any negative 
consequences of the light exposure. For 5 participants there was a timing error in the 
administration of the blue intermediate light condition, therefore this light condition was 
repeated on a subsequent visit to the centre and was substituted with the red intervention light 
condition and therefore these participants do not have data for the red intervention condition. 
One participant was unable to attend the dim light condition and another could not attend the 
blue enhanced light condition, these conditions were not repeated for these participants.
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Chapter 4
4.2.3.2 Polysomnography
PSG measures comprising the electroencephalogram (EEG), submental electromyogram 
(EMG) and electrooculogram (EOG) were recorded scheduled sleep periods as described in 
Chapter 2.2. Two sub-clavicular electrocardiogram (ECG) electrodes and a thoracic belt were 
also applied. On acclimation nights participants also wore a body position sensor, a nasal 
airflow sensor, an oximeter and leg electrodes to monitor leg movements.
No-tangle wire, gold-plated electrodes (Astro-Med®, Inc., Berkshire, UK) were used for PSG 
measures and the montage used included EEG electrodes positioned at F3, F4, C3, C4, 01  
and 02 . Electrodes were referenced to the A1 and A2 mastoid electrodes on the contralateral 
side of the scalp to minimise interference. The ground and reference electrodes were placed 
on the forehead and at scalp position Pz respectively. Sleep measures were recorded using 
Siesta 802 devices (Compumedics Ltd., Abbotsford, Victoria, Australia).
4.2.3.3 Polysomnography data analysis
4.2.3.3.1 Staging polysomnography recordings
The PSG data for each night following intervention with light were visually scored as 
described in Chapter 2.3.1, according to the criteria set by Rechtschaffen and Kales 
(Rechtschaffen & Kales, 1968).
4.2.3.3.2 Spectral analysis of sleep EEG recordings
Following completion of manual staging the sleep EEG EDF flies and staged hypnograms 
were used to perform FFT spectral analysis as described in Chapter 2.3.2 using Vitascore 
software version 1.40 (RC.l) (Temec Instruments, B.V., Kerkrade, The Netherlands). A total 
of 11 EEG recordings were unavailable for spectral analysis due participants missing a
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condition or due to technical errors. Artefacts were manually removed from the EEG 
derivations before FFT spectral analysis was performed on 4 second sub-epochs for sleep 
EEG. Power spectra were extracted for the entire night, per thirds of the night and per hour o f 
the night. The criteria set for the amount of sub-epochs o f data remaining in the entire night 
for each derivation following artefact removal was 62.5%; this resulted in a total o f 15 
derivations being excluded from analysis following artefact removal. For derivations meeting 
the criteria, corrections were applied to the power values as described in Chapter 2.4, and 
EEG power density values for matching contralateral EEG derivations were subjected to a 
weighted averaging within an individual for each light condition prior to performing 
statistical analyses (those derivations which no longer had a matching contralateral derivation 
due to exclusions were also excluded from analysis).
4.2.4 Statistical analyses
All analyses in this Chapter were performed in SAS® version 9.2 (SAS Institute Inc., Cary, 
NC, USA). In order to determine whether differences between each light condition and the 
dim light condition were significant paired t-tests were performed on individual IHz EEG 
frequency bins up to 32Hz using PROC TTEST in SAS® and all reported values are for 2- 
sided tests. Multiple t-test comparisons will increase the occurrence o f type 1 errors (false 
positive results) and a Bonferroni correction would have been too stringent for the 32Hz EEG 
power spectra. Therefore, in addition to the t-test analyses, general linear mixed model 
analyses with main effects of condition (the 6  light conditions) and period (the visit number 
at which each light condition occurred i.e. the order of the light conditions) were performed 
on the 8  traditional EEG frequency bands (described in Chapter 2.3.2.2) using PROC MIXED 
in SAS® in order to control for any spurious results observed within the analysis on IHz 
frequency bins.
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In order to establish whether there was trait-like inter-individual variability within the EEG 
that was robust to the light intervention intraclass correlation coefficients (ICCs) were 
computed for IHz EEG frequency bins up to 32Hz as well as 8 EEG frequency bands using 
PROC MIXED in SAS® with main effects of condition and period. ICCs were calculated by 
using the covariance parameter estimates from the mixed model output from which the 
between subject variance was divided by the total variance. The ICCs were interpreted by 
using ranges previously described (Landis and Koch, 1977). The general linear mixed model 
used for all analyses in this chapter can be found in Appendix B.
4.3 Results
4.3.1 Effects of polychromatic light on EEG power density spectra
The effects of the polychromatic light conditions on the nocturnal EEG immediately 
following the exposure within IHz frequency bins and 8 EEG frequency bands have been 
described for the entire night for both non-rapid eye movement (NREM) and rapid eye 
movement (REM) sleep. The t-test analysis results of each light condition compared to the 
dim light condition within IHz frequency bins up to 32Hz were grouped into broader 
frequency band ranges and summarised in Table 4.2 towards the end o f Chapter 4.3.1. It 
should be noted that in the summary tables there was no distinction made between low-delta 
and delta frequency ranges, since data in the IHz bin overlaps both ranges.
4.3.1.1 NREM sleep
Analysis of NREM sleep during the night immediately following light intervention showed 
that the varying light mixtures differentially affected the EEG power spectra. In addition, the 
occipital derivation displayed the greatest response to light compared with the frontal and 
central derivations (Figure 4.2).
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Compared to the dim light condition the frontal derivation was significantly affected by the 
red intervention light condition whereby alpha activity (9-lOHz) was significantly increased 
and by the blue intermediate light condition, which increased beta-1 activity (15-16Hz). Over 
the course of the entire night the central derivation was affected only by the blue depleted 
light condition which significantly decreased slow-wave activity (SWA) at IHz and beta-3 
activity (27Hz and 32Hz) compared to the dim light condition, the decrease at 3 IHz was also 
approaching significance (p=0.0668).
The occipital derivation was affected by blue depleted light, blue intermediate light and red 
intervention light conditions. Blue depleted light significantly decreased SWA at IHz, and 
approached a significant reduction at 3Hz and 5Hz (p=0.0591 and 0.0672 respectively). Blue 
depleted light also decreased activity in the beta-3 range at 26-27Hz and 29-32Hz and 
approached a significant decrease at 25Hz and 28Hz (p=0.0554 and 0.0617 respectively). 
Blue intermediate light significantly increased theta activity at 6 Hz, and approached 
significance at 5Hz (p=0.0685). The red intervention light affected the EEG spectral power in 
the occipital derivation over a much greater range than in the fi*ontal derivation with a 
statistically significant increase in power in the alpha, sigma and beta-1  frequency ranges (1 0 - 
12Hz and 14-20Hz) when compared to dim light, increases at 9Hz and 2 IHz also approached 
significance (p=0.053 and 0.0634 respectively).
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Figure 4.2: NREM sleep power density spectra following light intervention 
Entire night power densities (geometric mean ± 95% CFs) up to 32Hz (x-axis) for NREM 
sleep, with light condition expressed relative to the dim light condition ( 1 0 0 %, y-axis) for 
frontal (top figure), central (middle figure) and occipital (bottom figure) derivations. •  blue 
depleted light (n=17-18), •  blue intermediate light (n=18-20), •  red intervention light (n=14), 
•  blue enhanced light (n=16-17), and bright blue enhanced light (n=18-19). Coloured 
triangles along the x-axis indicate a significant difference between the corresponding 
coloured light condition and the dim light condition derived from paired t-tests, P<0.05.
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4.3.1.2 REM sleep
Analysis o f REM sleep during the night immediately following intervention with the different 
polychromatic light conditions revealed that only the blue depleted light significantly affected 
the EEG power spectra when compared to the dim light condition. Similarly to NREM sleep, 
the occipital derivation displayed the greatest response to light (Figure 4.3).
The frontal and central derivations were not significantly affected by any o f the light 
conditions when compared to the dim light condition. However, the blue intermediate light 
condition caused a decrease in SWA (3 Hz) in the fi*ontal derivation that approached 
significance (p=0.0571). The blue depleted light condition caused a reduction in SWA that 
approached significance in the central derivation (IHz) (p=0.0541) and the bright blue 
enhanced light condition caused a decrease in SWA (5Hz) that approached significance 
(p=0.0691).
The blue depleted light condition significantly affected the occipital derivation with SWA (1- 
5Hz) and beta-3 activity (27Hz and 30-32Hz) significantly reduced compared to the dim light 
condition. EEG power was also reduced compared to the dim light condition at 24-26Hz 
which approached significance (p=0.0692, 0.0656 and 0.0514 respectively).
Page 158 of 257
Chapter 4
160
-5
c
2
LL
SC
0
O
2  1 0 0
CD
0  60
160 1
C  140 4
! -
■o
2  1 0 0
80
o
Q .
0
0  60 
(T
40
-5
9 -
Üo
O
è  80
tr 60
4 4 4  4 4
10 15 20
Frequency (Hz)
25 30
Figure 4.3: REM sleep power density spectra following light intervention 
Entire night power densities (geometric mean ± 95% Cl’s) up to 32Hz (x-axis) for REM 
sleep, with light condition expressed relative to the dim light condition ( 1 0 0 %, y-axis) for 
frontal (top figure), central (middle figure) and occipital (bottom figure) derivations. •  blue 
depleted light (n=17-18), •  blue intermediate light (n=18-20), •  red intervention light (n=14), 
•  blue enhanced light (n=16-17), and bright blue enhanced light (n=18-19). Coloured 
triangles along the x-axis indicate a significant difference between the corresponding 
coloured light condition and the dim light condition derived from paired t-tests, P<0.05.
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4.3.2 Effects of polychromatic light on EEG frequency bands 
In order to quantify and further assess the significance of the t-test analyses performed on 
individual IHz bins across the 32Hz EEG power spectra, general linear mixed model 
analyses were performed on 8  EEG frequency bands. The main effects o f condition ( 6  light 
conditions; dim light, blue depleted light, blue intermediate light, blue enhanced light, bright 
blue enhanced light and red intervention light) and period (the visit number at which each 
light condition occurred, i.e. the order o f the light conditions) on the entire night EEG were 
assessed for NREM and REM sleep.
4.3.2.1 NREM sleep
The effects o f light condition on NREM sleep compared to the dim light condition are 
summarised in Table 4.3 and Figures 4.4 and 4.5 display each light condition relative to the 
dim light condition. The results from the analysis of the 8  EEG frequency bands were similar 
to those effects observed across the power density spectrum and summarised in Table 4.2, 
although they were somewhat reduced in comparison. Significant effects of condition were 
seen in the occipital derivation for the low-delta (p=0.004), delta (p=0.038), sigma (p=0.035) 
and beta-3 (p=0.015) frequency ranges, and also approached significance in the central 
derivation in the low-delta range (p=0.062).
Post hoc analyses comparing the effects of the light conditions on the central derivation 
revealed that whilst the main effect of condition only approached significance within the low- 
delta frequency band, the blue depleted light condition was significantly less than the dim 
light condition (p=0.02), and this effect was also observed within the t-test analyses. The blue 
depleted light condition was also significantly lower than the blue intermediate light and 
bright blue enhanced light conditions (p=0.0049 and 0.0481 respectively).
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Post hoc analyses on the occipital derivation revealed that within the low-delta frequency 
band the blue depleted light condition was significantly lower than the dim light, blue 
intermediate light, blue enhanced light and bright blue enhanced light conditions (p=0.0246, 
0.0013, 0.0009 and 0.009 respectively). Also within the low-delta band the red intervention 
light condition was significantly lower than the blue intermediate light, blue enhanced light 
and bright blue enhanced light conditions (p=0.0109, 0.0124 and 0.0493 respectively). 
Within the delta frequency band the blue depleted light condition was significantly lower 
than the dim light, blue intermediate light, red intervention light, blue enhanced light and 
bright blue enhanced light conditions (p=0.0276, 0.0061, 0.0456, 0.0022 and 0.0408 
respectively). The effect of blue depleted light compared to the dim light condition within the 
slow-wave frequency range was also seen within the t-test analyses.
The main effect o f condition on the sigma fi*equency range within the occipital derivation was 
induced by both the blue depleted and red intervention light conditions. The blue depleted 
light condition was significantly lower compared to the blue intermediate light, red 
intervention light and the bright blue enhanced light conditions (p=0.0092, 0.0037 and 0.0117 
respectively), the blue depleted light condition was also lower than the blue enhanced light 
condition and approached significance (p=0.0681). The red intervention light condition was 
higher within the sigma frequency range compared to the dim light condition and approached 
significance (p=0.0779) and this effect was also observed within the t-test analyses o f the 
32Hz spectra.
The effect o f condition on the beta-3 fi*equency range within the occipital derivation was due 
to significant differences between the blue depleted light condition and blue enhanced light 
and bright blue enhanced light conditions (p=0.0028 and 0 .0 0 1 2  respectively), whereby the
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blue depleted light condition was significantly lower. The blue depleted light condition was 
also lower than the dim light condition and approached significance (p=0.085), and this effect 
was significant in the t-test analyses. The red intervention light condition was also 
significantly lower than the bright blue enhanced light condition (p=0.0347) within this 
frequency range.
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Figure 4.4: Low-delta, delta, theta and alpha activity during NREM sleep 
Low-delta, delta, theta and alpha power densities (geometric mean ± 95% CFs) in frontal, 
central and occipital derivations during NREM sleep following intervention with 
polychromatic light conditions (x-axis) expressed relative to the dim light condition ( 1 0 0 %, 
y-axis). •  blue depleted light (n=17-18), •  blue intennediate light (n=18-20), •  red 
intervention light (n=14), •  blue enhanced light (n=16-17), and bright blue enhanced light 
(n=18-19). Asterisks indieate a significant difference from the dim light condition as 
evidenced by mixed model analyses, p<0.05.
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Figure 4.5: Sigma, beta-1, beta-2 and beta-3 activity during NREM sleep
Sigma, beta-1, beta-2 and beta-3 power densities (geometric mean ± 95% CFs) in frontal,
central and occipital derivations during NREM sleep following intervention with
polychromatic light conditions (x-axis) expressed relative to the dim light condition ( 1 0 0 %,
y-axis). •  blue depleted light (n=17-18), •  blue intermediate light (n= 18-20), # red
intervention light (n=14), •  blue enhanced light (n=16-17), and bright blue enhanced light
(n=18-19).
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4.3.2.2 REM sleep
The effects of light condition on NREM sleep compared to the dim light condition are 
summarised in Table 4.4 and Figures 4.6 and 4.7 display each light condition relative to the 
dim light condition. The results from the analysis of the 8 EEG frequency bands were similar 
to those effects observed across the power density spectrum and summarised in Table 4.2. 
Significant main effects of condition were seen in the frontal, central and occipital derivations 
within the low-delta band (p=0.044, 0.003 and 0.001 respectively). Significant main effects 
of condition were also seen in the occipital derivation within the delta and beta-3 frequency 
bands (p=0.009 and 0.024 respectively).
Post hoc analyses comparing the effects of the light condition on the frontal derivation 
revealed that the red intervention light condition was significantly lower than the blue 
intermediate light condition (p=0.0417), and the blue enhanced light condition was 
significantly higher than the blue depleted light, red intervention light and bright blue 
enhanced light conditions (p=0.0292, 0.0066 and 0.0116 respectively) within the low-delta 
frequency band.
Analysis of the central derivation revealed that the blue depleted light condition was 
significantly lower than the dim light, blue intermediate light, blue enhanced light and bright 
blue enhanced light conditions (p=0.0109, 0.0017, 0.0004 and 0.0314 respectively) within the 
low-delta band. There was not a significant difference between the blue depleted light and the 
dim light conditions within the low-delta band in the t-test analyses, however, there was a 
reduction in power at IHz following the blue-depleted light condition compared to the dim 
light condition that approached significance (p=0.0541). The red intervention light condition
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was also significantly lower than the blue intermediate light and blue enhanced light 
conditions (p=0.0261 and 0.0137 respectively) within the low-delta band.
Analysis o f the occipital derivation revealed that the blue depleted light condition was 
significantly lower than the dim light, blue intermediate light, blue enhanced light and bright 
blue enhanced light conditions (p=0.0282, 0.0023, 0.0001 and 0.0141 respectively) within the 
low-delta band. The red intervention light condition was also significantly lower than the blue 
intermediate light, blue enhanced light and bright blue enhanced light conditions (p=0.0087, 
0.0016 and 0.0399 respectively) within the low-delta band. Within the delta frequency band 
the blue depleted light condition was significantly lower than the dim light, blue intermediate 
light, red intervention light, blue enhanced light and bright blue enhanced light conditions 
(p=0.0011, 0.0078, 0.0207, 0.001 and 0.0375 respectively) and the effect of blue depleted 
light compared to the dim light condition within the slow-wave range was also observed in 
the t-test analyses. Within the beta-3 frequency range the blue depleted light condition was 
also significantly lower than the dim light, blue intermediate light, blue enhanced light and 
bright blue enhanced light conditions (p=0.0338, 0.0087, 0.0017 and 0.0036 respectively) and 
the significant difference between the blue depleted light and dim light condition within the 
beta-3 frequency range was also seen in the t-test analyses.
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Figure 4.6: Low-delta, delta, theta and alpha activity during REM sleep 
Low-delta, delta, theta and alpha power densities (geometric mean ± 95% CFs) in frontal, 
central and occipital derivations during REM sleep following intervention with 
polychromatic light conditions (x-axis) expressed relative to the dim light condition ( 1 0 0 %, 
y-axis). •  blue depleted light (n=17-18), •  blue intennediate light (n= 18-20), •  red 
intervention light (n=14), •  blue enhanced light (n=16-17), and bright blue enhanced light 
(n=18-19). Asterisks indicate a significant difference from the dim light condition as 
evidenced by mixed model analyses, p<0.05.
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Figure 4.7: Sigma, beta-1, beta-2 and beta-3 activity during REM sleep 
Sigma, beta-1, beta-2 and beta-3 power densities (geometric mean ± 95% CFs) in frontal, 
central and occipital derivations during REM sleep following intervention with 
polychromatic light conditions (x-axis) expressed relative to the dim light condition ( 1 0 0 %, 
y-axis). •  blue depleted light (n=17-18), •  blue intermediate light (n= 18-20), •  red 
intervention light (n=14), •  blue enhanced light (n=16-17), and bright blue enhanced light 
(n=18-19). Asterisks indicate a significant difference from the dim light condition as 
evidenced by mixed model analyses, p<0.05.
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4.3.3 Individual differences in EEG power spectra
4.3.3.1 Intra-individual robustness to light intervention
The ICC was calculated in order to assess whether there were robust individual differences 
within the EEG power spectra following intervention with the different experimental light 
conditions. Analysis of 8  EEG frequency band ranges revealed high ICCs for all 8  bands 
within NREM and REM sleep (Table 4.5).
Analysis of the 8  frequency bands showed that the ICCs across NREM sleep ranged from 
0.58 to 0.96 and according to previously determined benchmark ranges (Landis and Koch, 
1977), the ICCs can be considered as ranging from ‘moderate’ to ‘almost perfect’. The ICCs 
calculated across the 8  frequency bands during REM sleep were similar to those calculated 
for NREM sleep and ranged from 0.60 to 0.96, which are considered as ranging from 
‘substantial’ to ‘almost perfect’. In general, NREM sleep produced higher ICCs in the lower 
frequency ranges (low-delta, delta, theta and alpha) compared with those for REM sleep, 
whereas REM sleep produced higher ICCs in the higher frequency ranges (sigma, beta-1, 
beta-2 and beta-3) compared with NREM sleep. Some derivation dependent differences were 
also observed within the ICCs; in particular, higher ICCs were obtained for central and 
frontal derivations than for the occipital derivation for both NREM and REM sleep, 
particularly within the lower frequency ranges.
During NREM sleep particularly high ICCs were seen in the delta, theta and alpha frequency 
ranges in the frontal and central derivations, with the delta range being the highest in each 
derivation (ICC = 0.94 and 0.96 respectively). High ICCs for the occipital derivation were 
observed in particular within the alpha frequency range during both NREM and REM sleep 
(ICC = 0.92 and 0.91 respectively). Interestingly, the lowest ICCs observed were those
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obtained for the low-delta frequency band for all derivations during both NREM and REM 
sleep, however, the lowest ICC of 0.58 in the low-delta range would still be interpreted as 
‘moderately’ robust.
Analysis of the EEG frequency spectrum per IHz bin up to 32Hz for NREM and REM sleep 
(Figures 4.8 and 4.9) provided a better resolution for assessing ICCs. The ICCs calculated on 
individual IHz frequency bins ranged from 0.51 to 0.97 during NREM sleep and 0.48 to 0.96 
during REM sleep, both of which range from ‘moderate’ to ‘almost perfect’. There was 
greater variation observed within the ICCs across the 32Hz spectrum compared with the ICCs 
calculated for the 8  EEG frequency bands, however, there was still a tendency for higher 
ICCs during NREM sleep in the lower frequency ranges and higher ICCs during REM sleep 
in the higher frequency ranges, with frontal and central derivations tending to produce higher 
ICCs than the occipital derivation. ICCs for the IHz bin and some bins within the beta-3 
frequency range produced some of the lowest ICCs during both NREM and REM sleep.
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Figure 4.8: ICCs for log^  ^transformed EEG spectral data for NREM sleep
ICCs derived from log^  ^transformed EEG power density values (amplitude^) from nocturnal
EEG recordings. ICCs were obtained for 32 IHz frequency bins during NR£M sleep for
frontal (top figure), central (middle figure) and occipital (bottom figure) derivations (n=2 2 ).
Power within the frequency bands was analysed using a mixed model in SAS® to obtain
ICCs.
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Figure 4.9: ICCs for log’^  transfonued EEG spectral data for REM sleep 
ICCs derived from log^  ^transformed EEG power density values (amplitude^) from nocturnal 
EEG recordings. ICCs were obtained for 32 IHz frequency bins during REM sleep for frontal 
(top figure), central (middle figure) and occipital (bottom figure) derivations (n=22). Power 
within the frequency bands was analysed using a mixed model in SAS® to obtain ICCs.
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4.3.3.2 Robustness of intra-individual responses to light intervention 
In addition to determining the robustness of individuals’ absolute EEG power density values 
by calculating ICCs, the robustness of individuals’ responses to the light conditions was also 
assessed. Where possible, each individual’s EEG power density values obtained following 
light intervention were expressed relative to power density values obtained following 
intervention with the dim light condition and were compared both within and across 
individuals for each of the 8  EEG frequency bands for NREM (Figure 4.10) and REM 
(Figure 4.11) sleep. Since the analysis of the 32Hz EEG spectra revealed the greatest 
response to the light intervention was within the occipital derivation, the comparison is 
shown for that derivation only.
The ICC calculations for the 8  EEG frequency bands revealed high ICCs, and thus indicated 
that the intra-individual variation was smaller than the inter-individual variation. In contrast. 
Figures 4.10 and 4.11 displaying relative power density values demonstrate that whilst there 
was some variation across individuals, it is not as great as would be observed with the 
absolute power density values. Some individuals’ relative power density values clustered 
closely together, whereas others were more widespread, a few outliers were observed that 
demonstrated particularly high values following intervention with some light conditions 
compared to the dim light condition, and these outliers were particularly evident in the low- 
delta band, including subjects 17 and 18.
What was evident from inspection of Figures 4.10 and 4.11 was that the profile of each plot 
across the 8  power frequency bands and NREM and REM sleep was fairly similar with some 
individuals showing responses greater than the dim light condition and others clustering 
below the dim light condition. During both NREM and REM sleep the low-delta band
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showed the most intra-individual variation in response to the light conditions, whereas the 
response to light intervention in the delta, theta, alpha, sigma, beta-1, beta-2 and beta-3 bands 
were centred much more closely around the 100% reference line. Visually it appeared that 
there was slightly greater intra-individual variation within NREM sleep compared to REM 
sleep, in particular within the low-delta, sigma, beta-2 and beta-3 power frequency bands.
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Figure 4.10: Power densities per individual during NREM sleep
Power density values from the occipital derivation per individual (x-axis) with each condition 
expressed relative to the dim light condition (100%, y-axis) during NREM sleep across the 8  
EEG frequency band ranges: low-delta, delta, theta, alpha, sigma, beta-1, beta-2 and beta-3. •  
blue depleted light condition, # blue intermediate light condition, •  red intervention light 
condition, •  blue enhanced light condition, and bright blue enhanced light condition.
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Figure 4.11 : Power densities per individual during REM sleep
Power density values from the occipital derivation per individual (x-axis) with each condition 
expressed relative to the dim light condition (100%, y-axis) during REM sleep across the 8  
EEG frequency band ranges: low-delta, delta, theta, alpha, sigma, beta-1, beta-2 and beta-3. •  
blue depleted light condition, •  blue intermediate light condition, •  red intervention light 
condition, •  blue enhanced light condition, and i bright blue enhanced light condition.
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4.4 Discussion
To investigate whether different polychromatic light mixtures exert differential effects on the 
sleep EEG, spectral analysis of each light condition was performed in order to assess changes 
in spectral power at different frequencies compared to the dim light condition. Surprisingly, 
the results showed that the blue depleted light and red intervention light conditions had a 
greater effect on sleep EEG power spectra then did the light conditions containing enhanced 
levels of blue light.
Analysis of both the 32Hz frequency spectrum and the 8  EEG frequency bands revealed that 
the blue depleted light condition was the most influential at inducing changes within the 
EEG. Compared to the dim light condition, blue depleted light was sufficient to significantly 
supress SWA and beta-3 activity during both NREM sleep and REM sleep. Beta activity is 
associated with a more wake-like EEG and is often seen observed in the sleep EEG of older 
subjects (Carrier et al., 2001) and has also been seen in insomnia sufferers (Bastien et al., 
2003). Therefore a reduction in beta activity could be perceived as improved sleep, however, 
the reduction in this frequency range combined with a reduction in SWA more likely suggests 
that sleep after the blue depleted light condition became more superficial or Tighter’ and 
therefore could be an indication that sleep is less beneficial following this light condition. An 
alternative explanation is that there is a reduced need for sleep following blue depleted light.
The blue intermediate light condition was designed to most closely match evening lighting 
conditions within the home. Significant effects of the blue intermediate light condition were 
restricted to NREM sleep and included an increase in theta and beta-1 activity as evidenced 
by analysis of IHz bins. Theta activity in the waking EEG increases with time awake and is 
negatively correlated with alertness (Aeschbach et al., 1999), therefore increases during the
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night are suggestive of more intense sleep, however, given the increase was only significant 
at 6 Hz and since there was an increase in beta activity, the increased power within the mid- 
fi'equency range is more suggestive that there was an alerting effect of the blue intermediate 
light condition. In addition, the mixed model analysis of the 8  EEG fi*equency bands did not 
reveal any significant changes within the theta or beta-1 fi*equency bands during NREM sleep 
compared to the dim light condition indicating that any alerting effects were only mild. 
Although not significant, there was an increase in power at IHz during NREM and REM 
sleep following intervention with blue intermediate light and this was particularly prominent 
in the occipital derivation.
The most surprising results were the lack of effect that the blue enhanced light and bright 
blue enhanced light conditions had on the EEG. Neither condition significantly affect the 
EEG during either NREM or REM sleep in either the IHz bin analyses or the 8  EEG 
fi*equency bands analyses, when compared to the dim light condition. There was a trend 
towards the blue enhanced light condition increasing activity at IHz which was also evident 
in the analysis of the low-delta band during NREM and REM sleep when compared to the 
dim light condition, and this was particularly evident in the occipital derivation. These results 
contrast the hypothesis that the light conditions containing the most blue light content would 
have the greatest effect on the EEG. PSG staged data for this study also did not show any 
significant changes on sleep strueture when the blue enhanced light and bright blue enhanced 
light conditions were compared to the dim light condition (Santhi et al., 2011) and therefore 
may imply that whilst blue enriched light may be potent in inducing circadian phase shifts, its 
effects on sleep may be minimal.
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The red intervention light condition was designed to have a relaxing effect, since the 
melanopsin system is maximally sensitive to short wavelength blue light, and is relatively 
insensitive to longer wavelength light red light (Brainard et ah, 2008), it was therefore 
anticipated that this light condition might improve sleep. The results indicated that the red 
intervention light condition caused a more wake-like EEG during both NREM and REM 
sleep by increasing activity in the in the mid-frequency ranges compared to the dim light 
condition. Analysis of IHz bins revealed that the increase was significant during NREM 
sleep in the alpha, sigma and beta-1 ranges, however, mixed model analysis of the 8  EEG 
frequency bands did not reveal any significant increases, excepting an increase that 
approached significance in the sigma frequency range compared to the dim light condition. 
Alerting effects of red light have previously been reported during a study investigating the 
effeets of red light on wake EEG in the evening hours, where a decrease in alpha and an 
increase in beta EEG activity was observed (Figueiro et al., 2009). It is possible that the 3.5 
hours of blue intermediate light that preceded the 30 minutes of red light in the red 
intervention condition caused the changes in the EEG; however, the significant changes did 
not correspond with those observed following the blue intermediate light condition and would 
therefore suggest that the response was due to the red light or an interaction between the blue 
intermediate light and red light.
Research on light already tells us that it has alerting effects, even at low intensities and can 
induce changes in the EEG irrespective of the blue light content; therefore the alerting effects 
on the EEG in response to the polychromatic light conditions could have been expected. One 
would have predicted that there would be suppression of delta activity in the nocturnal sleep 
following light exposure given previous research detailing the effects of light on the time 
course of delta activity (Cajochen et al., 1992, Cajochen et al., 1998, Cajochen et al., 2008),
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and it was also expected that the short-wavelength blue light would be particularly efficient at 
supressing delta activity in light of more recent research on EEG measures and melatonin 
suppression (Munch et ah, 2006, Santhi et ah, 2011, Chellappa et ah, 2013); whilst this 
suppression of SWA was observed with the blue depleted light, this was not the case for the 
other light conditions.
Recently published research described a reduction in SWA during the first NREM-REM 
sleep cycle following 2 hours of evening exposure of blue enriched light (Chellappa et ah, 
2013), and this effect in our study was only observed following the blue depleted light 
condition. In fact, in opposition, our results showed that there was an increase in NREM and 
REM sleep SWA following the blue intermediate and blue enhanced light conditions, 
although not significant. Chellappa and colleagues did not report any changes to sleep latency 
measures after light exposure (Chellappa et ah, 2013), however, in our study sleep onset 
latency increased by 6.9 minutes and latency to persistent sleep increased by 7.5 minutes 
following both the blue enhanced conditions compared to the dim light condition (Santhi et 
ah, 2011). Therefore the increased SWA may have been due to a rise in homeostatic sleep 
pressure, however, it is unlikely that the differences in the sleep latencies were enough to 
account for the changes observed in SWA. In addition, participants from our study went to 
bed approximately 25 minutes following light exposure, whereas participants in the 
Chellappa study spent 45 minutes in dim light before going to bed and therefore there may 
have been a dissipation of the effects of light on sleep latency measures.
The occipital derivation was the most affected by the light interventions, which is not 
surprising given that the visual cortex is located in the occipital lobe of the brain and it was 
also in this region that the increases in SWA occurred. The synaptic homeostasis theory
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suggests that the SWA will increase in accordance with use of the neurons in the local area 
(reviewed in Tononi and Cirelli, 2003, Tononi and Cirelli, 2006); therefore overstimulation 
of the visual cortex from both the melanopsin and classical photoreceptor systems could have 
induced the increase in SWA. The suggestion that the rise in SWA is use dependent can also 
be supported by the fact that in order to more accurately reflect the time period of artificial 
light exposure at home during the winter months, the light exposure duration in our study was 
4 hours, this was longer than the exposure typically reported in other studies. The use 
dependent theory has previously been explored by others in an attempt to explain a rebound 
of SWA following suppression by monochromatic blue light (Munch et al., 2006).
Despite the differences observed within the EEG induced by the experimental challenge of 
light intervention, inter-individual differences were still observed within the EEG by means 
of calculating the ICC. The results from the ICC analysis indicated that the inter-individual 
differences within the EEG were moderately to almost perfectly robust to the intervention. 
Whether these inter-individual differences constitute trait-like individual differences or not is 
dependent upon whether three criteria can be met, including that the differences are 
significant, robust to experimental challenge and stable over time (Van Dongen et al., 2005). 
A high ICC value can only be obtained if the inter-differences are significant and measures 
within a subject were obtained following intervention with different experimental challenges 
indicating that the differences were robust. However, the stability of such differences was not 
possible to be determined given the experimental design of the study which lacked repeated 
EEG collection whilst under the same experimental condition.
The ICCs obtained for the EEG power density spectra were in accordance with those 
previously reported for the delta range, in particular those reported by Tucker et al., ranged
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from 0.78 to 0.89 during NREM sleep (Tucker et al., 2007), whereas ours were slightly 
higher ranging from 0.85 to 0.96. In order to further quantify individual differences within 
the EEG and in order to establish whether there are individual differences within the response 
to intervention, it would have been ideal to demonstrate ICCs for relative EEG spectral data 
(power densities expressed relative to the dim light condition), however, there where 
limitations in the study design since the dim light condition was not repeated prior to each of 
the other experimental light conditions, therefore, ICCs calculated with all the data expressed 
to the one dim light condition could be scrutinized as to the validity of such a calculation. It 
would be expected, however, that the ICCs calculated with relative spectral data would 
become less robust to the intervention, since once data are normalised this reduces the 
between subject variation, thereby lowering the ICC. This effect was seen with the melatonin 
suppression data for the same study, which demonstrated that the relative values where less 
robust at 0.44, although still moderate (Santhi et al., 2011). In order to gain a feel for how 
expressing the data relative to the dim light condition affected the variation within the data, 
the relative values per individual were presented in scatter plots across the 8  EEG frequency 
bands for NREM and REM sleep, and it appeared to confirm the expectation that inter­
individual variability would be reduced, however, it appeared that even so, some inter­
individual differences remained, and the profile of the plots also suggested that individuals 
were more similar to themselves across sleep stages and across the frequency spectrum.
Another primary purpose of quantifying inter-individual variation within sleep is to 
determine the origin of trait-like differences, which may contribute to our understanding of 
sleep-wake regulation, as well as identifying any traits which are conducive to susceptibility 
towards negative health consequences. The PER3 gene is a clock gene associated with sleep- 
wake regulation that has been linked with diurnal preference (Archer et al., 2003) and
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susceptibility to the effects of sleep loss (Viola et al., 2007). Given that an individuals’ 
diurnal preference can influence an individuals’ daily light exposure, it may be possible to 
explain some of the individual differences within the EEG with the PERS VNTR 
polymorphism. Recent work by others has begun to look into the effects of sleep pressure, 
circadian phase and the PER3 polymorphism on the response to light intervention and 
research does suggest there may be some genotype dependent individual differences 
(Vandewalle et al., 2011). Whilst participants from this study were genotyped for the PER3 
polymorphism, it was not possible to stratify the analyses by genotype due to the small 
population number and an unbalanced number of participants within each genotype. 
Assessment of the contribution of genotype to the response to light intervention would be 
interesting future directive given the link between PER3 and regulation of circadian and 
homeostatic processes.
4.4.1 Conclusions
The results in this chapter support previous findings that light affects the power spectra of the 
sleep EEG in somewhat of an alerting manner. Perhaps the most surprising finding was the 
lack of effect on the EEG from the blue intermediate, blue enhanced and bright blue 
enhanced light conditions. The blue intermediate light condition was designed to most closely 
reflect the light we would be exposed to during the evening hours at home, and it could 
therefore be cautiously suggested that individuals may have become habitualised to such 
lighting conditions and therefore have adapted some tolerance to the effects. It should also be 
considered that ranking within the visual efficacy system may play a role in the effects 
observed in the EEG power spectra and indeed the blue depleted light condition that had the 
greatest effects on the EEG ranked very highly for visual efficacy. In order to accurately 
predict the EEG response to light intervention, physical characteristics other than the
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contributing wavelengths of light also need to be taken into consideration given the 
complexity of polychromatic light mixtures. The results presented here taken in the context of 
the current literature are somewhat equivocal and although they will contribute to broadening 
knowledge about the effects of polychromatic light mixtures on sleep architecture, the 
functional significance of the changes induced by such conditions will need to be further 
established, as well as the effects of chronic exposure to different polychromatic light 
conditions on sleep architecture.
The changes in the EEG induced by the light conditions are difficult to quantify in terms of 
unique signatures on the EEG, as is sometimes observed after pharmacological intervention 
or sleep deprivation and therefore at present it would be difficult to use the overall response 
in the EEG as a biomarker for activity induced by light. However, the ICC analysis 
confirmed the hypothesis that the ICC results would demonstrate inter-individual differences 
within the sleep EEG that were robust to light intervention. Although further analysis would 
be required in order to determine whether these differences were trait-like, it can be 
concluded, at least in the context of this study, that the EEG can be effectively used as a 
biomarker for individual differences in EEG. ICCs were high for absolute EEG power 
densities, but it would appear that ICCs calculated for power densities expressed relative to 
the dim light condition would be somewhat reduced, therefore suggesting that whilst the 
amplitude of the EEG is most definitely a trait-like individual difference, it is less clear 
whether the responses to manipulations of sleep are individual. Whilst these data contribute 
to the existing and ever expanding knowledge of individual differences within healthy 
individuals, further investigation of the response to various interventions is necessary in order 
to quantify individual differences in sleep-wake regulation and what physiological relevance 
such differences hold.
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Chapter 5: Biomarkers and individual differences: The effects of
pharmacological intervention on sleep
5.1 Introduction
Insomnia is the complaint of difficulty with initiating or maintaining sleep and is 
characterised in the electroencephalogram (EEG) as an increase in in high frequency activity 
(Buysse et al., 2008). Insomnia is a complex disorder which is a common comorbidity in 
psychiatric disorders as well as being prevalent amongst the elderly population and current 
pharmacological treatments target receptors within the central nervous system (CNS) 
involved in sleep-wake regulation. The most common line of treatment includes hypnotics 
which act as positive allosteric modulators at y-aminobutyric acid (GABA) receptors, 
including the classical benzodiazepines such as temazepam and non-benzodiazepines such as 
the imiadazopyridine Z-drug (e.g. zolpidem). Another drug target for the pharmacological 
treatment of insomnia are the melatonin receptors MTl and MT2, and the prolonged-release 
formulation of melatonin known as Circadin® acts as an agonist at these receptors within the 
CNS. See Figure 5.1 for chemical structures of temazepam, zolpidem and Circadin®.
OH-
Figure 5.1: Structure of temazepam, zolpidem and Circadin®
GABAa receptor positive allosteric modulators: temazepam (C16H 13CIN2O2 ; left figure) and 
zolpidem (C19H21N3O; middle figure). MTl and MT2 receptor agonist: prolonged-release 
melatonin, Circadin® (C13H16N2O2 ; right figure) (www.emolecules.com).
Page 189 of 257
Chapter 5
The role of the neurotransmitter GABA in sleep-wake regulation provides a rational basis for 
GABAa receptors being the primary target for pharmacotherapies in the treatment of 
insomnia (reviewed in Nutt and Stahl, 2010, Winsky-Sommerer, 2009). GABA is the primary 
inhibitory neurotransmitter of the CNS and the ventrolateral preoptic nucleus (VLPO) located 
in the hypothalamus is densely populated with GABAergic neurons which project to the 
ascending arousal system and therefore promote sleep (reviewed in Saper et al., 2001, Saper 
et al., 2005). GABAa receptors are ionotropic receptors containing five protein subunits, of 
which there are several isoforms (reviewed in Barnard et al., 1998). GABAa receptors most 
commonly consist of two alpha (al-6), two beta (p i-3) and one gamma (yl-3) subunit 
(Figure 5.2), and GABA binds to two active sites located between a and p subunits. 
Benzodiazepines and Z-drugs bind specifically to GABAa receptors containing a y subunit, 
and bind the benzodiazepine complex at the interface between a and y subunits, however, 
those receptors where U4 and ae subunit isoforms are present are insensitive to such 
compounds (reviewed in Mohler et al., 2002). Temazepam and zolpidem both act as positive 
allosteric modulators at GABAa receptors by causing a conformational change which 
increases the affinity of GABA for the receptor, however, whilst zolpidem binds the same site 
as benzodiazepines it is more selective and has a higher affinity for GABAa receptors 
containing ui subunits (reviewed in Winsky-Sommerer, 2009), and this specificity leads to 
fewer side effects than those associated with benzodiazepines.
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Figure 5.2: GABAa receptor strueture
GABAa ionotropic receptor structure containing five subunits with the typical structure 
2a2piy depicted. Each subunit Alpha (a) subunits may be al-6, beta (P) subunits may be pl- 
3 and gamma (y) subunits may be yl-3. Whilst GABAa receptors most commonly contain the 
y subunit, other variations of the GABAa receptor contain delta (5), epsilon (s), theta (0), or 
pi (ti) subunits in place of the y subunit. Benzodiazepines (BZs) and other psyeboactive drugs 
bind to the receptor at a complex located at the interface between a and y subunits which 
results in an increased affinity of GABA for the receptor (adapted from Jacob et al., 2008).
The close association between melatonin secretion and the endogenous circadian and sleep 
propensity rhythms, as well as characteristics of the sleep EEG such as spindles (Dijk et al., 
1997, and reviewed in Dijk and Lockley, 2002, Cajochen et al., 2003, Lewy et al., 2006, 
Skene and Arendt, 2006), indicates a role for melatonin in sleep regulation and thus provides 
the rationale behind pharmacotherapies targeting the melatonin receptors. Endogenous 
melatonin is synthesised from serotonin in the pineal gland located in the hypothalamus and 
is secreted from pinealocytes during the dark phase, peaking at around 2-4am (reviewed in 
Skene and Arendt, 2006). In mammals melatonin binds MTl and MT2 (Figure 5.3), which
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are G protein-coupled receptors containing seven transmembrane domains (reviewed in 
Dubocovich, 2007). It is not entirely clear how melatonin binds and activates its receptors, 
however, various amino acid residues have been implicated in binding melatonin which 
causes activation of signalling pathways, most notably inhibiting cAMP (reviewed in 
Dubocovich et ah, 2010). Both MTl and MT2 receptors are expressed in the SCN, however, 
MT2 is primarily expressed in the retina, whereas MTl is primarily expressed in the SCN and 
the pars tuberalis of the pituitary gland (Reppert et ah, 1994, Reppert et ah, 1995, and 
reviewed in Reppert et ah, 1996). Prolonged-release formulations of melatonin have been 
developed which act as agonists at MTl and MT2 receptors within the CNS to induce sleep, 
and the efficacy of such formulations of melatonin in the treatment of insomnia has 
previously been reported (Lemoine et ah, 2007, Wade et ah, 2007, Wade et ah, 2010, Wade 
et ah, 2011), however the exact mechanisms by which sleep is induced remains unclear. 
Circadin® is a prolonged-release formulation of melatonin (N-acetyl-5-methoxytryptamine) 
available on prescription in Europe for insomnia sufferers aged 55 years and over.
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Figure 5.3: Melatonin receptor MTl.
Amino acid structure of G protein-coupled melatonin receptor MTl. The receptor contains an 
extracellular N-terminus, N-linked glycosylation sites (Y), an intracellular C-terminus, and 
seven transmembrane domains (adapted from Reppert, 1997).
Following pharmacological intervention changes are often observed within the EEG and the 
nature of such changes depends on the mechanism of action of the drug. Benzodiazepines and 
non-benzodiazepine allosteric modulators of GABAa receptors typically decrease visually 
scored slow-wave sleep (SWS) and EEG slow-wave activity (SWA), as well as increase EEG 
spindle activity (Dijk et al., 1989b, Brunner et al., 1991). The changes induced in the EEG 
following exogenous melatonin administration are not well documented and are somewhat 
equivocal. Daytime administration of melatonin resulted in no changes in SWS, enhancement 
of spindle activity and some reduction in SWA (Dijk et al., 1995, Aeschbach et al., 2009), 
although the latter was not always found (Rajaratnam et al., 2004). Evening administration of 
melatonin has not been shown to significantly affect visually scored SWS or the spectral 
composition of the sleep EEG (Cajochen et al., 1997). Whilst it may be possible to attribute
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distinct EEG changes to particular drug classes and the pharmacological activity they have 
within the CNS, individual differences following pharmacological intervention are still 
present; for example, gender differences have been observed in the EEG in response to 
hypnotic treatment (Dijk et al., 2010). Assessing whether inter-individual differences are 
stable and robust in response to pharmacological intervention will be an important factor in 
broadening our understanding of processes underlying sleep-wake regulation.
Assessing individual differences in sleep in response to pharmacological intervention serves 
two primary purposes, the first being that it allows for tailoring pharmacotherapies to 
individuals which could enhance treatment benefits whilst reducing risks and side effects. 
The second purpose for establishing whether there are individual differences in sleep 
following pharmacological intervention is to broaden the current understanding of sleep-wake 
regulation. The quantitative EEG (qEEG) method known as spectral analysis has been 
previously used as a sensitive tool for assessment of drug safety and drug efficacy 
(Luthringer et al., 1995, Bastien et al., 2003). Using spectral analysis the stability and 
robustness of the EEG following different pharmacological interventions can be assessed.
The primary aim of the EEG spectral analysis in this study was to directly compare the 
effects of a single dose of temazepam, zolpidem and prolonged-release melatonin on the 
nocturnal EEG and it was hypothesised that due to their differing mechanisms of action, that 
they would differentially affect sleep measures and the EEG. Exploratory aims of the study 
were to establish whether there were robust individual differences following pharmacological 
intervention and whether the response to treatment was robust within an individual. It was 
hypothesised that there would be robust inter-individual differences within sleep and the EEG 
following pharmacological intervention, and this has previously been found with
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pharmacotherapies (Dijk et al., 2010). It was also hypothesised that there would be individual 
differences in the response to pharmacological intervention.
5.2 Methods
The study protocol was reviewed by Brent Medical Ethics Committee of the NHS National 
Research Ethics Service and received a favourable opinion in March 2009. The Medicines 
and Healthcare products Regulatory Agency (MHRA) provided a Clinical Trials 
Authorisation. The study was conducted at the Surrey Clinical Research Centre of the 
University of Surrey in accordance with the principles based upon the Declaration of 
Helsinki. Written informed consent was obtained from all participants prior to any study 
specific procedures. The clinical trial was registered at Clinicaltrials.gov: NCT00940550.
5.2.1 Participants
Sixteen healthy men and women aged 55-64 years (12 men; mean age 58.8 years, SD 2.9), 
with no sleep complaints, were selected from the general population of the UK to participate 
in the study. One participant only completed 3 out of 4 possible treatment visits to the Centre 
and was not included in the data presented in this chapter, resulting in a per protocol set 
population (11 men; mean age 58.8 years, SD 3.0).
Participants were non-smokers, healthy by physical examination, 12 lead ECG, medical and 
psychiatric history, haematology and clinical chemistry. Key inclusion criteria included a 
regular sleep-wake pattern, with a habitual bedtime between 22:00 and 00:00 hours, and total 
sleep duration of between 6.5 and 8.5 hours. Exclusion criteria included being of childbearing 
potential, known sensitivity to any of the study drugs; Body Mass Index (BMI) < 19 or > 33 
kg/m^; and a score of > 5 on the Pittsburgh Sleep Quality Index (PSQI). In addition.
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participants were not taking any other medications, were not shift workers, had not recently 
travelled through more than 2 time zones, did not consume more than 5 caffeinated beverages 
per day, or more than 3 (men) or 2 (women) units of alcohol per day.
5.2.2 Study design
The study was a single-centre, randomised, double-blind, placebo-controlled, 4-way cross­
over trial to study the effects of temazepam, zolpidem and prolonged-release melatonin in 
healthy middle-aged men and women. The study included 6 visits to the laboratory and a 
post-study telephone contact. Participants were required to wear actiwatches (Actiwatch 4®, 
Cambridge Neurotechnology Ltd, Cambridge, UK) to document their sleep-wake schedules 
throughout the study. Actiwatches were attached to participants at the first visit to the Centre 
and were worn for the duration of the study. Participants were asked to go to bed between 
22:00 and 00:00 hours and wake between 06:00 and 08:00 hours and have between 6.5 and 
8.5 hours’ sleep the night before each visit to the Centre. Participants were also asked to 
adhere to this sleep-wake schedule for five nights out of seven per week for the duration of 
the study. At each visit to the Centre, participants’ actigraphy data were downloaded and 
viewed as an actogram (Actiwatch analysis v.5.54, Cambridge Neurotechnology Ltd, 
Cambridge, UK) and checked for compliance to the schedule.
The first visit to the Centre comprised a full medical screening of participants and this took 
place up to 28 days prior to the first treatment. The medical screening included assessment of 
general health by history and examination, bloods for biochemistry and serology. A urinary 
screening for drugs of abuse and an alcohol breath test were also performed. For female 
participants a urine pregnancy test was also required. At subsequent visits to the Centre, a
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reduced screening was performed on arrival and included urinary drugs of abuse screening, 
an alcohol breath test and a urine pregnancy test for female participants.
Visits 2-6 required one overnight stay at the Centre, with lights off time scheduled from 
23:00 to 07:00 hours for all participants. At night, participants slept in a windowless, sound 
attenuated, temperature controlled room and during the day participants remained within the 
unit. See Figure 5.4 for a diagram of the study design. Visit 2 took place at least two days 
prior to the first treatment visit and served as an acclimation visit to allow participants to 
become acclimatised with the sleep laboratory environment and included an overnight 
polysomnography (PSG) recording from 23:00 to 07:00 hours which served as a screening 
for any clinically significant sleep pathology. Visits 3-6 (treatment periods 1-4) were dosing 
visits and were separated by a minimum of 5 days. During these visits participants were 
randomised to receive placebo, temazepam, zolpidem or prolonged-release melatonin 
Circadin® in the evening prior to lights out.
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Figure 5.4: Study design for adaptation and treatment visits
Example sleep-wake schedule for the acclimation (top schedule) and treatment (bottom 
schedule) visits. Yellow bars represent waking periods and black bars represent 8 hour sleep 
opportunities (lights off; 23:00-07:00 hours). Dosing of prolonged-release melatonin 
Circadin® or matching placebo occurred at 21:00 hours and dosing of temazepam, zolpidem 
or matching placebo occurred at 22:45 hours. PSG was recorded during all sleep 
opportunities.
5.2.3 Procedures
5.2.3.1 Dosing
Participants were randomised in a balanced order to one of four treatment orders and at each 
visit received either placebo, temazepam (20mg), zolpidem (lOmg) or prolonged-release 
melatonin (2mg). In order to allow to different drugs to peak at the same time prolonged- 
release melatonin or matching placebo was administered at 21:00 hours, 2 hours before lights 
off and placebo, temazepam (20mg) or zolpidem (lOmg) or matching placebo was 
administered at 22:45 hours, 15 minutes before lights off. Adverse events were recorded from 
the time of the first dose of study medication until the follow up contact.
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Prolonged-release melatonin 2 mg tablets were sourced from H. Lundbeck A/S (Valby, 
Denmark); Temazepam 20 mg tablets and zolpidem 10 mg tablets were sourced from Teva 
Pharmaceutical bidustries Ltd (Eastbourne, UK). All study drugs and placebo were supplied 
by clinical supply management vendor Bilcare GCS (Europe) Ltd (Powys, UK) and were 
over-encapsulated so that they were identical in appearance. All drugs were administered 
once and at the recommended prescribed doses.
5.2.3.2 Polysonmograpby
PSG measures comprising the EEG, submental electromyogram (EMG) and 
electrooculogram (EOG) were recorded throughout scheduled sleep periods as described in 
Chapter 2.2. Participants also wore a thoracic band, a nasal airflow sensor, an oximeter, a 
snoring microphone, a position monitor, left and right leg EMG electrodes and two sub- 
clavicular ECG electrodes during the acclimation visit.
The electrode montage used silver-silver chloride electrodes (Astro-Med®, Inc., Berkshire, 
UK) and included EEG electrodes positioned at F3, F4, C3, C4, 01 and 02. Electrodes were 
referenced to the A1 and A2 mastoid electrodes on the contralateral side of the scalp to 
minimise interference. The ground and reference electrodes were placed on the forehead and 
scalp position Pz respectively. Siesta 802 devices (Compumedics Ltd., Abbotsford, Victoria, 
Australia) were used to record sleep PSG measures.
5.2.3.3 Polysomnography data analysis
5.2.3.3.1 Staging polysomnography recordings
The PSG data for all treatment nights were visually scored as described in Chapter 2.3.1, 
according to the criteria set by Rechtschaffen and Kales (Rechtschaffen & Kales, 1968).
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5.2.3.3.2 Spectral analysis of sleep recordings
Following completion of manual staging the sleep EEG EDF files and staged hypnograms 
were used to perform FFT spectral analysis as described in Chapter 2.3.2 using Vitascore 
software version 1.40 (RC.l) (Temec Instruments, B.V., Kerkrade, The Netherlands). 
Artefacts were manually removed from EEG derivations before FFT spectral analysis was 
performed on 4 second sub-epochs. Power spectra were extracted for entire night, thirds of 
the night and per hour of the night for sleep EEG recordings. For the purpose of data 
reduction one central derivation (C3 or C4; C3 in preference to C4) was selected per 
participant, per visit, for analysis. The criteria set for the amount of sub-epochs of data 
remaining in the entire night for each derivation following artefact removal was 62.5%; this 
resulted in a total of 6 derivations being excluded from analysis following artefact removal.
Following extraction of the sleep EEG power spectra data, corrections were applied to the 
EEG spectral power values as described in Chapter 2.4. Except for the EEG data in Chapter
5.3.2 in which the analyses were performed by a statistician at the Centre and the only 
adjustment to the raw data was that 0.25Hz bins were summed to create IHz bins for the 
power density spectra.
5.2.4 Statistical analysis
Data in Chapters 5.3.1 and 5.3.2 were performed by a statistician at the Centre and analyses 
were carried out in SAS® version 9.1 (SAS Institute Inc., Cary, NC, USA). All remaining 
analyses in this chapter were performed in SAS® version 9.2. To determine whether there 
were significant differences between treatment conditions, paired t-tests were performed on 
PSG derived sleep measures using PROC TTEST in SAS®.
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The stability and robustness of trait-like inter-individual differences within the EEG 
following pharmacological intervention was assessed by computing intraclass correlation 
coefficients (ICCs) using PROC MIXED in SAS®, with main effects of condition (drug 
received at each visit) and period (the visit number at which the condition occurred i.e. the 
order of the conditions). ICCs were calculated for PSG derived sleep measures, individual 
IHz EEG frequency bins up to 32Hz as well as the 8 traditional EEG frequency bands 
(described in Chapter 2.3.2.2) by taking the ratio of the estimates for between-subject 
variance to total variance (Van Dongen et al., 2004a, 2004b) as given in the covariance 
parameter estimates of the mixed model output. The general linear mixed model used for all 
analyses in this chapter can be found in Appendix C.
5.3 Results
5.3.1 Effect of treatment on PSG sleep measures
A summary of PSG sleep variables derived from manual staging of EEG recordings can be 
seen in Table 5.1. There were no significant effects of prolonged-release melatonin on any of 
the sleep variables when compared with placebo. Temazepam and zolpidem did, however, 
affect some of the PSG sleep variables when compared with placebo and prolonged-release 
melatonin.
Total sleep time (TST), sleep efficiency (SE), as well as the duration (minutes) and 
proportion (% of sleep period time) of stage 2 sleep, all significantly increased following 
treatment with a single dose of temazepam and zolpidem compared with the placebo 
condition and compared with the prolonged-release melatonin condition. Wake after sleep 
onset (WASO; until lights on) and duration of wake significantly decreased following 
treatment with both temazepam and zolpidem compared with the placebo condition and the
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prolonged-release melatonin condition. Additionally, Stage 1 sleep duration and proportion 
decreased following treatment with temazepam compared with prolonged-release melatonin. 
Whereas, following zolpidem SWS duration and proportion increased and REM minutes and 
proportion decreased compared with prolonged-release melatonin.
The contrasts between temazepam and zolpidem were not significant for any o f the sleep 
PSG variables. In addition, sleep latency (SL; lights off to any epoch of sleep) and latency to 
persistent sleep (EPS; lights off to 10 minutes continuous sleep) were not significantly 
affected by treatment with prolonged-release melatonin, temazepam or zolpidem.
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Chapter 5
5.3.2 Effects of treatment on EEG power density spectra
In order to visualise the differential effects of the drugs on the full 32Hz EEG frequency 
spectrum, power density values for temazepam, zolpidem and prolonged-release melatonin 
were expressed relative to the placebo condition per IHz bin up to 32Hz during non-rapid eye 
movement (NREM) and rapid eye movement (REM) sleep.
5.3.2.1 NREM sleep
Analysis of the night following treatment with either placebo or an active compound revealed 
that the lower frequency ranges were particularly affected and a reduction in power was 
observed following all treatments compared with placebo condition (Figure 5.5).
Treatment with temazepam had the greatest effect on the EEG power density spectrum, and 
caused a decrease from placebo condition in the delta or slow-wave, theta and alpha activity 
ranges by approximately 30% at 2-9Hz. Temazepam also marginally increased activity in the 
spindle frequency range at 13Hz compared to placebo. Zolpidem exerted similar effects to 
temazepam on the NREM sleep EEG power density spectrum, also causing a decrease from 
placebo condition by approximately 25% in the delta, theta and alpha activity ranges and also 
caused a marginal increase in the spindle frequency range at 13-14Hz. Prolonged-release 
melatonin exerted minimal effects on the EEG power density spectrum compared to the 
placebo condition, however, a reduction in power of approximately 10% was observed in 
low-delta and delta frequency ranges up to 4Hz.
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Figure 5.5: NREM sleep power density spectra following treatment
Entire night power densities (geometric mean ± 95% CFs) up to 32Hz (x-axis) for NREM 
sleep, with treatment expressed relative to the placebo condition (100%; n=13; y-axis) for 
temazepam (top figure; n=12), zolpidem (middle figure; n=12) and prolonged-release 
melatonin (bottom figure; n=13) fi*om the central derivation.
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5.3.2.2 REM sleep
Analysis of REM sleep in the night following dosing revealed that the EEG power density 
tended to decrease in the lower frequency ranges following temazepam and zolpidem when 
compared with placebo condition and the temazepam induced the greatest effects on the EEG 
compared to the placebo condition (Figure 5.6).
The effects of the treatments were less pronounced during REM sleep than were observed 
during NREM sleep and there were no discernible effects of prolonged-release melatonin on 
the power density spectrum during REM sleep. Both temazepam and zolpidem caused a 
reduction in power that also tended to be at the lower end of the power density spectrum, the 
reduction was over a much smaller range and at slightly higher frequencies compared with 
NREM sleep. Temazepam again induced the greatest changes in the EEG power density 
spectra compared to placebo and reduced power in the theta and alpha frequency ranges at 6- 
7Hz and 9-1 IHz by approximately 30%. Zolpidem also reduced power in the alpha and theta 
frequency ranges at 6-7Hz and 10-1 IHz compared with placebo condition by approximately 
209L
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Figure 5.6: REM sleep power density spectra following treatment
Entire night power densities (geometric mean ± 95% CFs) up to 32Hz (x-axis) for REM 
sleep, with treatment expressed relative to the placebo condition (100%; n=13; y-axis) for 
temazepam (top figure; n=12), zolpidem (middle figure; n=12) and prolonged-release 
melatonin (bottom figure; n=13) from the central derivation.
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5.3.3 Individual differences in sleep
5.3.3.1 Intra-individual robustness of PSG measures to pharmacological 
intervention
ICCs were calculated across the PSG sleep variables derived from visual scoring of EEG 
recordings in order to assess whether there were individual differences within the PSG 
parameters that were robust to pharmacological intervention. Analysis of the PSG variables 
revealed high ICCs across PSG variables assessed (Table 5.2).
ICCs across PSG variables ranged from 0.40 to 0.73 which is classified as ‘moderate’ to 
‘substantial’ according to established criteria for interpreting ICCs (Landis and Koch, 1977). 
The lowest values were observed for REM sleep duration and proportion, and the highest 
values were observed for SWS duration and proportion. Other variables with particularly 
high ICCs included SL, LPS, as well as duration and proportion of stage 1 and stage 2 sleep, 
produced ‘substantial’ ICCs. WASO, SE, and duration of wake all remained within the 
‘moderate’ ICC range.
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Chapter 5
5.3.3.2 Intra-individual robustness of the EEG to pharmacological intervention 
ICCs were calculated for the 8 EEG power density bands during NREM and REM sleep in 
order to assess whether there were robust individual differences within the EEG following 
intervention with placebo, temazepam, zolpidem, and prolonged-release melatonin. The ICCs 
indicated that there were robust inter-individual differences within the EEG for the 8 EEG 
power density bands (Table 5.3) and individual IHz bins up to 32Hz (Figure 5.7).
NREM sleep was highly robust to intervention across individuals with ICCs for the 8 EEG 
frequency bands ranging from 0.80 to 0.96 which would be considered as ‘almost perfect’ for 
all values obtained (Landis and Koch, 1977). The alpha and sigma activity ranges achieved 
the highest ICCs during NREM sleep and analysis of the EEG power density spectrum on a 
IHz resolution revealed that values were particularly high in the 7-19Hz range. Analysis of 
IHz bins also revealed a slightly larger range o f ICCs than did the analysis of the 8 EEG 
frequency bands. However, values for all IHz bins would be considered as ‘almost perfect’, 
except for 3 IHz and 32Hz for which ICCs were 0.79, and would achieve ‘almost perfect’ at 
0 .8.
REM sleep was slightly less robust to intervention within individuals than was NREM sleep 
and ICCs for the 8 traditional EEG power density bands ranged from 0.59 to 0.95, which 
would be interpreted as ranging from ‘moderate’ to ‘almost perfect’. The highest values were 
observed at the opposite end of the frequency spectrum to NREM sleep and were in the beta 
frequency ranges. Analysis o f the frequency spectrum on a IHz resolution during REM sleep 
revealed that ICCs held almost the same range as the 8 EEG frequency bands and ranged 
from 0.58 to 0.95 and the highest ICCs were largely within the beta frequency ranges.
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Figure 5.7: ICCs for log^  ^transformed spectral data for NREM and REM sleep 
ICCs derived from log^  ^transformed EEG power density values (amplitude^) from nocturnal 
EEG recordings (n=15). ICCs were obtained for 32 IHz frequency bins during NREM (top 
figure) and REM (bottom figure) sleep from the central derivation. Power within the 
frequency bands was analysed using a mixed model in SAS® to obtain ICCs.
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5.3.3.3 Robustness of intra-individual responses in the EEG to pharmacological 
intervention
The robustness of individuals’ response to intervention with the pharmacological compounds 
was assessed by taking EEG power density values per individual and expressing them 
relative to their placebo condition where possible for NREM and REM sleep across the 8 
EEG power density bands (Figures 5.8 and 5.9).
Inter-individual differences in the response to pharmacological intervention were smaller than 
those for absolute power density values as evidenced by the ICCs (Table 5.3 and Figure 5.7). 
The majority of individuals’ power density values following the different pharmacological 
interventions clustered closely together i.e. intra-individual variability was low; however, a 
few individuals displayed more widespread responses to the intervention. In addition, some 
individuals clustered above baseline levels and others below for certain frequency bands and 
this pattern of clustering tended to be similar within individuals across each o f the 8 
traditional power density bands.
The responses were similar within individuals during both NREM and REM sleep within the 
low-delta, sigma and beta frequency bands, whereas the delta, theta, and alpha frequency 
bands were the most contrasting between the two vigilance states. During NREM sleep 
individual responses to pharmacological intervention in the delta, theta and alpha frequency 
bands tended to be below or around placebo levels (100%) and inter-individual variability 
was relatively low, whereas during REM sleep there was a tendency for greater inter­
individual variation. The distribution of responses in the delta, theta, alpha and sigma 
frequency bands during NREM sleep reflects the decrease in power in these frequency ranges 
observed in the 32Hz power density spectrum (Figure 5.5).
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Within each frequency band the effect o f each pharmacological intervention varied across 
individuals i.e. the compound causing the smallest/largest response compared with placebo in 
one individual may not have been the same in the next individual. The low-delta band 
displayed the greatest intra-individual variation compared to the other EEG frequency bands 
and therefore the inter-individual variation was reduced. However, there appeared to be a 
more uniform response in the delta, theta and alpha bands during NREM sleep, whereby 
prolonged-release melatonin values were usually the highest in these bands, and temazepam 
and zolpidem the lowest. This more uniform response in the delta, theta and alpha bands 
again reflects the results seen in Figure 5.5 whereby prolonged-release melatonin caused little 
change compared to placebo condition, whereas, temazepam and zolpidem caused a 
reduction in power in the low-frequency bands.
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Figure 5.8: Power densities per individual during NREM sleep
Power density values from the central derivation per individual (x-axis) with each condition 
expressed relative to placebo condition (100%; y-axis) during NREM sleep across the 8 EEG 
frequency band ranges: low-delta, delta, theta, alpha, sigma, beta-1, beta-2 and beta-3. •  
temazepam, # zolpidem and •  prolonged-release melatonin.
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Figure 5.9: Power densities per individual during REM sleep
Power density values from the central derivation per individual (x-axis) with each condition 
expressed relative to placebo condition (100%; y-axis) during REM sleep across the 8 EEG 
frequency band ranges: low-delta, delta, theta, alpha, sigma, beta-1, beta-2 and beta-3. •  
temazepam, •  zolpidem and •  prolonged-release melatonin.
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5.4 Discussion
This study is the first to our knowledge to directly compare the effects of temazepam, 
zolpidem and prolonged-release melatonin on the spectral composition of the nocturnal EEG 
over the course of the entire night. The effect o f treatment on the power density spectra 
confirmed the hypothesis that the drugs would differentially affect the EEG, and this is likely 
due to their differing mechanisms of action. Temazepam and zolpidem affected the EEG in 
accordance with the effects previously reported for benzodiazepines and Z-drugs by reducing 
activity in the delta, theta and alpha frequency bands (Dijk et al., 1989b, Brunner et al., 
1991). However, neither temazepam nor zolpidem caused a marked increase in activity in the 
spindle frequency range, this may be due to age-related attenuation of spindle activity 
(Landolt et al., 1996) or indeed, the EEG montage analysed in our study may have caused 
limitations in analysing this frequency range since spindles are not evenly distributed in all 
EEG derivations (Werth et al., 1997). It could be interpreted from the PSG derived sleep 
measures that temazepam and zolpidem improved sleep by increasing TST and SE, and there 
was also no significant difference in measures of SWS compared with placebo following 
treatment. The dissonance between PSG analysis and spectral analysis of the EEG has been 
previously reported (Dijk et al., 1990a) and without the spectral analysis of the EEG the 
suppression of SWA would have gone undetected and results may have been misleading. Our 
data gives further support to the notion that spectral analysis is a sensitive tool for assessing 
drug efficacy and safety.
Prolonged-release melatonin exerted very little effect on the nocturnal EEG and only caused 
a slight reduction in power in the low-delta frequency range and did not significantly affect 
any of the PSG derived sleep measures. The lack of effect of prolonged-release melatonin on 
the EEG is not surprising since effects of exogenous melatonin administered in the evening
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hours are yet to be reported (Cajochen et al., 1997). It is likely that exogenous melatonin 
administration cannot facilitate sleep when administered in-phase with endogenous melatonin 
and major effects on the EEG have only been reported following daytime administration and 
these effects more closely resemble those of a typical benzodiazepine (Dijk et al., 1995, 
Rajaratnam et al., 2004, Aeschbach et al., 2009). The effects of melatonin on the EEG are 
somewhat equivocal, however, there may be many factors contributing to the dissonance 
between results observed following administration of exogenous melatonin at different times 
of day, such as circadian influences on receptor sensitivity (reviewed in Witt-Enderby et al., 
2003), or the interaction between melatonin and GABAa receptors (Wan et al., 1999).
SWA is a well-established EEG biomarker for sleep homeostasis that reflects sleep intensity 
(Dijk et al., 1987a, Dijk et al., 1990a), and following total sleep deprivation a rebound of 
SWA is observed in the EEG (Brunner et al., 1993). The exact roles of SWS and SWA are 
unclear, however, it is generally accepted that SWS is restorative and research suggests that is 
has roles in sleep continuity (Dijk et al., 2006), synaptic homeostasis (reviewed in Tononi 
and Cirelli, 2003, Tononi and Cirelli, 2006) and memory consolidation (reviewed in Maquet, 
2001). The consequences of a reduction of power in the slow-wave frequency range 
following pharmacological intervention with hypnotics remains unclear, however, such 
changes are perhaps undesirable consequences of pharmacological intervention and the 
general consensus is that an ideal pharmacotherapy for insomnia would be one where the 
effects on the EEG closely resembles a physiological night’s sleep without altering the 
architecture of the nocturnal EEG. Whilst it is clear that the EEG can effectively serve as a 
biomarker for pharmacological activity within the CNS, the lack of understanding regarding 
the role o f specific EEG frequency components makes it somewhat difficult for the EEG to 
serve as a biomarker for drug efficacy.
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At present, the efficacy of hypnotics is largely assessed by subjective measures of sleep; 
however, factors affecting subjective ratings o f sleep quality are complex and may be 
influenced by level o f alertness (Van Dongen et al., 2003), expectation of treatment (Fratello 
et al., 2005), gender (Vitiello et al., 2004), and age (O'Donnell et al., 2009). Therefore, there 
is a need to improve our understanding of frequency components within the EEG and their 
role in sleep-wake regulation in order to objectively assess the significance o f EEG responses 
to intervention. Interestingly, spectral analysis of the EEG has been usefiil in assessing drug 
safety by dissipating dissonance between subjective and objective measures of sleep (Bastien 
et al., 2003). In addition, spectral analysis has also shown promise as a tool for assessing drug 
efficacy whereby baseline markers within the EEG were able to predict responsiveness to 
clinical treatment (Luthringer et al., 1995), indicating the scope of the method for being a 
clinical and/or diagnostic tool.
Identifying individual differences within the EEG will be important for improving efficacy 
and safety o f pharmacological treatment. In addition, pharmacological intervention studies 
may be useful for identifying receptors and pathways involved in sleep-wake regulation. In 
order to establish whether individual differences are trait-like, it is necessary to show that 
results are significant, stable across time and robust to intervention (Van Dongen et al., 
2005). In our study the stability of individual differences could not be assessed since 
treatment conditions were not repeated within in an individual, a design feature that would be 
necessary for assessing stability over time. However, it was possible to assess whether there 
were individual differences within PSG derived sleep measures and within the spectral 
composition of the EEG that were robust to the pharmacological intervention. ICCs for PSG 
derived sleep measures ranged fi*om ‘moderate’ to substantial’, whilst ICCs derived for the 
EEG power density spectra tended to be slightly more robust and with those for NREM sleep
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all in the ‘almost perfect’ range and those for REM sleep ranged from ‘substantial’ to ‘almost 
perfect’ according to established benchmark ranges (Landis and Koch, 1977). The ICCs on 
the whole showed that aspects of sleep and the sleep EEG are robust to pharmacological 
intervention, and are in accordance with those previously observed under sleep restriction 
conditions (Tucker et al., 2007). Our study confirmed the hypothesis that there would be 
individual differences within the EEG that were robust to pharmacological intervention, 
although further investigation would be required to determine whether there are trait-like 
individual differences within the EEG that are stable and robust to pharmacological 
intervention.
ICCs calculated from absolute EEG power density values only indicates that there are robust 
inter-individual differences in the amplitude of the EEG, and in order to establish whether 
there are inter-individual differences in components controlling sleep-wake regulation it 
would be necessary to determine whether there are individual differences in the response to 
pharmacological intervention. The robustness o f individuals’ responses to pharmacological 
intervention compared to placebo was also assessed by expressing power density values for 
each treatment condition relative to placebo condition across the 8 EEG power density bands 
for NREM and REM sleep per individual and presenting in a scatter plot. The scatter plots of 
individuals’ response to pharmacological intervention indicated that whilst the absolute 
spectra showed high inter-individual variation, responses of each individual to treatment was 
more variable and thus the inter-individual variation was reduced. Ideally the study design 
would have incorporated a placebo condition prior to each treatment condition, thereby 
allowing the robustness of individuals’ responses to be assessed by calculating ICCs using 
power density values for each treatment condition expressed relative to the placebo condition; 
however, the assessment of inter-individual differences was a retrospective aim of the study.
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There may be several factors that contribute to inter-individual differences within the EEG 
and uncovering these factors is necessary for elucidating mechanisms underlying sleep-wake 
regulation. Age and gender for example, may account for some of the individual differences 
in response to pharmacological intervention. Gender differences have been reported in 
normal physiological sleep (Dijk et al., 1989a, Carrier et al., 2001), as well as in sleep 
disorders and following pharmacological intervention (Buysse et al., 2008, Dijk et al., 2010). 
It is therefore likely that gender relates to some of the individual differences observed in 
sleep and may be a factor in susceptibility to sleep disorders such as insomnia. In this study 
the ratio o f male to female subjects was 3:1 making for an unbalanced design for assessing 
the contribution of gender to inter-individual differences. It is well documented that sleep 
significantly changes with age (Ohayon et al., 1996, Dijk et al., 1999, Carrier et al., 2001, 
Klerman and Dijk, 2008), and it is likely that the influence of age on specific frequency 
components of the EEG is greater than that of gender (Ehlers and Kupfer, 1997), it would 
therefore be reasonable to suggest that, despite the fairly restricted age range in our study 
population, age may be contributing to some of the inter-individual variation observed with 
the amplitude of the EEG and therefore is reflected in the high ICCs for absolute power 
densities in NREM and REM sleep. Assessment of the contribution of age to ICCs calculated 
for EEG parameters would make an interesting project given the literature detailing the 
effects of age on sleep.
Ethnicity may also play a role in individual differences, and it has previously been reported 
that aspects of sleep, in particular SWS, are different amongst ethnic groups in normal 
physiological sleep (Profant et al., 2002, Stepnowsky et al., 2003), as well as within clinical 
populations (Mendlewicz and Kerkhofs, 1991, Giles et al., 1998, Poland et al., 1999). Since 
the primary purpose of this research was to compare the effects of temazepam, zolpidem and
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prolonged-release melatonin on the nocturnal EEG, our study population did not contain a 
balance of ethnic groups and therefore it was also not possible to assess the contribution of 
ethnicity to individual differences.
5.4.1 Conclusions
The study of pharmacology and sleep is important for developing new drug targets, as well as 
enhancing current understanding of sleep-wake regulation and establishing inter-individual 
difference therein can only serve to improve pharmacotherapies for sleep disorders such as 
insomnia. We have shown that the EEG is indeed a useful biomarker for demonstrating 
pharmacological activity within the CNS, but it does not necessarily demonstrate drug 
efficacy and further characterisation of the EEG response to pharmacological intervention is 
necessary in order to be able to characterise the responses into physiological consequences. 
We have also shown that the EEG can effectively serve as a biomarker for inter-individual 
differences that are robust to pharmacological intervention, however, there is a need for a 
better understanding of individual differences in the stability and robustness o f the EEG in 
response to pharmacological intervention and studies that assess the contribution o f study 
population demographics such as age, gender and ethnicity to inter-individual differences will 
also be important for aiding the bidirectional relationship between understanding the 
mechanisms controlling sleep-wake regulation and development of psychoactive drugs.
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Chapter 6: Discussion
6.1 Study aims
The aims of the three studies presented in this thesis were to establish whether the 
electroencephalogram (EEG) can effectively serve as a biomarker for trait-like inter­
individual differences in sleep-wake regulation that are stable and robust to interventions 
such as sleep-wake manipulations, intervention to polychromatic light and to 
pharmacological intervention. In one study the contribution of the PERIODS {PERS) gene 
Variable Number Tandem Repeat (VNTR) polymorphism to inter-individual differences 
within sleep and the sleep EEG was also assessed.
In the sleep manipulation study (Chapter 3) we assessed whether polysomnography (PSG) 
measures and the sleep EEG demonstrated trait-like inter-individual differences in healthy 
young men and women under different sleep-wake paradigms, including baseline sleep (8 
hour sleep opportunity), sleep extension (10 hour sleep opportunity), sleep restriction (6 hour 
sleep opportunity) and recovery sleep (12 hour sleep opportunity) following an 
approximately 40 hour total sleep deprivation period. The light intervention study (Chapter 4) 
investigated the effects of five different polychromatic light mixtures with varying 
wavelength contributions on the EEG in healthy young men and women and whether trait­
like inter-individual differences were present was determined. Finally, the pharmacological 
intervention study (Chapter 5) investigated trait-like inter-individual differences within PSG 
measures and the sleep EEG following intervention with placebo, temazepam, zolpidem and 
prolonged-release melatonin in healthy middle aged men and women.
This thesis aimed to address some o f the shortcomings o f existing literature on sleep-wake 
regulation, including the assessment o f inter-individual variation within sleep, an important
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and necessary task for characterising individual differences in sleep within the healthy 
population, and also for elucidating mechanisms underlying sleep-wake regulation. Van 
Dongen and colleagues have reviewed the existing literature on individual differences in 
human sleep and identified research needs (Van Dongen et al., 2005), we have attempted to 
meet the current research demands in the studies presented in this thesis by investigating the 
stability and robustness o f individual differences in sleep and the sleep EEG. Investigation of 
individual differences within sleep will also be important for forming the basis o f identifying 
traits, such as genetic polymorphisms, that may be predictive of vulnerability to sleep loss, 
shift work, sleep disorders as well as other clinical disorders. Additionally, identifying 
predictors of individual differences may also evidence populations of individuals that possess 
advantageous differences, and as such may identify those that are resilient to the effects of 
sleep loss or to sleep disorders.
6.2 Study findings
Within each study presented in this thesis, the interventions were effective at eliciting 
changes within PSG measures and the sleep EEG power density spectrum when compared 
with baseline, dim light or placebo conditions in each study and we have therefore shown that 
the EEG is a useful tool for demonstrating neurological changes that were induced either 
directly by manipulation of sleep-wake patterns or indirectly by using interventions that 
altered sleep such as light or pharmacological agents.
The effect of sleep extension and sleep restriction resulted in reduced and increased EEG 
power densities in the former and latter conditions respectively. Total sleep deprivation 
induced an increase in power density within these bands irrespective of whether the previous 
condition was sleep extension or sleep restriction. The effects of the sleep manipulations on
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EEG power density demonstrated that the EEG is useful for demonstrating changes in 
homeostatic sleep pressure. The effect o f light intervention on the EEG power spectra was 
somewhat equivocal. Nonetheless, the EEG was affected by the light conditions and 
interestingly, the occipital derivation was the most affected. The derivation dependent effects 
were likely due enhanced activity in brain areas associated with processing light information, 
indicating that the EEG is useful for elucidating topographical differences which are related 
to underlying mechanisms. Temazepam, zolpidem and prolonged-release melatonin 
differentially affected PSG measures and the sleep EEG, with the former two treatments 
eliciting typical benzodiazepine and non-benzodiazepine EEG signatures, which further 
confirms the usefulness of the EEG as a tool for demonstrating pharmacological activity 
within the CNS.
6.2.1 Polysomnography measures
PSG measures were assessed for individual differences by calculating intraclass correlation 
coefficients (ICCs) in two studies: the sleep manipulation study and the pharmacological 
intervention study. Participants on the study investigating the effects of sleep manipulations 
received 8 hour sleep opportunities on baseline nights prior to sleep-wake manipulations and 
participants on the pharmacological intervention study received 8 hour sleep opportunities on 
all nights. Interesting comparisons can be made between the PSG measures ICCs obtained for 
baseline nights for the sleep manipulation study and those obtained for the pharmacological 
intervention study (Table 6.1).
The ICCs for the sleep manipulation study are those derived from baseline sleep and 
therefore no interventions were implemented on those nights, and are therefore representative 
of a young healthy population of individuals. The ICCs derived from the pharmacological
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intervention study are calculated from four experimental nights per individual which included 
single doses o f placebo, temazepam, zolpidem and prolonged-release melatonin. Those for 
the sleep manipulation study were found to be comparable with those calculated by others 
(Tucker et al., 2007) and those obtained for the pharmacological intervention study were also 
comparable. Comparing the data across studies further confirms that some PSG sleep 
measures are trait-like i.e. they are robust to the pharmacological interventions.
When considering the benchmark ranges typically used to interpret ICCs (Landis and Koch, 
1977), across the studies ICCs ranged from ‘moderate’ to ‘almost perfect’. However, it 
became apparent that sleep latency (SL), latency to persistent sleep (LPS), stage 1 minutes 
and proportion, stage 2 minutes, and slow-wave sleep (SWS) minutes and proportion, were 
the PSG variables that fell into different benchmark ranges when comparing the two studies. 
For these variables that differed, the ICCs were higher, i.e. more robust, for the 
pharmacological intervention study on all accounts except for SWS minutes and proportion 
which were lower, i.e. less robust, for the pharmacological intervention study compared with 
the sleep manipulation study.
The differences between the studies are interesting given the differences in the demographics 
of the study populations. Participants on the sleep manipulation study were young, healthy, 
men and women, whereas those on the pharmacological intervention study were middle-aged, 
men and women. It should be noted however, that gender was not balanced for the latter 
study. It is known that there is an age related attenuation of SWS and slow-wave activity 
(SWA) (Dijk et al., 1999, Carrier et al., 2001), and this may be reflected in the ICCs derived 
for SWS which were lower for the pharmacological intervention study. Additionally, latency 
measures and stage 1 and 2 sleep were higher for the pharmacological intervention study.
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which may be a compensatory measure for the reduced stability in SWS and may also be 
related to the age-related reduction in capacity for sleep (Klerman and Dijk, 2008). 
Nonetheless, the SWS ICC for the pharmacological intervention study was still interpreted as 
‘substantial’ and was the highest ICC across variables, and thus demonstrates the stability and 
robustness of this variable. The comparison of ICCs across the studies may therefore indicate 
that the stability and robustness of sleep may shift across the life-span, and changes in certain 
variables may be compensated for by reduced or increased stability in others.
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6.2.2 EEG spectral analysis
EEG power densities were assessed for individual differences by calculating ICCs in all three 
studies. ICCs obtained for the 8 EEG frequency bands during NREM and REM sleep for 
baseline nights on the sleep manipulation study, as well as those obtained for the light 
intervention and pharmacological intervention studies, were all derived from nights with a 
duration o f 8 hours and therefore these ICCs are compared (Table 6.2). The central derivation 
was selected for comparison due to this being the only derivation possible for analysis in the 
pharmacological intervention study.
ICCs obtained for the 8 EEG frequency bands were particularly high during both NREM and 
REM sleep and across all three studies and were comparable to those reported by others 
(Tucker et al., 2007, Geiger et al., 2011, Tarokh et al., 2011). When interpreting the ICCs 
using the established benchmark ranges (Landis and Koch, 1977), the ICCs for the sleep 
manipulation study ranged from ‘substantial’ to ‘almost perfect’ for both NREM and REM 
sleep, as did those for the light intervention study. The pharmacological intervention study 
had the same range as the other studies for NREM sleep, however, REM sleep differed 
slightly and ranged from ‘moderate’ to ‘almost perfect’. Whilst the ICCs derived from 
baseline nights on the sleep manipulation study are not those derived from EEG which has 
been subject to any intervention, those from the other two studies are derived from EEG 
recorded following intervention with polychromatic light and pharmacological intervention 
respectively. The high ICCs in all studies indicate that EEG power density was robust to the 
interventions.
Inspection of the ICCs obtained for individual EEG frequency bands highlights some small 
changes between studies. For example, for NREM sleep the delta, theta and alpha frequency
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bands produced the highest ICCs for the sleep manipulation and the light intervention study, 
whereas, for the pharmacological intervention study there is a shift towards the mid 
frequency bands with the alpha and sigma frequency bands producing the highest ICCs. This 
is interesting given that for PSG measures, SWS was also less robust for this population of 
participants, and it was hypothesised that this may be an age related change. Interestingly, a 
reduction in SWA and an increase in power in the sigma frequency range have previously 
been observed with increasing age (Carrier et al., 2001). The sleep EEG further supports this 
hypothesis that there may be age related changes in the stability and robustness of aspects of 
sleep, including frequency components o f the EEG.
Comparison of ICCs obtained for REM sleep across the studies revealed that for the sleep 
manipulation study and the pharmacological intervention study the highest ICCs were 
observed for the beta frequency ranges, however, for the light intervention study there was a 
shift towards the middle EEG frequency bands being the most stable and the theta, alpha and 
sigma frequency ranges produced the highest ICCs for this study. The fact that there was a 
shift towards greater stability in the middle of the frequency spectrum is interesting since the 
intervention was light. Light is the most potent zeitgeber to set the time of the circadian clock 
and can be used to induce phase shifts (Zeitzer et al., 2000). Since REM sleep is under 
circadian control (Dijk and Czeisler, 1995), it could be suggested that the shift in stability in 
REM sleep observed in the light intervention study could be due to light induced circadian 
disruption of sleep. The comparison of ICCs derived from EEG frequency bands across the 
studies provides further support for the EEG being a successful biomarker for trait-like inter­
individual differences in sleep. In addition, the comparison of the stability and robustness of  
ICCs across the studies also provides some suggestion as to the mechanisms underlying such 
differences.
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6.3 Conclusions and future work
Research investigating individual differences in sleep is sparse and our studies make a 
substantial contribution to this area of research. The high ICCs obtained within each study 
confirm that aspects of sleep, particularly the amplitude of the EEG, as well as some PSG 
measures, display individual differences. In the sleep manipulation study we were able to 
demonstrate that the individual differences were both stable across time and robust to the 
state manipulations, and can therefore be considered trait-like. In the light and 
pharmacological intervention studies we were also able to demonstrate robustness of 
individual differences to light and pharmacological interventions, although conclusive 
evidence of trait-like inter-individual differences was not possible due to study design. The 
studies presented in this thesis have contributed to current understanding of individual 
differences in the healthy population.
Identifying where trait-like individual differences arise from will be another important step 
towards understanding sleep-wake regulation. The question remains whether individual 
differences constitute differences in sleep-wake regulatory mechanisms or whether the 
differences arise due to other factors, for example, structural differences (Buchmann et al., 
2011, Piantoni et al., 2013). In the sleep manipulation study we attempted to identify whether 
differences could be attributed to the PER3 VNTR polymorphism and it was observed that 
there were significant genotype dependent differences in both PSG measures and the EEG 
frequency spectrum. In addition, we also assessed whether there were individual differences 
in the response to intervention by means of calculating ICCs based on relative values for PSG 
measures and the EEG frequency bands. These ICCs were extremely low, this was perhaps to 
be expected since standardising each participant to the same value would invariably reduce 
the inter-individual variation. However, one would expect that if such individual differences
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constitute trait-like individual differences in sleep-wake regulation, that participant’s 
magnitude of response should also be individual.
It is likely that differences in sleep-wake regulatory factors contributed to some extent to the 
individual differences observed in our studies; particularly since we demonstrated that a 
polymorphism in a circadian clock gene induced genotype dependent differences in PSG 
measures and in EEG frequency bands. However, the high ICCs observed for the EEG 
frequency bands are also likely influenced by aspects inherent to the EEG since we could not 
demonstrate individual responses to intervention. It was not possible to calculate ICCs using 
relative data for the light intervention and pharmacological intervention studies due to 
inadequate study design for such analyses; however, this would have been useful for 
confirming or opposing the results seen in the sleep manipulation study. In our studies we 
have demonstrated that the EEG can effectively serve as a biomarker for individual 
differences in sleep and established that the amplitude of the EEG is certainly trait-like, but 
whether response to intervention also constitutes a trait remains to be determined and requires 
further investigation.
There are many advantages of using EEG analysis methods, including sensitivity, high 
temporal resolution, non-invasive and not to mention the wide accessibility and relatively 
inexpensive, thus making it an appealing option compared with other methods. Given the 
wide availability of EEG analysis it also makes it a useful preliminary measure for 
identifying interesting populations for more specialised brain analysis methods such as 
positron emission tomography (PET), magnetoencephalography (MEG), functional magnetic 
resonance imaging (fMRI) and high density (HD) EEG analysis. EEG analysis methods such
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as Fast Fourier Transform (FFT) spectral analysis will likely remain a popular tool for 
assessment of neurological activity.
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